

# Funding Opportunities Monthly Edition March 2024 Due Dates

#### <u>Introduction</u>

This funding opportunity packet contains information on funding opportunities with deadlines in March 2024. The opportunities are organized in the following order:

- 1. National Institutes of Health (NIH)
- 2. National Science Foundation (NSF)
- 3. Other Federal
- 4. Non Federal

SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
113746		Utilization of Cohorts and Prospective ssay Validation for Early Detection of	National Cancer Institute/NIH/DHHS	NOT-CA-23-004	05-Jan-2024	Not Specified
	Contact Name	Matthew Young, Ph.D.				
	Contact Telephone	240-276-5846				
	Contact Email	matthew.young@nih.gov				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	05-Jan-2024, 07-Jan-2024, 05-Feb-2024 2024, 12-Jun-2024, 01-Jul-2024, 05-Sep Jan-2025, 07-Jan-2025, 05-Feb-2025, 1 , 01-Jul-2025	o-2024 , 07-Sep-2024 , 01	-Oct-2024 , 05-Oct-2024	4 , 10-Oct-2024 , 11-0	Oct-2024 , 05-
	Synopsis	The purpose of this Notice of Special Into biomarker technology developers with a and biorepository researchers. Proposals and validation utilizing statistically powe populations with a sound study design a	ssays for early cancer de s that facilitate early can red retrospective cohort	tection, and population- cer biomarker assay dev s and/or through prospe	based researchers, ir elopment, verificatio	ncluding cohort n, qualification,
11177/4X -	Modular R01s in Cancer Control a	and Population Sciences (R01 Clinical Trial	National Cancer Institute/NIH/DHHS	PAR-21-190	07-Mar-2024	1,250,000 USD
	Contact Name	Scott Rogers, MPH				
	Contact Telephone	240-276-6932				
	Contact Email	rogerssc@mail.nih.gov				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	07-Mar-2024				
	Synopsis	This funding opportunity announcement sciences. The overarching goal is to prov potential to substantially advance cance cancer-related behaviors and behavioral	ide support to promote i r research in statistical ai	esearch efforts on novend analytic methods, epi	l scientific ideas that demiology, cancer su	have the



SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
	Notice of Special Interest (NOSI): land Coordination During Cancer D	Research on Interprofessional Teamwork Diagnosis and Treatment	National Cancer Institute/NIH/DHHS	NOT-CA-22-014	28-Dec-2023	Not Specified
	Contact Name	Sallie J. Weaver, PhD, MHS				
	Contact Telephone	240-276-6254				
	Contact Email	sallie.weaver@nih.gov				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	07-Jan-2024 , 25-Jan-2024 , 05-Feb-2024 2024 , 16-Jun-2024 , 07-Sep-2024 , 25-Se			May-2024 , 05-Jun-2	024 , 07-Jun-
	Synopsis	This Notice of Special Interest (NOSI) high applications focused on understanding a and treatment.	•	,		•
1112212	Notice of Special Interest (NOSI): Utilization and Health Outcomes A	Disparities Affecting Healthcare Among Childhood Cancer Survivors	National Cancer Institute/NIH/DHHS	NOT-CA-22-029	28-Dec-2023	Not Specified
	Contact Name	Veronica Chollette, RN, MS				
	Contact Telephone	240-276-6969				
	Contact Email	cholletv@mail.nih.gov				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	07-Jan-2024 , 25-Jan-2024 , 05-Feb-2024 2024 , 16-Jun-2024 , 25-Sep-2024 , 08-Oc		2024 , 07-May-2024 , 25-I	May-2024 , 05-Jun-2	024 , 07-Jun-
	Synopsis	The purpose of this Notice is to highlight Population Sciences (DCCPS) in receiving to disparities in survivorship care, health that focus on factors that extend beyond intervention that involves healthcare tea contribute to disparities in health outcome	applications to understal care utilization, and healt the individual (e.g., surv ms, healthcare system, c	nd and address the full sp th outcomes among child ivor, caregiver, clinician) ommunity, payer, and/or	pectrum of factors the hood cancer survive to include an examinations policy-level factors	nat contribute ors. Studies nation or that
113233	Bioengineering Research Grants (I	BRG) (R01 Clinical Trial Optional)	National Cancer Institute/NIH/DHHS	PAR-22-243	07-Jan-2024	Not Specified

Title
-------

Contact Name Rao Divi, Ph.D.

Contact Telephone 240-276-6913

Contact Email divir@mail.nih.gov

Sponsor Website

Program URL Link to program URL

Deadline Dates (ALL)

07-Jan-2024, 05-Feb-2024, 05-Mar-2024, 07-May-2024, 05-Jun-2024, 05-Jul-2024, 07-Sep-2024, 05-Oct-2024, 05-Nov-2024, 07-Jan-2025, 05-Feb-2025, 05-Mar-2025, 07-May-2025, 05-Jun-2025, 05-Jul-2025, 07-Sep-2025

The purpose of this funding opportunity announcement is to encourage collaborations between the life and physical sciences that: 1) apply a multidisciplinary bioengineering approach to the solution of a biomedical problem; and 2) integrate, optimize, validate, translate or otherwise accelerate the adoption of promising tools, methods, and techniques for a specific research or clinical problem in basic, translational, or clinical science and practice. An application may propose design-directed, developmental, discovery-driven, or hypothesis-driven research and is appropriate for small teams applying an integrative approach to increase our understanding of and solve problems in biological, clinical, or translational science. This FOA will support clinical trials that test functionality or validate performance in the chosen setting. This FOA is not intended to support conventional clinical trials that lack translation as the primary motivation. Applications that propose phase III clinical trials in any area of research are not sought by and will not be supported through this FOA. This FOA does

Synopsis

106261 Basic Research in Cancer Health Disparities (R01 Clinical Trial Not Allowed)

National Cancer
Institute/NIH/DHHS

PAR-21-322

05-Feb-2024

Not Specified

Contact Name Anu Sharman, Ph.D.

Contact Telephone 240-276-6250

Contact Email sharmananu@nih.gov

Sponsor Website

Program URL Link to program URL

Deadline Dates (ALL) 05-Feb-2024, 05-Mar-2024, 05-Jun-2024, 05-Jul-2024

not propose to support commercial production.

Synopsis

National Cancer Institute (NCI) invites applications from investigators interested in conducting basic, mechanistic research into the biological/genetic causes of cancer health disparities. These research project grants (R01) will support innovative studies designed to investigate biological/genetic bases of cancer disparities, such as (1) mechanistic studies of biological factors associated with cancer disparities, including those related to basic research in cancer biology or cancer prevention

SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
		strategies, (2) the development and test also designed to aid and facilitate the gr in cancer health disparities research who models, and methods that are necessary Research Project (R01) award mechanism	owth of a nationwide coho can expand available re to conduct basic researc	nort of scientists with a l sources and tools, such	high level of basic res as biospecimens, pat	earch expertise ient derived
1116787	Mechanisms that Impact Cancer rial Optional)	Risk after Bariatric Surgery (R01 Clinical	National Cancer Institute/NIH/DHHS	PAR-21-331	05-Feb-2024	2,500,000 USD
	Contact Name	Edward R. Sauter, M.D., Ph.D.				
	Contact Telephone	240-276-7657				
	Contact Email	edward.sauter@nih.gov				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	05-Feb-2024 , 05-Mar-2024 , 05-Jun-202	4 , 05-Jul-2024			
	Synopsis	Through this Funding Opportunity Annoof investigator-initiated studies addressi talented scientists who study bariatric suas weight loss and diabetes.	ng mechanisms by which	bariatric surgery impac	ts cancer risk, and se	eks to draw in
	Notice of Special Interest (NOSI): creening and Prevention of Early	Research on the Etiology, Early Detection y-Onset Colorectal Cancer	, National Cancer Institute/NIH/DHHS	NOT-CA-23-018	28-Dec-2023	Not Specified
	Contact Name	Gary Della'Zanna				
	Contact Telephone	240-276-7042				
	Contact Email	Gary.DellaZanna@nih.gov				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	07-Jan-2024 , 25-Jan-2024 , 05-Feb-2024 2024 , 07-May-2024 , 25-May-2024 , 05- 25-Sep-2024 , 08-Oct-2024 , 10-Oct-2024 2025	Jun-2024 , 07-Jun-2024 ,	12-Jun-2024 , 16-Jun-20	024 , 25-Jun-2024 , 07	-Sep-2024 ,



		, - [-]			
SPIN ID Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
Synopsis mi	e purpose of this Notice of Special Int tigating risk factors, identifying bioma rly-onset colorectal cancer (EOCRC), o	arkers for early detection	, best screening modalities,		
112442 NCI Clinical and Translational Explora Clinical Trial Optional)	atory/Developmental Studies (R21	National Cancer Institute/NIH/DHHS	PAR-22-216	13-Feb-2024	275,000 USD
Contact Name W Contact Telephone 24	illiam C. Timmer, Ph.D 0-276-6130				
,	lliam.timmer@nih.gov				
Sponsor Website	-				
Program URL <u>Lir</u>	ık to program URL				
	-Feb-2024 , 01-Mar-2024 , 12-Jun-20 25 , 01-Jul-2025	24 , 01-Jul-2024 , 10-Oct-2	2024 , 01-Nov-2024 , 13-Fe	b-2025 , 01-Mar-20	)25 , 12-Jun-
stu ma fol tre ap vit lin ag rai rai an	is Funding Opportunity Announcemendies, directly related to advancement anagement, or reduction of cancer discounting: new molecular agents or biolicatment-related toxicity; cancer screet proaches; predictive and prognostic for tumor models (including genetical es); and strategies to address therape ents, new treatment strategies may indication), based on established mechalicial/ethnic, or health disparities are ed toxicity) and resistance to therape estiment and diagnosis of human dise	its in cancer treatment, disparities. This includes (but logics for cancer treatment ening or diagnostic tools, so biomarkers for patient selly engineered mouse mode entic outcome disparities involve repurposed agents in isms of action. Comparancouraged to explore meditic interventions. Comparance	agnosis, prevention, compart is not limited to) developed; management strategies such as imaging techniques ection or stratification; clinically, patient-derived xenog among underserved population or novel combinations of tive correlative studies in correlative oncology studies in corr	arative oncology, soment and testing of for cancer-related; cancer preventive ically relevant in viraft models, organations. In addition interventions (incluancer patients with differential responsions investigating s	ymptom of the symptoms or e agents or vo or in oids, and cell to novel ading n age, gender, es (efficacy trategies for

cancer biology (such as studies of cancer-related pathways, molecular mechanisms, or mechanisms of metastasis), late-stage clinical trials, risk assessment studies, epidemiological studies, or studies of behavioral interventions. These applications will be deemed not responsive to this FOA and will not be reviewed (see below for a more detailed description of studies that are not responsive for this FOA). The R21 mechanism is intended to encourage exploratory and developmental research projects by providing support for the early and conceptual stages of these projects. These studies may involve considerable

			T			
SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
		risk but may lead to breakthroughs in par models, or applications that could have a				thodologies,
106264	Basic Research in Cancer Health [	Disparities (R21 Clinical Trial Not Allowed)	National Cancer Institute/NIH/DHHS	PAR-21-323	16-Feb-2024	400,000 USD
	Contact Name	Anu Sharman, Ph.D.				
	Contact Telephone	240-276-6250				
	Contact Email	sharmananu@nih.gov				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	16-Feb-2024 , 16-Mar-2024 , 16-Jun-2024	4 , 16-Jul-2024			
	Synopsis	National Cancer Institute (NCI) invites appint to the biological/genetic causes of cancer studies designed to investigate biological factors associated with cancer disparities strategies, (2) the development and testicals of designed to aid and facilitate the growin cancer health disparities research who models, and methods that are necessary	cer health disparities. The /genetic bases of cancer is, including those related ng of new methodologies with of a nationwide cohe can expand available res	ese research project grand disparities, such as (1) meto basic research in cand sand models, and (3) secont of scientists with a head cources and tools, such a	its (R01) will support nechanistic studies of cer biology or cancer condary data analyse igh level of basic rese s biospecimens, pati	innovative f biological prevention es. This FOA is earch expertise
111/1X5U	Notice of Special Interest (NOSI): Care Delivery Models to Improve	New Information Technology-Enabled Depression Care in Cancer	National Cancer Institute/NIH/DHHS	NOT-CA-21-085	07-Jan-2024	Not Specified
	Contact Name	Gurvaneet S. Randhawa, M.D., M.P.H.				
	Contact Telephone	240-276-6940				
	Contact Email	Gurvaneet.Randhawa@nih.gov				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	07-Jan-2024 , 05-Feb-2024 , 16-Feb-2024	, 07-Mar-2024			
	Synopsis	This Notice of Special Interest (NOSI) high and Population Sciences in receiving inve	nlights interest of the Natestigator-initiated applica	tional Cancer Institute (N tions for conducting rese	ICI)'s Division of Can earch on the design a	cer Control and



SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
		mplementation of new information tech ancer.	nnology (IT)-enabled care	delivery models to imp	prove depression-relate	ed care in
122688 <mark>S</mark>		ons for Incorporation of Novel NCI- e Cancer Research (P50 Clinical Trial	National Cancer Institute/NIH/DHHS	RFA-CA-24-014	02-Mar-2024 [Optional][LOI/Pre- App]	150,000 USD
	Contact Name K	elly Crotty, Ph.D.				
	Contact Telephone :2	240-255-0917				
	Contact Email <u>k</u> ı	elly.crotty@nih.gov				
	Sponsor Website					
	Program URL <u>L</u> i	ink to program URL				
	Deadline Dates (ALL) 0	2-Mar-2024 [Optional][LOI/Pre-App], 0	1-Apr-2024 , 01-Sep-2024	[Optional][LOI/Pre-Ap	p], 01-Oct-2024	
	P. av Synopsis si ir	he purpose of this Notice of Funding Op 50 specialized centers proposing to exp ccelerate progress for the parent study upport from the NCI Innovative Molecu acentivize independent validation and a communities. As a component of the NC evelopment of innovative tools and me	band upon original researce by incorporating a new to lar Analysis Technologies accelerate the suitability o I IMAT program, this NOF	ch question(s) from spe echnical approach or in (IMAT) program. Awar f these emerging techr O aims to promote into	ecific projects or othervistrument developed the developed the developed the developed the from this NOFO are nologies for appropriate developed the develop	vise nrough meant to e research
122689 <mark>S</mark>	•	ons for Incorporation of Novel NCI- e Cancer Research (P30 Clinical Trial	National Cancer Institute/NIH/DHHS	RFA-CA-24-015	02-Mar-2024 [Optional][LOI/Pre- App]	150,000 USD
	Contact Name K	elly Crotty, Ph.D.				
	Contact Telephone :2	240-255-0917				
	Contact Email <u>k</u>	elly.crotty@nih.gov				
	Sponsor Website					



Program URL Link to program URL

Deadline Dates (ALL) 02-Mar-2024 [Optional][LOI/Pre-App], 01-Apr-2024, 01-Sep-2024 [Optional][LOI/Pre-App], 01-Oct-2024

SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
	Synopsis	The purpose of this Notice of Funding Op Center Support Grants (CCSG) to support new technical approach or instrument de (IMAT) program into a pilot cancer resea promote interdisciplinary collaboration is independent validation and accelerate the accelerate scientific discovery.	an expansion of cancer leveloped through suppor rch project. As a comporn the development of inn	research conducted in a ca t from the NCI Innovative nent of the NCI IMAT prog novative tools and method	ancer center by inco Molecular Analysis <sup>-</sup> ram, this NOFO is m s as well as incentiv	rporating a Technologies eant to ize
111611		ecular and Cellular Analysis Technologies arch (R61 Clinical Trial Not Allowed)	National Cancer Institute/NIH/DHHS	RFA-CA-24-008	02-Mar-2024 [Optional][LOI/Pre- App]	450,000 USD
	Contact Name	Kelly Crotty, Ph.D.				
	Contact Telephone	240-255-0917				
	Contact Email	kelly.crotty@nih.gov				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	02-Mar-2024 [Optional][LOI/Pre-App], 03	L-Apr-2024 , 01-Sep-2024	l [Optional][LOI/Pre-App],	01-Oct-2024	
	Synopsis	This Notice of Funding Opportunity (NOF the early-stage development of highly in basic, clinical, or epidemiological cancer capabilities involving a high degree of ted features of cancer biology. Well-suited a areas of cancer biology, early detection a issues associated with cancer health disp widespread applicability but must be foc Projects proposing the application of exist target/question being pursued are not repart of a broader NCI-sponsored Innovation	novative technologies off research. The emphasis of chnical innovation for tar oplications must offer the and screening, clinical dia arities. Technologies pro used on improving molec sting technologies where esponsive to this solicitation	fering novel molecular or of of this NOFO is on supporting geting, probing, or assessing the potential to accelerate a gnosis, treatment, control posed for development manular and/or cellular character the novelty resides in the tion and will not be reviewed	cellular analysis capa ing the developmen ng molecular and ce nd/or enhance rese , epidemiology, and ay be intended to ha cterizations of cance biological or clinical ed. This funding opp	abilities for t of novel ellular arch in the l/or address ave er biology.
1 / /h /x	FA-CA-24-010 Innovative Biosp nd Clinical Cancer Research (R61	pecimen Science Technologies for Basic Clinical Trial Not Allowed)	National Cancer Institute/NIH/DHHS	RFA-CA-24-010	02-Mar-2024 [Optional][LOI/Pre- App]	450,000 USD



SPIN ID Title Sponsor Name Sponsor Number Deadline Date Amount
--

Contact Name Kelly Crotty, Ph.D.

Contact Telephone 240-255-0917

Contact Email kelly.crotty@nih.gov

Sponsor Website

Program URL Link to program URL

Deadline Dates (ALL) 02-Mar-2024 [Optional] [LOI/Pre-App], 01-Apr-2024, 01-Sep-2024 [Optional] [LOI/Pre-App], 01-Oct-2024

This Notice of Funding Opportunity (NOFO) solicits grant applications proposing exploratory research projects focused on the early-stage development of highly innovative technologies that improve the quality of the samples used for cancer research or clinical care. This includes new capabilities to address issues related to pre-analytical degradation of targeted analytes during the collection, processing, handling, and/or storage of cancer-relevant biospecimens. The overall goal is to support the development of highly innovative technologies capable of maximizing or otherwise interrogating the quality and utility of biological samples used for downstream analyses. This NOFO will support the development of tools, devices, Synopsis instrumentation, and associated methods to preserve or protect sample integrity, or establish verification criteria for quality

assessment/quality control and handling under diverse conditions. These technologies are expected to accelerate and/or enhance research in cancer biology, early detection and screening, clinical diagnosis, treatment, or epidemiology, or address issues associated with cancer health disparities, by reducing pre-analytical variations that affect biospecimen sample quality. Projects proposing the application of existing technologies where the novelty resides in the biological or clinical target/question being pursued are not responsive to this solicitation and will not be reviewed. This funding opportunity is part of a broader NCI-sponsored Innovative Molecular Analysis Technologies (IMAT) Program.

RFA-CA-24-011 -- Advanced Development and Validation of Emerging 02-Mar-2024 **National Cancer** 900,000 122679 Biospecimen Science Technologies for Basic and Clinical Cancer Research RFA-CA-24-011 [Optional][LOI/Pre-Institute/NIH/DHHS USD (R33 Clinical Trial Not Allowed) App]

Contact Name Kelly Crotty, Ph.D.

Contact Telephone 240-255-0917

Contact Email kelly.crotty@nih.gov

Sponsor Website

Program URL Link to program URL

Deadline Dates (ALL) 02-Mar-2024 [Optional] [LOI/Pre-App], 01-Apr-2024, 01-Sep-2024 [Optional] [LOI/Pre-App], 01-Oct-2024

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount

This Notice of Funding Opportunity (NOFO) solicits grant applications proposing exploratory research projects focused on further development and validation of emerging technologies that improve the quality of the samples used for cancer research or clinical care. This includes new capabilities to address issues related to pre-analytical degradation of targeted analytes during the collection, processing, handling, and/or storage of cancer-relevant biospecimens. This NOFO solicits R33 applications where major feasibility gaps for the technology or methodology have been overcome, as demonstrated with supportive preliminary data, but still require further development and rigorous validation to encourage adoption by the research community. The overall goal is to support the development of highly innovative technologies capable of maximizing or otherwise interrogating the quality and utility of biological samples used for downstream analyses. This NOFO will support the development of tools, devices, instrumentation, and associated methods to preserve or protect sample integrity, or establish verification criteria for quality assessment/quality control and handling under diverse conditions. These technologies are expected to accelerate and/or enhance research in cancer biology, early detection and screening, clinical diagnosis, treatment, or epidemiology, or address issues associated with cancer health disparities, by reducing pre-analytical variations that affect biospecimen sample quality. Projects proposing to use existing technologies where the novelty resides in the application of the technology or the biological or clinical question being pursued, and not the technical capabilities being developed, are not appropriate for this NOFO and will not be reviewed. This funding opportunity is part of a broader NCI-sponsored Innovative Molecular Analysis Technologies (IMAT) Program.

RFA-CA-24-013 -- Revision Applications for Incorporation of Novel NCI-122686 Supported Technology to Accelerate Cancer Research (U01 Clinical Trial Optional)

Synopsis

National Cancer Institute/NIH/DHHS

RFA-CA-24-013

02-Mar-2024 [Optional][LOI/Pre-App]

150,000 USD

Contact Name Kelly Crotty, Ph.D.

Contact Telephone :240-255-0917

Contact Email kelly.crotty@nih.gov

Sponsor Website

Program URL Link to program URL

Day III - - Day - - (ALL) 02 A4 - 2024 [Oath - - III | OL/Day A - - I

Deadline Dates (ALL) 02-Mar-2024 [Optional][LOI/Pre-App], 01-Apr-2024 , 01-Sep-2024 [Optional][LOI/Pre-App], 01-Oct-2024

The purpose of this Notice of Funding Opportunity (NOFO) is to encourage revision applications from currently funded NCI U01 research projects. The applicants should propose to expand upon the original research question(s) or otherwise accelerate progress for the parent study by incorporating a new technical approach or instrument developed through support from the NCI Innovative Molecular Analysis Technologies (IMAT) program. Awards from this NOFO are meant to incentivize independent validation and accelerate the suitability of these emerging technologies for appropriate research

SPIN ID Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
	communities. As a component of the NC development of innovative tools and me				ation in the
RFA-CA-24-012 Revision Applic 122683 Supported Technology to Acceler Optional)	ations for Incorporation of Novel NCI- rate Cancer Research (R01 Clinical Trial	National Cancer Institute/NIH/DHHS	RFA-CA-24-012	02-Mar-2024 [Optional][LOI/Pre- App]	150,000 USD
Contact Name	Kelly Crotty, Ph.D.				
Contact Telephone	:240-255-0917				
Contact Emai	kelly.crotty@nih.gov				
Sponsor Website					
Program URL	Link to program URL				
Deadline Dates (ALL)	02-Mar-2024 [Optional][LOI/Pre-App], 0	1-Apr-2024 , 01-Sep-202	4 [Optional][LOI/Pre-A	pp], 01-Oct-2024	
Synopsis	The purpose of this Notice of Funding Op R01 research projects. The applicants sh accelerate progress for the parent study support from the NCI Innovative Molecu incentivize independent validation and a communities. As a component of the NCI development of innovative tools and me	ould propose to expand by incorporating a new that lar Analysis Technologies accelerate the adoption of I IMAT program, this NO	upon the original reseatechnical approach or its (IMAT) program. Awa of these emerging techits or improve in	rch question(s) or othen nstrument developed t rds from this NOFO are nologies by appropriate terdisciplinary collabor	erwise hrough e meant to e research ation in the
106265 Basic Research in Cancer Health I	Disparities (R03 Clinical Trial Not Allowed)	National Cancer Institute/NIH/DHHS	PAR-21-324	16-Feb-2024	100,000 USD
Contact Name	Anu Sharman, Ph.D.				
Contact Telephone	240-276-6250				
Contact Emai	sharmananu@nih.gov				
Sponsor Website					
Program URL	Link to program URL				
Deadline Dates (ALL)	16-Feb-2024 , 16-Mar-2024 , 16-Jun-202	4 , 16-Jul-2024			
Synopsis	This Funding Opportunity Announcemer basic, mechanistic research into the biol				



SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
		will support projects on cancer health disprojects should propose innovative studiemechanistic studies of biological factors cancer biology or cancer prevention strasecondary data analyses.	es designed to investigat associated with cancer di	e biological/genetic bases sparities, including those r	of cancer disparitie	s, such as (1) earch in
1116787	Mechanisms that Impact Cancer I rial Not Allowed)	Risk after Bariatric Surgery (R21 Clinical	National Cancer Institute/NIH/DHHS	PAR-21-332	L6-Feb-2024	550,000 USD
	Contact Name	Edward R. Sauter, M.D., Ph.D.				
	Contact Telephone	240-276-7657				
	Contact Email	edward.sauter@nih.gov				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	16-Feb-2024 , 16-Mar-2024 , 16-Jun-202	4 , 16-Jul-2024			
	Synopsis	Through this Funding Opportunity Annou of investigator-initiated studies addressing talented scientists who study bariatric sures weight loss and diabetes.	ng mechanisms by which	bariatric surgery impacts of	ancer risk, and see	ks to draw in
122738 <u>N</u>		lopment and Validation of Emerging echnologies for Basic and Clinical Cancer llowed)	National Cancer Institute/NIH/DHHS	RFA-CA-24-009 [	)2-Mar-2024 Optional][LOI/Pre- App]	900,000 USD
	Contact Name	Kelly Crotty, Ph.D.				
	Contact Telephone	240-255-0917				
	Contact Email	kelly.crotty@nih.gov				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	02-Mar-2024 [Optional][LOI/Pre-App], 0				
	Synopsis	This Notice of Funding Opportunity Anno projects focused on further developmen				



SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount

probing, or assessing molecular and cellular features of cancer biology for basic, clinical, or epidemiological cancer research. This NOFO solicits R33 applications where major feasibility gaps for the technology or methodology have been overcome, as demonstrated with supportive preliminary data, but still requires further development and rigorous validation to encourage adoption by the research community. Well-suited applications must offer the potential to accelerate and/or enhance research in the areas of cancer biology, early detection and screening, clinical diagnosis, treatment, control, epidemiology, and/or address issues associated with cancer health disparities. Technologies proposed for development may be intended to have widespread applicability but must be focused on improving molecular and/or cellular characterizations of cancer. Projects proposing the application of existing technologies where the novelty resides in the biological or clinical target/question being pursued are not responsive to this solicitation and will not be reviewed. This funding opportunity is part of a broader NCI-sponsored Innovative Molecular Analysis Technologies (IMAT) Program.

Integration of Imaging and Fluid-Based Tumor Monitoring in Cancer 499,999 **National Cancer** 105645 PAR-21-290 07-Jan-2024 Therapy (R01 Clinical Trial Optional) Institute/NIH/DHHS USD

Contact Name Shane Woodward

Contact Telephone 240-276-6624

Contact Email woodwars@mail.nih.gov

Sponsor Website

Program URL Link to program URL

Deadline Dates (ALL)

07-Jan-2024, 05-Feb-2024, 05-Mar-2024, 07-May-2024, 05-Jun-2024, 05-Jul-2024, 07-Sep-2024, 05-Oct-2024, 07-Jan-

National Cancer Institute (NCI) invites applications for research projects that integrate imaging and fluid-based tumor monitoring (liquid biopsy) assays during cancer therapy in patients to determine the optimal use of those modalities in the characterization of therapy response and/or emergence of resistance. This FOA will use the NIH Research Project (R01) award mechanism.

RFA-CA-24-021 -- Cancer Adoptive Cellular Therapy Network (Can-ACT) for National Cancer Pediatric Cancers (UG3/UH3 Clinical Trial Required)

Institute/NIH/DHHS

RFA-CA-24-021

05-Feb-2024 Not [Optional][LOI/Pre-Specified App]

Contact Name Anju Singh, B.V.Sc, Ph.D. Contact Telephone 240-276-7603

Contact Email anju.singh@nih.gov

			_				
SPIN ID	Program Title	Sp	oonsor Name	Sponsor Number		Deadline Date	Funding Amount
	Sponsor Website						
	Program URL	Link to progr	ram URL				
	Deadline Dates (ALL)	05-Feb-2024	[Optional][LOI/Pre-App], 0	5-Mar-2024			
	Synopsis	innovation a younger) wit new drug (IN therapies in Adoptive Cel of solid tumo	s Notice of Funding Opportuind establishment of adoptive the solid tumors. Specifically, ND)-enabling studies that lay pediatric patients with solid Ilular Therapy (Can-ACT) New ors in pediatric and adult can to preclinical and translation	re cellular therapy clinical UG3 phase of the awards groundwork for UH3 earl tumors. The successful aptwork, dedicated to developer patients. This Network	trials for treatment of ped will support preclinical, trally-stage clinical trials testin oplications will add to -the oping innovative cell therally of investigators will, through	iatric patients (18 anslational and inv g adoptive immun newly established py approaches for bugh novel and col	years or vestigational ne cell l Cancer the treatment
1 / / / / / 1	Notice of Special Interest (NOSI): A he Development of Digital Twins			National Cancer Institute/NIH/DHHS	NOT-CA-24-015 2	1-Mar-2024	250,000 USD
	Contact Name	Jeff Buchsba	um, M.D., Ph.D., A.M.				
	Contact Telephone	240-276-569	90				
	Contact Email	jeff.buchsba	um@nih.gov				
	Sponsor Website						
	Program URL	Link to progr	ram URL				
	Deadline Dates (ALL)	21-Mar-2024	4				
	Synopsis	Technology ( administration in the development	of Cancer Treatment and Di (CBIIT) at the National Cance we supplement opportunity opment of digital twins. For (DTC) is a "a virtual represer	er Institute (NCI) announce that seeks to support colla the purposes of this notice	e the Digital Twins Radiatic aborative, multidisciplinary e, a digital twin as defined	on Oncology (DTRC research in radiat by the Digital Twir	D) tion oncology 1
113232 <u>E</u>	Bioengineering Research Grants (I	BRG) (R01 Cli	nical Trial Not Allowed)	National Cancer Institute/NIH/DHHS	PAR-22-242 0	7-Jan-2024	Not Specified
	Contact Name Contact Telephone	-					



		······································	Opportunities			
SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
	Contact Email	divir@mail.nih.gov				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	07-Jan-2024 , 05-Feb-2024 , 05-Mar-202 2024 , 07-Jan-2025 , 05-Feb-2025 , 05-M	•	•		24 , 05-Nov-
	Synopsis	sciences that: 1) apply a multidisciplinar integrate, optimize, validate, translate of unmet need and address specific resear capable of enhancing our understanding propose design-directed, developmental small teams applying an integrative applicational science.	or accelerate adoption of ch or clinical problem in b g of health and disease, a ll, discovery-driven, or hy	promising tools, methods ar pasic, translational, and/or c nd/or c) improve practice of pothesis-driven research, ar	nd techniques: a) linical science and medicine. Applicated and this FOA is applicated	that fulfill and practice, b) ations may ropriate for
104713	-	ICCIH Multi-Site Investigator-Initiated nterventions (Collaborative UG3/UH3	National Center for Complementary and Integrative Health/NIH/DHHS	PAR-21-243 2	0-Feb-2024	Not Specified
	Contact Name	Lanay Mudd, Ph.D.				
	Contact Telephone	301-594-9346				
	Contact Email	lanay.mudd@nih.gov				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	20-Feb-2024 , 11-Mar-2024				
		This Funding Opportunity Announcement		<del>-</del>		



(e.g. efficacy, effectiveness or pragmatic trials) to study the effects of complementary and integrative health approaches with physical and/or psychological therapeutic inputs (often called mind and body interventions) in NCCIH designated areas Synopsis of high research priority. Clinical Coordinating Centers should develop and implement the proposed fully powered multi-site clinical trial. The objective of a Clinical Coordinating Center application is to present the scientific rationale and a comprehensive scientific and operational plan for the clinical trial. Clinical Coordinating Center applications are expected to describe plans for project management, participant recruitment and retention strategies, performance milestones, scientific

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	------------------	--------------	----------------	---------------	-------------------

conduct, and dissemination of results. Clinical Coordinating Center applications submitted under this FOA will utilize a twophase, milestone-driven cooperative agreement (UG3/UH3) funding mechanism. In addition, an accompanying Data Coordinating Center application (U24), submitted under PAR-21-242 proposing a data analysis and data management plan for the clinical project is required. Both a Clinical Coordinating Center application and a corresponding Data Coordinating Center (DCC) application need to be submitted simultaneously for consideration by NCCIH. For additional information about the mission, strategic vision, and research priorities of the NCCIH, applicants are encouraged to consult the NCCIH website: (https://nccih.nih.gov/about/plans). Applicants are encouraged to contact the appropriate the Scientific/Research contact for the area of science for which they are planning to develop an application prior to submitting to this FOA.

NCCIH Multi-Site Feasibility Clinical Trials of Mind and Body Interventions (R01 Clinical Trial Required)

National Center for Complementary and Integrative Health/NIH/DHHS

PAR-21-241

20-Feb-2024

Not Specified

Contact Name Della White, Ph.D.

Contact Telephone 301-827-6538

Contact Email della.white@nih.gov

Sponsor Website

Program URL Link to program URL

Deadline Dates (ALL) 20-Feb-2024, 11-Mar-2024

the science area of the planned application.

This Funding Opportunity Announcement (FOA) invites applications for investigator-initiated clinical trials of complementary and integrative health approaches with physical and/or psychological therapeutic inputs (often called mind and body interventions) in NCCIH-designated areas of high research priority. Applications submitted under this FOA are expected to propose a multi-site feasibility clinical trial to assess whether the intervention can be delivered with fidelity across sites; demonstrate feasibility of recruitment, accrual, and randomization of participants across sites; demonstrate participant adherence to the intervention, as well as retention of participants throughout the study across sites; and/or demonstrate Synopsis feasibility of data collection across sites in preparation for a future fully powered, multi-site efficacy/ effectiveness trial. The need for multi-site feasibility trials is expected to be justified by sufficient preliminary data from previous single site feasibility or acceptability trial(s) or the published literature. This FOA will not support clinical trials that determine efficacy or effectiveness. The data collected should be used to fill gaps in scientific knowledge and be necessary to develop a competitive fully powered multi-site clinical trial that has the potential to make a significant impact on public health Prior to submitting to this FOA, applicants are encouraged to contact the appropriate NCCIH Scientific/Research contact person for

SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
104712	~	CIH Multi-Site Investigator-Initiated Interventions (Collaborative U24 Clinical	National Center for Complementary and Integrative Health/NIH/DHHS	PAR-21-242	20-Feb-2024	Not Specified
	Contact Name	Lanay Mudd, Ph.D.				
	Contact Telephone	301-594-9346				
	Contact Email	lanay.mudd@nih.gov				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	20-Feb-2024 , 11-Mar-2024				
	Synopsis	collaborating Data Coordinating Center (Phase III and beyond) application subm Clinical Coordinating Center (CCC) application overall project coordination, and clinical trial. Both a DCC application and consideration by NCCIH. Trials for which a high priority by the Center. For additionapplicants are encouraged to consult NCC appropriate the Scientific/Research content of the submitting to this FOA	itted under PAR-21-243. The objective of the dadministrative, data material accorresponding CCC apporthis FOA applies must be unal information about the CCIH website: (http://www.	The DCC application made DCC application is to an agement, and biost lication need to be surelevant to the reseate mission, strategic visw.nccih.nih.gov). Appl	nust be specific to the copropose a compreher atistical support for the bmitted simultaneously rch mission of NCCIH ausion, and research prioricants are encouraged to	ompanion asive plan that e proposed for ad considered ities of NCCIH, co contact the
1 / 2 / 5 /	Feasibility Clinical Trials of Mind a Priority Research Topics (R34 Clin	and Body Interventions for NCCIH High ical Trial Required)	National Center for Complementary and Integrative Health/NIH/DHHS	PAR-24-084	20-Feb-2024	450,000 USD
	Contact Name	Jennifer N. Baumgartner, Ph.D.				
	Contact Telephone	301-402-4084				
	Contact Email	jennifer.baumgartner@nih.gov				
	Sponsor Website					
	Program URL	Link to program URL				



SPIN ID	Program	Sponsor Name	Sponsor Number	Deadline Date	Funding
SPIN ID	Title	Sponsor Name	Sponsor Number	Deaumie Date	Amount

20-Feb-2024, 11-Mar-2024, 20-Jun-2024, 15-Jul-2024, 21-Oct-2024, 13-Nov-2024, 20-Feb-2025, 10-Mar-2025, 20-Jun-Deadline Dates (ALL) 2025, 14-Jul-2025, 20-Oct-2025, 17-Nov-2025, 20-Feb-2026, 17-Mar-2026, 22-Jun-2026, 13-Jul-2026, 20-Oct-2026, 13-Nov-2026

The goal of this notice of funding opportunity (NOFO) is to support feasibility trials of complementary and integrative health approaches with physical and/or psychological therapeutic inputs (often called mind and body interventions) for conditions that have been identified by NCCIH as high-priority research topics. This funding opportunity is intended to support feasibility clinical trials that provide new information that are scientifically necessary for the planning and conduct of a subsequent clinical efficacy or effectiveness study, pragmatic trial, or dissemination and implementation trial within NCCIH's mission. NCCIH expects that applications to this NOFO will describe the planned future clinical trial and in so doing demonstrate that the proposed (R34) research is scientifically necessary to design or plan the subsequent competitive fullscale clinical trial. Under this R34, the data collected should be used to fill gaps in scientific knowledge necessary to develop a competitive full-scale clinical trial, including, but not limited to the following: examining feasibility and acceptability of Synopsis interventions lacking published data; tailoring or adapting the content or structure of an intervention to a specific population, modality, or setting; refining the intervention to determine the most appropriate frequency or duration; determining feasibility of recruitment, retention, and data collection procedures; refining and assessing the feasibility of protocolized multi-component interventions; or examining acceptability and adherence of control conditions. The subsequent full-scale clinical trial should have the potential to make a significant impact on public health. Prior to submitting to this NOFO, applicants are encouraged to contact the appropriate NCCIH Scientific/Research contact person for the science area of the planned application. This NOFO requires a Plan for Enhancing Diverse Perspectives (PEDP), which will be assessed as part of the scientific and technical peer review evaluation. Applications that fail to include a PEDP will be

considered incomplete and will be withdrawn. Applicants are strongly encouraged to read the NOFO instructions carefully

Clinical Coordinating Center for NCCIH Multi-Site Investigator-Initiated 123160 Clinical Trials of Mind and Body Interventions (Collaborative UG3/UH3 Clinical Trial Required)

**National Center for** Complementary and Integrative Health/NIH/DHHS

PAR-24-090

11-Mar-2024

Not Specified

Contact Name Elizabeth Ginexi, Ph.D.

Contact Telephone 301-827-0160

Contact Email elizabeth.ginexi@nih.gov

and view the available PEDP guidance material.

Sponsor Website

Program URL Link to program URL

			• •			
SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
	Deadline Dates (ALL)	11-Mar-2024 , 20-Jun-2024 , 15-Jul-2024 2026 , 22-Jun-2026 , 13-Jul-2026	, 20-Feb-2025 , 10-Mar-	2025 , 20-Jun-2025 , 14	-Jul-2025 , 20-Feb-202	.6 , 17-Mar-
	Synopsis	This notice of funding opportunity (NOFC collaborating Data Coordinating Center ((Phase III and beyond) application submicompanion Clinical Coordinating Center (comprehensive plan that provides overal support for the proposed clinical trial. Besimultaneously for consideration by NCC NCCIH and considered a high priority by research priorities of NCCIH, applicants a website (http://www.nccih.nih.gov). Ap the area of science for which they are plarequires a Plan for Enhancing Diverse Pereview evaluation. Applications that fail are strongly encouraged to read the NOF	DCC) application that accepted under companion P (CCC) application. The object coordination, a path a DCC application and IH. Trials for which this late Center. For additional are encouraged to consult applicants are encouraged anning to develop an apprespectives (PEDP), which to include a PEDP will be	companies an investigated AR-24-090. The DCC applicative of the DCC applied administrative, data as a corresponding CCC and a corresponding CCC and a corresponding to the NCCIH to contact the approproblem of the appropriate of the appropriate app	tor-initiated multi site plication must be specication is to propose a management, and big application need to be elevant to the researce mission, strategic visitate Scientific/Research to the scientific and the and will be withdraw	clinical trial cific to the  ostatistical submitted ch mission of cion, and ch contact for nis NOFO cechnical peer
1/3/4/	NCCIH Multi-Site Feasibility Clinic R01 Clinical Trial Required)	cal Trials of Mind and Body Interventions	National Center for Complementary and Integrative Health/NIH/DHHS	PAR-24-083	20-Feb-2024	Not Specified
	Contact Name	Pete Murray, Ph.D.				
	Contact Telephone	301-496-4054				
	Contact Email	peter.murray@nih.gov				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	20-Feb-2024 , 11-Mar-2024 , 20-Jun-202- 2025 , 20-Oct-2025 , 18-Nov-2025 , 20-Fe	4 , 15-Jul-2024 , 21-Oct-2 eb-2026 , 17-Mar-2026 ,	2024 , 13-Nov-2024 , 20 22-Jun-2026 , 14-Jul-20	-Feb-2025 , 20-Jun-20 26 , 20-Oct-2026 , 17-	25 , 15-Jul- Nov-2026
	Synopsis	This notice of funding opportunity (NOFC integrative health approaches with physic interventions) in NCCIH-designated areas propose a multisite feasibility clinical tria	cal and/or psychological s of high research priorit	therapeutic inputs (oft y. Applications submitte	en called mind and bo ed under this NOFO ar	dy e expected to

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
				/	

and conduct of a subsequent clinical efficacy or effectiveness study, pragmatic trial, or dissemination and implementation trial within NCCIH's mission. NCCIH expects that applications to this NOFO will describe the planned future clinical trial and in so doing demonstrate that the proposed (R01) research is scientifically necessary to design or plan the subsequent fully powered, full-scale clinical trial. Under this R01, the data collected should be used to fill gaps in scientific knowledge, including, but not limited to the following: assessing whether the intervention can be delivered with fidelity across sites; demonstrating feasibility of recruitment, accrual, and randomization of participants across sites; demonstrating participant adherence to the intervention, as well as retention of participants throughout the study across sites; refining and assessing the feasibility of protocolized multimodal interventions, and/or demonstrating feasibility of data collection across sites in preparation for a future fully powered, multisite efficacy or effectiveness trial. The need for multisite feasibility trials is expected to be justified by sufficient preliminary data from previous single site feasibility or acceptability trial(s) or the published literature. The data collected should be used to fill gaps in scientific knowledge and be necessary to develop a competitive fully powered multisite clinical trial that has the potential to make a significant impact on public health. Prior to submitting to this NOFO, applicants are encouraged to contact the appropriate NCCIH Scientific/Research contact person for the science area of the planned application. This NOFO requires a Plan for Enhancing Diverse Perspectives (PEDP), which will be assessed as part of the scientific and technical peer review evaluation. Applications that fail to include a PEDP will be considered incomplete and will be withdrawn. Applicants are strongly encouraged to read the NOFO instructions carefully and view the available PEDP guidance material.

Data Coordinating Center for NCCIH Multi-Site Investigator-Initiated 123155 Clinical Trials of Mind and Body Interventions (Collaborative U24 Clinical Trial Required)

National Center for Complementary and Integrative Health/NIH/DHHS

PAR-24-087

11-Mar-2024

Not Specified

Contact Name Elizabeth Ginexi, Ph.D.

Contact Telephone 301-827-0160

Contact Email elizabeth.ginexi@nih.gov

Sponsor Website

Program URL Link to program URL

11-Mar-2024, 20-Jun-2024, 15-Jul-2024, 20-Feb-2025, 10-Mar-2025, 20-Jun-2025, 14-Jul-2025, 20-Feb-2026, 17-Mar-Deadline Dates (ALL) 2026 , 22-Jun-2026 , 13-Jul-2026

This notice of funding opportunity (NOFO), utilizing the U24 grant funding mechanism, encourages applications for a Synopsis collaborating Data Coordinating Center (DCC) application that accompanies an investigator-initiated multi site clinical trial (Phase III and beyond) application submitted under companion PAR-24-090. The DCC application must be specific to the

|--|

companion Clinical Coordinating Center (CCC) application. The objective of the DCC application is to propose a comprehensive plan that provides overall project coordination, and administrative, data management, and biostatistical support for the proposed clinical trial. Both a DCC application and a corresponding CCC application need to be submitted simultaneously for consideration by NCCIH. Trials for which this NOFO applies must be relevant to the research mission of NCCIH and considered a high priority by the Center. For additional information about the mission, strategic vision, and research priorities of NCCIH, applicants are encouraged to consult the NCCIH

website (http://www.nccih.nih.gov). Applicants are encouraged to contact the appropriate Scientific/Research contact for the area of science for which they are planning to develop an application prior to submitting to this NOFO. This NOFO requires a Plan for Enhancing Diverse Perspectives (PEDP), which will be assessed as part of the scientific and technical peer review evaluation. Applications that fail to include a PEDP will be considered incomplete and will be withdrawn. Applicants are strongly encouraged to read the NOFO instructions carefully and view the available PEDP guidance material.

Investigator Initiated Clinical Trials of Complementary and Integrative 123153 Interventions Delivered Remotely or via mHealth (R01 Clinical Trial Required)

**National Center for** Complementary and Integrative Health/NIH/DHHS

PAR-24-086

20-Feb-2024

Not Specified

Contact Name Beda Jean-Francois, Ph.D.

Contact Telephone 202-313-2144

Contact Email beda.jean-francois@nih.govr01

Sponsor Website

Program URL Link to program URL

20-Feb-2024, 11-Mar-2024, 20-Jun-2024, 15-Jul-2024, 21-Oct-2024, 13-Nov-2024, 20-Feb-2025, 10-Mar-2025, 20-Jun-Deadline Dates (ALL) 2025, 14-Jul-2025, 20-Oct-2025, 17-Nov-2025, 20-Feb-2026, 17-Mar-2026, 22-Jun-2026, 13-Jul-2026, 20-Oct-2026, 13-

This Notice of Funding Opportunity (NOFO) encourages applications for investigator-initiated fully remotely delivered and

Nov-2026

conducted clinical trials to assess the efficacy or effectiveness of complementary and integrative health interventions in NCCIH- designated areas of high research priority. Applications submitted under this NOFO are expected to propose a remotely delivered and conducted fully powered clinical trial with no in-person contact between research staff and study participants and may utilize mHealth tools or technologies. Applicants must provide justification for the remotely delivered approach and provide preliminary data on the feasibility and safety of the approach, along with evidence that the

Synopsis

intervention has promise of clinical benefit. Applicants are encouraged to contact the appropriate NCCIH Scientific/Research contact for the area of science for which they are planning to develop an application prior to submitting

SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
		to this NOFO. This NOFO requires a Plar scientific and technical peer review evaluable will be withdrawn. Applicants are strong guidance material.	uation. Applications that	fail to include a PEDP w	rill be considered incor	nplete and
	RFA-HL-23-003 Physician Scient Science Research (R00 - Clinical T	tist Transition to Independence in Blood rial Optional)	National Heart, Lung, and Blood Institute/NIH/DHHS	RFA-HL-23-003	27-Feb-2024 [Optional][LOI/Pre- App]	750,000 USD
	Contact Name	Lisbeth Welniak, PhD				
	Contact Telephone	301-435-0050				
	Contact Email	welniakla@mail.nih.gov				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	27-Feb-2024 [Optional][LOI/Pre-App], 28	8-Mar-2024			
	Synopsis	The purpose of the NHLBI Career Pathwal increase and maintain a strong cohort of This program is designed to facilitate a tidegree from mentored research position opportunity for current RFA-HL-20-001 oppogram. In the R00 phase, successful blocontinue their research activity with supcompetition review.	new and talented, NHLB mely transition of outstants to independent, tenure or RFA-HL-20-002 K99 awa bood science physician scie	I supported, independe nding blood science reso -track or equivalent fac ardees to apply for the i entist scholars will recei	nt investigators in bloce earchers with a clinical ulty positions. This FO ndependent phase (RC ve up to three years o	od science. I doctorate A offers the OO) of the f funding to
1113477	RFA-HL-23-004 NHLBI Outstand Trial Optional)	ding Investigator Award (OIA) (R35 Clinical	National Heart, Lung, and Blood Institute/NIH/DHHS	RFA-HL-23-004	16-Jan-2024 [Optional][LOI/Pre- App]	4,900,000 USD
	Contact Name	Narasimhan Danthi, Ph.D.				
	Contact Telephone	301-451-5170				
	Contact Email	ndanthi@nhlbi.nih.gov				
	Sponsor Website					
	Program URL	Link to program URL				



SPIN ID	Program Title	Sponsor Name	Sponsor Number		מזכנו מתווחבמנוו	Funding Amount
		16-Jan-2024 [Optional][LOI/Pre-App], 15 The purpose of the NHLBI Outstanding In providing long-term support and increas are currently PD/PIs on at least two NHL their ability to make major contributions research program, rather than a research individual grant awards. The OIA will support oil will provide investigators increased discoveries in new directions. It will also timeframe. Research supported by the CP Provide a stable funding environment, the Accelerate scientific innovation by enable be bound to specific aims proposed in accelerate.	nvestigator Award (OIA) is sed flexibility to experience. BI R01-equivalent awards to heart, lung, blood and h project, by providing the poort the research prografreedom to conduct research allow PD/PIs to take great DIA must be within the scothereby improving product ling flexibility in pursuing dvance of the studies; Records	s to promote scientific project Program Directors/Pris and whose outstanding it sleep (HLBS) research. The primary and most likely mof NHLBI-funded invest arch that breaks new grouter risks and to pursue respected of the NHLBI mission. It is to provide the time researchers aduce the time researchers.	oductivity and innovancipal Investigators (record of research de he OIA is intended to sole source of NHLB tigators for up to seven und or extends previous esearch that requires It is anticipated that ole, ambitious, creatings they arise, since PE is spend writing grant	PD/PIs) who emonstrates is support a I funding on en years. The bus a longer is the OIA will: we research; D/PIs will not applications
	RFA-HL-23-005 NHLBI Emerging Trial Optional)	and managing multiple grant awards, the commitment to research through increa mentoring students and junior scientists Investigator Award (EIA) (R35 Clinical	sed stability of funding; a	nd Enable PD/PIs to devo	_	
	Contact Name	Narasimhan Danthi, Ph.D.	, ,		11.2	
	Contact Telephone	·				
		ndanthi@nhlbi.nih.gov				
	Sponsor Website					
	•	Link to program URL				
	•	16-Jan-2024 [Optional][LOI/Pre-App], 15	5-Feb-2024 . 26-Mar-2024	[Optional][LOI/Pre-App]		
	Synopsis	The purpose of the NHLBI Emerging Inverproviding long-term support and increase are currently PD/PIs on at least two NHL	estigator Award (EIA) is to sed flexibility to experienc BI R01-equivalent awards s to heart, lung, blood and h project, by providing the	promote scientific produced Program Directors/Prisand whose outstanding Isleep (HLBS) research. Te primary and most likely	ncipal Investigators ( record of research de he EIA is intended to sole source of NHLB	PD/PIs) who emonstrate support a I funding on



SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
		EIA will provide investigators increased f discoveries in new directions. It will also timeframe. Research supported by the E Provide a stable funding environment, th Accelerate scientific innovation by enabl be bound to specific aims proposed in ac and managing multiple grant awards, the commitment to research through increase mentoring students and junior scientists	allow PD/PIs to take great IA must be within the scop tereby improving producti ing flexibility in pursuing n Ivance of the studies; Red ereby allowing more time sed stability of funding; an	ter risks and to pursue rese be of the NHLBI mission. It ivity and facilitating nimble new research directions as to uce the time researchers so to be devoted to conduction and Enable PD/PIs to devote	earch that requires is anticipated that e, ambitious, creati they arise, since P pend writing grant ng research; Facilit	a longer the EIA will: ive research; D/PIs will not t applications tate PD/PIs'
		NIAID Administrative Supplement to untermeasures Against Chemical Threats	National Institute of Allergy and Infectious Diseases/NIH/DHHS	NOT-AI-22-030 0:	1-Mar-2024	100,000 USD
	Contact Name	Dave Yeung, Ph.D.				
	Contact Telephone	301-796-7237				
	Contact Email	dy70v@nih.gov				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	01-Mar-2024				
	Synopsis	The NIAID is inviting administrative supp the research and early development of n their MCM research focus into this critical additional supplemental work. The proportion award.	nedical countermeasures ( al field. There must be suf	(MCMs) against chemical the ficient progress on the pare	hreats to allow the ent project to just	em to expand ify the
121313 <u>L</u>		th Administration Development Award for Institutions (G11 Clinical Trial Not	National Institute of Allergy and Infectious Diseases/NIH/DHHS	PAR-23-300 13	3-Mar-2024	100,000 USD
	Contact Name	Madelyn Reyes, DNP, FAAN				
	Contact Telephone	301-594-5945				



Contact Email <u>AlTrainingHelpDesk@niaid.nih.gov</u>

		_	• •			
SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
	· ·	Link to program URL 13-Mar-2024, 13-Mar-2025, 13-Mar-20	26			
	The purpose of this notice of funding opportunity (NOFO) is to invite applications from research institutions in low- and middle-income countries (LMICs) to provide senior administrators from these institutions with advanced training in the management of NIH grants. The goal is to improve oversight of NIAID grant awards and compliance with NIH funding pand Federal research funding requirements for NIAID-supported foreign institutions in LMICs.					
		y Research to Accelerate Hepatitis B Cure BV (U19 Clinical Trial Not Allowed)	National Institute of Allergy and Infectious Diseases/NIH/DHHS	RFA-AI-23-057 [	.2-Feb-2024 Optional][LOI/Pre- .pp]	Not Specified
	Contact Name	Josh Radke, PhD				
	Contact Telephone	301-761-6525				
	Contact Email	josh.radke@nih.gov				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	12-Feb-2024 [Optional][LOI/Pre-App], 13	3-Mar-2024			
	The purpose of this Notice of Funding Opportunity (NOFO) is to support research to better understand the impact of hand viral heterogeneity on pathogenesis of disease, viral persistence, and immunopathology of Hepatitis B (HBV) and i cure strategies for HBV in people living with HIV (PLWH). Applicants will establish multidisciplinary teams that span the clinical and basic/translational research arenas and establish an observational cohort to accelerate discovery and increclinical impact.					
122105 P		Preclinical Development of Biological ted Cells (UG3/UH3 Clinical Trial Not	National Institute of Allergy and Infectious Diseases/NIH/DHHS	RFA-AI-23-060 [	.2-Feb-2024 Optional][LOI/Pre- App]	Not Specified
	Contact Telephone	stephen.smiley@nih.gov				



SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
	Program URL	Link to program URL				
	Deadline Dates (ALL)	12-Feb-2024 [Optional][LOI/Pre-App], 1	3-Mar-2024			
	Synopsis	The purpose of this Notice of Funding O development of innovative biological pr but are not limited to broadly neutralizing	oducts that safely and spe	cifically kill HIV-infected o	ells. Products of in	terest include
	NIAID Research Opportunities for Promote Workforce Diversity (RO	New and "At-Risk" Investigators to 1 Clinical Trial Optional)	National Institute of Allergy and Infectious Diseases/NIH/DHHS	PAR-22-241	07-Jan-2024	Not Specified
	Contact Name	Diane Adger-Johnson, MPH				
	Contact Telephone					
	Contact Email	AlTrainingHelpDesk@niaid.nih.gov				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	07-Jan-2024 , 05-Feb-2024 , 05-Mar-202 2024 , 07-Jan-2025 , 05-Feb-2025 , 05-N	•		•	024 , 05-Nov-
	Synopsis	The purpose of this funding opportunity mission. This FOA seeks to support either successfully for substantial, independent support as a PD/PI on a substantial indegrant award in the current fiscal year, we diverse backgrounds, including those from	er (a) a New Investigator (I t funding from NIH, or (b) pendent research award a ill have no substantial reso	NI), an individual who has are an 'At-Risk' investigat and unless successful in se earch grant funding in the	not previously con or, an individual w curing a substantia following fiscal ye	npeted ho had prior Il research
1/1/5/	HIV Vaccine Research and Design Allowed)	(HIVRAD) Program (P01 Clinical Trial Not	National Institute of Allergy and Infectious Diseases/NIH/DHHS	PAR-24-037	13-Mar-2024	12,500,000 USD
	Contact Name	Bimal Chakrabarti, Ph.D.				
	Contact Telephone	240-627-3385				
	Contact Email	bimal.chakrabarti@nih.gov				
	Sponsor Website					



	Program Fitle	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
	Drogram LIDI	Link to program URL				
	· ·		20			
	Deadline Dates (ALL)	13-Mar-2024, 13-Mar-2025, 13-Mar-20		nnart multi campanant n	aulti dissiplipanup	raiaats that
	Synopsis	The purpose of this Notice of Funding Op address scientific questions relevant to A concepts in non-human primate models	AIDS prophylactic vaccine	• •		•
11/111/6	egrated Preclinical/Clinical AID CAVD) (U19 Clinical Trial Not A	S Vaccine Development Program llowed)	National Institute of Allergy and Infectious Diseases/NIH/DHHS	PAR-23-033 [	.4-Feb-2024 Optional][LOI/Pre- App]	Not Specified
	Contact Name	Sujata Vijh, Ph.D.				
	Contact Telephone	301-761-7713				
	Contact Email	sujata.vijh@nih.gov				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	14-Feb-2024 [Optional][LOI/Pre-App], 15	-Mar-2024 , 13-Feb-2025	[Optional][LOI/Pre-App],	14-Mar-2025	
	Synopsis	The purpose of this Funding Opportunity candidates from pre-clinical studies thro Manufacturing Practice (CGMP) manufactechnology transfer, preclinical immunog development, qualification, validation, to Pharma/Biotech/Contract Manufacturing activities, product release and storage, g programs, Investigational New Drug (IND	ugh different phases of preturing and regulatory filing enicity and optimization sesting, small scale pilot or g Organizations (CMO), queneration of reference states	rocess and product developing to the point of clinical to studies, process developm engineering runs, CGMP nationality assurance/quality co andard, drug substance an	pment, Current Go esting. The FOA wil ent, analytical assa nanufacture in par ntrol oversight, fill d drug product sta	ood Il support ay tnership with -finish
122981 of N		d Agency Announcement: "Development Biodefense and Emerging Infectious	National Institute of Allergy and Infectious Diseases/NIH/DHHS	HHS-NIH-NIAID-BAA- 2024-1	.2-Mar-2024	Not Specified
_	Contact Name	JD Alexandra Buck				
	Contact Telephone					
	Contact Email	NIAID DMIDOmnibusBAAQuestions@nil	n.gov			
	Sponsor Website					



SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	------------------	--------------	----------------	---------------	-------------------

Program URL Link to program URL

Deadline Dates (ALL) 12-Mar-2024

Health and Human Services (DHHS) supports research related to the basic understanding of microbiology and immunology leading to the development of vaccines, therapeutics, and medical diagnostics for the prevention, treatment, and diagnosis of infectious and immune-mediated diseases. This Broad Agency Announcement is soliciting proposals that possess the research and development (R&D) expertise necessary for successfully carrying out research toward meeting the program objectives of the Division of Microbiology and Infectious Diseases (DMID), NIAID, NIH. The Research Areas included in this NIAID DMID OMNIBUS BROAD AGENCY ANNOUNCEMENT No. HHS-NIH-NIAID-BAA2024-1, as well as the projected amounts of available funding, are discussed below. Research Areas 001, 002, and 003: For FY 25, the NIAID estimates up to \$16 million for the award of 5 cost reimbursement type base contracts across all three Research Areas (001, 002 & 003). The estimated FY 25 funding is for the non-severable Base Requirement (direct and indirect costs combined) only. If options are proposed by an Offeror, they will be evaluated in accordance with Section 6 of the BAA. The number of awarded contracts will depend on the number of technically meritorious proposals, agency priorities, and availability of funds. DIVISION OF MICROBIOLOGY AND INFECTIOUS DISEAES (DMID), NIAID, NIH Research Area 001: Vaccine Candidates The goal of Research Area 001 is to protect human health and well-being by advancing specific vaccine candidates that utilize technology platforms that ideally elicit a rapid onset of immunity following a single dose, provide a durable response and are readily Synopsis adaptable to multiple emerging pathogens. These vaccine technologies and platforms may include, but are not limited to, any of the following: novel adjuvant vaccine formulations, delivery platforms that are scalable or produce mucosal immunity, nucleic acid-based platforms, viral vectors, and nanoparticle/VLP approaches. Research Area 002: Therapeutic Candidates The objective of Research Area 002 is the development of new therapeutic products for diseases caused by specific viral, bacterial and fungal pathogens and their drug resistant variants in the following list: Viral Hemorrhagic Fever viruses (e.g., https://www.cdc.gov/vhf/index.html) Coronaviruses, targeting a novel mechanism of action (MOA) different from SARS-CoV-2 approved drugs or with demonstrated pan-coronavirus activity Pseudomonas aeruginosa Candida auris, Aspergillus fumigatus or Mucorales Important notice to Offerors: Research Area 002 only supports development of therapeutic products. "Therapeutic" activity refers to elimination or substantial reduction of infective pathogens by administration of a pharmaceutical agent after challenge. "Pan-coronavirus" activity requires demonstrated SARS-CoV-1, SARS-CoV-2 and MERS-CoV activity. A candidate therapeutic may be a lead series, a preclinical candidate, or a clinical candidate. The product must be based on a small molecule (e.g., natural products, nucleosides, oligonucleotides or peptides) or bacteriophages. The following are not included: proteins, monoclonal antibodies, other biologic entities (except bacteriophages), and conjugates of such entities. Research Area 003: In Vitro Diagnostics NIAID is interested in supporting the development of promising diagnostics technologies in three areas for detection of signatures from biothreat pathogens and toxins, as well as pathogens causing emerging, reemerging, antimicrobial resistant infectious diseases, and for pandemic

The National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH), of the Department of

SPIN ID	Program	Sponsor Name	Sponsor Number	Deadline Date	Funding
SPIN ID	Title	Sponsor warne	Sponsor Number	Deadine Date	Amount

preparedness. 1. Untargeted (Agnostic) and Targeted Nucleic Acid Sequencing on Portable or Laboratory-Automated Systems The first objective of Research Area 003 is to improve the overall performance of nucleic acid sequencing solutions on portable or laboratory-automated commercial sequencing platforms for the targeted or agnostic detection and identification of viral pathogens for biodefense, emerging infectious diseases, and pandemic preparedness. 2. Multiplex Protein or Nucleic Acid Detection in Near-Patient Testing Systems The second objective of Research Area 003 is to develop methods that improve pathogen analyte detection in one of two ways: First, protein technology improvements such as protein sequencing or mass spectrometry, especially in ways that bring protein-identification testing nearer to the patient; or near-patient rapid antigen testing improvements for rapid and highly sensitive toxin or other protein detection; or solutions for rapid development of synthetic binding moieties for capture of novel proteins. The emphasis here is on methods improvement in time and analytical sensitivity. Second, multiplex nucleic acid detection that is near-patient, rapid, low-complexity, low-cost, and sensitive for detection of sexually transmitted infections. Design and development can be for testing from care provider-collected or self-collected specimens. The emphasis here is on expanded breadth of infectious pathogens detected, especially, but not limited to, those identifiable from genital ulcer diagnostic (GUD) testing. 3. Bacterial Identification and Phenotypic Antimicrobial Resistance Characterization The third objective of Research Area 003 is to improve direct-from-blood or other biofluid detection and identification of microbial infection coupled with phenotypic antibiotic susceptibility testing (AST) characterization Contract Proposal Receipt Date: Proposals submitted in response to the BAA Solicitation must be received by 3:00 p.m. Eastern Standard Time on March 12, 2024. Any responsible offeror may submit a proposal which shall be considered by the Agency. For this solicitation, the NIAID requires proposals to be submitted online via the NIAID electronic Contract Proposal Submission (eCPS) website. Submission of proposals by facsimile or e-mail is not acceptable. For directions on using eCPS, go to the website: https://ecps.nih.gov and then click on "How to Submit."

123010 RFA-AI-23-065 -- Centers of Excellence for Translational Research (CETR) (U19 Clinical Trial Not Allowed)

National Institute of Allergy and Infectious Diseases/NIH/DHHS

RFA-AI-23-065

30-Mar-2024 [Optional][LOI/Pre-App]

25,000,000 USD

Contact Name Candace Kerr, Ph.D.

Contact Telephone 301-761-6257

Contact Email candace.kerr@nih.gov

Sponsor Website

Program URL Link to program URL

Deadline Dates (ALL) 30-Mar-2024 [Optional][LOI/Pre-App], 29-Apr-2024

SPIN ID Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
Synopsis	The purpose of this Notice of Funding Opinstitutions to participate in the Centers multidisciplinary translational research Cagainst bacteria or fungi listed in the NO	for Excellence in Translatio enters focused on generati	nal Research (CETR) prog ing, validating, and advan	ram. This program cing medical coun	will support
122359 Exploratory Clinical Trial Grants in Diseases (R61 Clinical Trial Requirements)	n Arthritis and Musculoskeletal and Skin red)	National Institute of Arthritis and Musculoskeletal and Skin Diseases/NIH/DHHS	PAR-24-035 0	4-Mar-2024	600,000 USD
Contact Name	Yan Wang, M.D., Ph.D.				
Contact Telephone	301-594-5032				
Contact Email	wangy1@mail.nih.gov				
Sponsor Website					
Program URL	<u>Link to program URL</u>				
Deadline Dates (ALL)	04-Mar-2024 , 02-Jul-2024 , 01-Nov-2024 2026	1 , 04-Mar-2025 , 02-Jul-20.	25 , 04-Nov-2025 , 04-Ma	r-2026 , 02-Jul-202	26 , 02-Nov-
Synopsis	This Notice of Funding Opportunity (NOF frame. A broad range of types of explora questions related to the mission and goa surgical, dietary, behavioral or rehabilita	tory studies may be submit Is of the NIAMS and may e	tted to this NOFO. The tri	als must address r	esearch
122361 Clinical Observational (CO) Studies Diseases (R01 Clinical Trial Not Al	es in Musculoskeletal, Rheumatic, and Skir llowed)	National Institute of Arthritis and Musculoskeletal and Skin Diseases/NIH/DHHS	PAR-24-036 0	4-Mar-2024	475,000 USD
Contact Name	Yan Wang, M.D., Ph.D.				
Contact Telephone	301-594-5032				
Contact Email	wangy1@mail.nih.gov				
Sponsor Website					
Program URL	Link to program URL				



SPIN ID Program Title	Sponsor Name	Sponsor Number	II)eadline I)ate	Funding Amount
Deadline Dates (ALL)	04-Mar-2024 , 02-Jul-2024 , 01-Nov-2024 2026	1 , 04-Mar-2025 , 02-Jul-2025 , 04-Nov-2025 , 04-l	Mar-2026 , 02-Jul-202	6 , 02-Nov-
Synopsis	pursue clinical observational (CO) studies rheumatic, or skin diseases or conditions clinical study design by providing essenticomorbid conditions; availability of poter can facilitate efforts to develop and/or viclinical study. A future clinical study may encouraged to propose studies that addred determining the appropriate primary or state.	pportunity (NOFO) is to encourage Research Projects to obtain data necessary for designing clinical states. Research data from observational studies supported information about disease symptoms, stages, and information about disease symptoms, stages, antial research participants; and outcomes that are alidate objective biomarkers or subjective outcominclude a clinical trial or an observational study. Press significant obstacles or questions in the design secondary outcome measures or identifying the significant only observational studies will be significant.	udies for musculoskel orted by this NOFO can and timing of disease perimportant to patient ne measures for use in Applicants to this NOF and a clinical project, tages of disease during the project,	etal, n enhance progression; ts. They also n a future tO are such as ng which
122319 RFA-HD-25-008 Development of Methods (R61/R33 - Clinical Trial	of Novel Nonsteroidal Contraceptive Not Allowed)	National Institute of Child Health and Human RFA-HD-25-008 Development/NIH/DHHS	29-Feb-2024 [Optional][LOI/Pre- App]	Not Specified
Contact Name	Leigh Allen, PhD			
Contact Telephone	301-594-9151			
Contact Email	leigh.allen@nih.gov			
Sponsor Website				
Program URL	Link to program URL			
Deadline Dates (ALL)	29-Feb-2024 [Optional][LOI/Pre-App], 29	-Mar-2024		
Synopsis	for the development of novel nonsteroid	portunity (NOFO) is to support and facilitate multilal contraceptive products for men and women these, and devices. This NOFO aims to position innoverses.	nat act prior to fertiliza	ation using
Discovery of the Genetic Basis of  122995 Defects: Gabriella Miller Kids First Trial Not Allowed)	Childhood Cancers and of Structural Birth t Pediatric Research Program (X01 Clinical		13-Feb-2024 [Optional][LOI/Pre- App]	Not Specified
	James Coulombe, Ph.D.			



SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount	
	Contact Telephone	301-451-1390					
	Contact Email	CoulombeJ@mail.nih.gov					
	Sponsor Website						
	Program URL	Link to program URL					
	Deadline Dates (ALL)	13-Feb-2024 [Optional][LOI/Pre-App], 13	-Mar-2024				
		As part of the Gabriella Miller Kids First Pediatric Research Program (Kids First Program), the NIH invites applications to submit samples from pediatric cohorts for whole genome sequencing at a Kids First Program supported sequencing centers. Applicants are encouraged to propose sequencing of existing pediatric cancer or structural birth defect cohorts to elucidate the genetic contribution (somatic and/or germline) to childhood cancers, to investigate the genetic etiology of structural birth defects, to study the molecular basis of the associations between birth defects and increased cancer risk, or to expand the range of pediatric disorders included within the Kids First Data Resource. The program will accept applications that propose whole genome, exome, and transcriptome sequencing, as well as long-read sequencing, proteomics, and epigenomic assays of tumor or affected tissue, when justified. Applicants are encouraged to propose cohorts of underrepresented racial and ethnic groups or to increase racial and ethnic representation of existing Kids First Program projects. These data, and associated clinical and phenotypic data, will become part of the Kids First Data Resource Center for sharing with the research community.					
	Continuation or Revision of NIDCF Cooperative Agreement (UH3 Clin		National Institute of Dental and Craniofacial PAR Research/NIH/DHHS	R-22-068 06	5-Mar-2024	Not Specified	
	Contact Name	Dena Fischer, DDS, MSD, MS					
	Contact Telephone						
	Contact Email	<u>301-594-4876</u>					
	Sponsor Website	<u>Link to sponsor website</u>					
	Program URL	<u>Link to program URL</u>					
	Deadline Dates (ALL)						
	Synopsis	This Funding Opportunity Announcement ongoing clinical trials supported by the Nongoing clinical trial through a competing complete the trial or when an extended revisions will be supported when there is	ational Institute of Dental and g renewal application will be su period of follow-up is well justi	Craniofacial Research upported when there is ified to assess longer to	(NIDCR). Extensions need for addition erm outcomes. Co	n of an nal time to ompetitive	



SPIN ID	Title	Sponsor Name	Sponsor Number		Deadline Date	Amount
		s are strongly encouraged to co ey are planning a competing ren				
106245	NIDCR Behavioral and Social Intervention Cl Implementation Cooperative Agreement (U	inical Trial Planning and G3/UH3 Clinical Trial Required)	National Institute of Dental and Craniofacial Research/NIH/DHHS	PAR-21-317 07	7-Jan-2024	Not Specified

Contact Name Melissa W. Riddle, PhD

Contact Telephone 301-451-3888

Contact Email riddleme@mail.nih.gov

Sponsor Website

**Program** 

Program URL Link to program URL

Deadline Dates (ALL) 07-Jan-2024, 06-Feb-2024, 06-Mar-2024, 07-May-2024

The purpose of this Funding Opportunity Announcement (FOA) is to encourage UG3/UH3 phased cooperative agreement research applications to plan and implement behavioral and social intervention clinical trials. Studies appropriate for this FOA include clinical trials to develop and test behavior change interventions related to dental, oral, or craniofacial conditions. Applications for NIDCR support of clinical trials research are expected to identify research proposals using the NIH Stage Model framework, described in detail here and incorporate an experimental medicine approach. Awards made under this FOA will initially support a milestone-driven UG3 planning phase for up to 2 years, with possible transition to a UH3 clinical trial implementation phase (UH3) of up to five years. The UG3 phase for behavioral and social intervention clinical trials will permit both scientific and operational planning activities. Scientific planning activities include small-scale data collection to assess the feasibility and/or acceptability of a planned behavioral or social intervention and associated study procedures (e.g., acceptability of study content or mode of delivery; feasibility of proposed data collection procedures; preliminary testing of intervention training and fidelity monitoring procedures). Operational planning activities include, at a minimum, development of: the final clinical protocol; the intervention manual or equivalent; the data management system and other tools for data and quality management, safety and operational oversight plans; recruitment and retention strategies; and other essential documents. The UH3 phase will support the conduct of investigator-initiated intervention research at all stages, from early mechanistic research and intervention development (e.g., Stages 0/ I) through implementation and health services research (Stages IV/V). This FOA may also support basic behavioral experimental studies with humans that are considered clinical trials based on the NIH's revised clinical trial definition (please see Clinical Trial Requirements for Grants and Contracts for guidance).

Synopsis

Funding

SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
11/160	NIDDK Central Repository Non-re Not Allowed)	newable Sample Access (X01 Clinical Trial	National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS	PAR-22-171 C	01-Mar-2024	Not Specified
	Contact Name	Rebecca M. Rodriguez, Ph.D				
	Contact Telephone	301-451-0323				
	Contact Email	rebecca.rodriguez2@nih.gov				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	01-Mar-2024 , 27-Jun-2024 , 29-Oct-2024	4 , 04-Mar-2025 , 25-Jun-2	2025		
	Synopsis	The NIDDK Central Repository houses valinitiative allows investigators to apply for about the samples available can be found assessment report from the NIDDK Central	r access to non-renewable d at the Repository's webs	e samples from one or mo	re of these studies de a volume and ir	. Information npact
114//4-	imited Competition: Small Grant Recipients (R03 Clinical Trial Option	Program for NIDDK K01/K08/K23/K25 onal)	National Institute of Diabetes and Digestive and Kidney Diseases/NIH/DHHS	PAR-22-129 C	07-Jan-2024	150,000 USD
	Contact Name	Lisa M. Spain, Ph.D.				
	Contact Telephone	301-451-9871				
	Contact Email	SpainL@niddk.nih.gov				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	07-Jan-2024 , 16-Feb-2024 , 16-Mar-2024 2024 , 07-Jan-2025 , 25-Feb-2025 , 16-M				24 , 16-Nov-
	Synopsis	The National Institute of Diabetes and Di supported K01, K08, K23, and K25 recipie the award period of their K award. Throu K01, K08, K23, and K25 award recipients	ents the opportunity to ap	ply for Small Grant (RO3) s nism, the NIDDK is seeking	support during the to enhance the ca	latter years of pability of its



	Program					Funding
SPIN ID	Title	Sponsor Name	Sponsor Number		Deadline Date	Amount
		investigator status. The RO3 grant mecha secondary analysis of existing data; small development of new research technolog out in a short period of time with limited equivalent, application.	l, self-contained research y. The R03 is, therefore, i	projects; development of ntended to support resear	research methodol ch projects that car	ogy; and n be carried
	FA-ES-22-010 Environmental I P30 Clinical Trial Optional)	Health Sciences Core Centers (EHSCC)	National Institute of Environmental Health Sciences/NIH/DHHS	RFA-ES-22-010 [	.9-Mar-2024 Optional][LOI/Pre- App]	3,400,000 USD
	Contact Name	Claudia Thompson, Ph.D.				
	Contact Telephone	984-287-3330				
	Contact Email	thomps14@niehs.nih.gov				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	19-Mar-2024 [Optional][LOI/Pre-App], 19	9-Apr-2024			
	Synopsis	This Funding Opportunity Announcemen (EHS CC). As intellectual hubs for environ for the field and advance the goals of the Centers provide critical research infrastructure conducting environmental health science individual and/or collaborative research identify and capitalize on emerging issue environmental exposures, human biology research as key approaches to improving	mental health science research science research (http://www.science.com/shared facilities, sees research. An EHS CC exprojects more efficiently sees that advance improvingly, and disease. The EHS CC expressions.	search, the EHS CC is expect tp://www.niehs.nih.gov/ak ervices and/or resources, t nables researchers to cond and/or more effectively. The the understanding of the	cted to be the thou cout/strategicplan/ co groups of investi uct their independ- ne overall goal of a relationships amon	ght leaders (). The Core gators ently-funded in EHS CC is to
1//305	FA-MH-24-181 Bidirectional Ir Media Use and Mental Health (R2	nfluences Between Adolescent Social 21 Clinical Trial Optional)	National Institute of Mental Health/NIH/DHHS	RFA-MH-24-181 [	11-Feb-2024 Optional][LOI/Pre- App]	275,000 USD
	Contact Name	Julia Zehr, Ph.D.				
	Contact Telephone	301-443-1617				
	Contact Email	Zehrj@mail.nih.gov				



SPIN ID Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
Sponsor Website					
Program URL	Link to program URL				
Deadline Dates (ALL)	01-Feb-2024 [Optional][LOI/Pre-App], 01	L-Mar-2024			
	Adolescents have increasing access to an consuming content on social media platf interact with adolescent mental illness a (NOFO) is to encourage applications that adolescent mental illness, psychiatric syrrisk R21 grant applications, whereas its coproposing longer term projects with sup	forms, yet there is limited nd risk for psychopatholog focus on understanding kaptoms, and risk or resilie companion funding opport	knowledge of how online gy. The purpose of this No oldirectional relationships nce for psychopathology.	social behavior and tice of Funding Opp between social me This NOFO seeks sh	d experiences portunity dia use and norter, higher
122304 RFA-MH-24-180 Bidirectional In Media Use and Mental Health (RO	fluences Between Adolescent Social Of Clinical Trial Optional)	National Institute of Mental Health/NIH/DHHS	RFA-MH-24-180 [	01-Feb-2024 Optional][LOI/Pre- App]	Not Specified
Contact Name	Julia Zehr, Ph.D.				
Contact Telephone	301-443-1617				
Contact Email	Zehrj@mail.nih.gov				
Sponsor Website					
Program URL	Link to program URL				
Deadline Dates (ALL)	01-Feb-2024 [Optional][LOI/Pre-App], 01	L-Mar-2024			
Synopsis	Adolescents have increasing access to ar consuming content on social media platf interact with adolescent mental illness a (NOFO) is to encourage applications that adolescent mental illness, psychiatric syr mechanism, whereas its companion NOF	forms, yet there is limited nd risk for psychopatholog focus on understanding b nptoms, and risk or resilie	knowledge of how online gy. The purpose of this No oldirectional relationships nce for psychopathology.	social behavior and tice of Funding Opp between social me This NOFO uses the	d experiences portunity dia use and
107420 Data Harmonization, Curation and Datasets (R61/R33 Clinical Trial No.	d Secondary Analysis of Existing Clinical ot Allowed)	National Institute of Neurological Disorders and Stroke/NIH/DHHS	PAR-22-055 1	.4-Mar-2024	Not Specified
Contact Name	Christine Swanson-Fischer, PhD				



		Will Fullating	Opportunities			
SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
	Contact Telephone	301-496-5680				
	Contact Email	christine.swanson-fischer@nih.gov				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	14-Mar-2024				
	Synopsis	This funding opportunity announcement analysis, using existing datasets from two studies, and/or comparative effectiveness that can advance the understanding or compased award funding mechanism, applicate harmonization and curation, assess existing clinical data. Consistent with the opportunity expects open-source catalog well as controlled access to the curated of	o or more multi-site clinical stress research. Secondary and are of neurological disordications are required to system using go/no-go data-que FAIR (findable, accessible ging of the processes and the processes are processes and the processes and the processes are processes are processes are processes and the processes are processes ar	al research projects, includ alyses should address scier ers and conditions within t stematically and comprehe ality metrics, prior to perfor, interoperable and reusab	ing clinical trials, r ntific and / or clinion he NINDS mission ensively perform corming secondary ole) data principles	natural history cal hypotheses . In this ross-project analyses of s, this funding
	Data Harmonization, Curation and Datasets (R61/R33 Clinical Trial N	d Secondary Analysis of Existing Clinical ot Allowed)	National Institute of Neurological Disorders and Stroke/NIH/DHHS	PAR-23-089 1	4-Mar-2024	Not Specified
	Contact Name	Christine Swanson-Fischer, PhD				
	Contact Telephone	301-496-5680				
	Contact Email	christine.swanson-fischer@nih.gov				
	Sponsor Website					
	Program URL	<u>Link to program URL</u>				
	Deadline Dates (ALL)	14-Mar-2024				
		This funding opportunity announcement	invites applications from	multidisciplinary teams to	perform secondar	y data



analysis, using existing datasets from two or more multi-site clinical research projects, including clinical trials, natural history studies, and/or comparative effectiveness research. Secondary analyses should address scientific and / or clinical hypotheses

phased award funding mechanism, applications are required to systematically and comprehensively perform cross-project data harmonization and curation, assessed using go/no-go data-quality metrics, prior to performing secondary analyses of existing clinical data. Consistent with the FAIR (findable, accessible, interoperable and reusable) data principles, this funding

Synopsis that can advance the understanding or care of neurological disorders and conditions within the NINDS mission. In this

SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
		opportunity expects open-source catalowell as controlled access to the curated		tools used for harmonizat	ion, curation, and	analysis, as
	Notice of Special Interest (NOSI): ateral Sclerosis (ALS)	Advancing Research for Amyotrophic	National Institute of Neurological Disorders and Stroke/NIH/DHHS	NOT-NS-23-062 (	)5-Jan-2024	Not Specified
	Contact Name	Amelie Gubitz, PhD				
	Contact Telephone	301-332-6453				
	Contact Email	gubitza@nih.gov				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	05-Jan-2024 , 20-Feb-2024 , 22-Feb-202	24 , 14-Mar-2024 , 05-Apr-	2024 , 22-Jun-2024		
	Synopsis	The purpose of this Notice of Special In Stroke (NINDS) encourages application community identified in a recent plann	s to advance research activ		_	
	NINR Areas of Emphasis for Reseated Health Equity (R01 Clinical Trial O	arch to Optimize Health and Advance Optional)	National Institute of Nursing Research/NIH/DHHS	PAR-22-230 (	)7-Jan-2024	Not Specified
	Contact Name	David L. Tilley, MPH, MS, CPH				
	Contact Telephone	301-827-6014				
	Contact Email	david.tilley@nih.gov				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	07-Jan-2024 , 05-Feb-2024 , 05-Mar-20 2024 , 07-Jan-2025 , 05-Feb-2025 , 05-I		-2024 , 05-Jul-2024 , 07-Se <sub>l</sub>	p-2024 , 05-Oct-20	024 , 05-Nov-
	Synopsis	This funding announcement solicits RO with the scientific framework detailed		•	• •	



research will be rooted in nursing's holistic, contextualized approach to understanding people and their health, address the

SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
		nation's most pressing and persistent he study designs to inform practice and poli	•	lutions orientation, and	l I employ innovative ar	
	NINR Areas of Emphasis for Reseated Health Equity (R21 Clinical Trial O	arch to Optimize Health and Advance ptional)	National Institute of Nursing Research/NIH/DHHS	PAR-22-231	07-Jan-2024	200,000 USD
	Contact Name	David L. Tilley, MPH, MS, CPH				
	Contact Telephone	301-827-6014				
	Contact Email	david.tilley@nih.gov				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	07-Jan-2024 , 16-Feb-2024 , 16-Mar-202- 2024 , 07-Jan-2025 , 16-Feb-2025 , 16-M		-2024 , 16-Jul-2024 , 07	-Sep-2024 , 16-Oct-20	24 , 16-Nov-
	Synopsis	This funding announcement solicits R21 are consistent with the research framew Strategic Plan. This research will be roote health, address the nation's most pressir innovative and rigorous study designs to	ork detailed in the 2022- ed in nursing's holistic, cong and persistent health o	2026 National Institute Intextualized approach Challenges with a soluti	of Nursing Research ( to understanding peo	NINR) ple and their
113465	•	Development of Radiotracers for Alzheimer's Disease (AD) and AD-Related	National Institute on Aging/NIH/DHHS	NOT-AG-22-032	05-Jan-2024	Not Specified
	Contact Name	Lorenzo M. Refolo, Ph.D.				
	Contact Telephone	301-594-7576				
	Contact Email	refolol@nia.nih.gov				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	05-Jan-2024 , 05-Jan-2024 , 07-Jan-2024 2024 , 05-Sep-2024 , 07-Sep-2024 , 05-O 05-Jun-2025 , 05-Sep-2025		•	•	



SPIN ID Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
Synops	This Notice of Special Interest (NOSI) invosors  Positron Emission Tomography (PET) for targeting new and/or emerging biologic etiology and pathophysiology of neuroo	r use in Alzheimer's diseas al process or molecular pa	e (AD) and AD-related d	ementias (ADRD) res	earch
Notice of Special Interest (NOSI)  108282 Epidemiology of Alzheimer's Dis Dementias (AD/ADRD) and Cogr	ease and Alzheimer's Disease-Related	National Institute on Aging/NIH/DHHS	NOT-AG-21-045	11-Mar-2024	Not Specified
Contact Telephon Contact Ema Sponsor Websit Program UR	il dallas.anderson@nih.gov e L Link to program URL .) 11-Mar-2024, 09-Jul-2024, 12-Nov-202	4			
Synops	This Notice of Special Interest (NOSI) en s relevant to AD/ADRD and cognitive resi well as gaps and opportunities identified	ience, but identifies speci	fic areas that build on co	urrent efforts suppor	
Notice of Special Interest (NOSI)	s relevant to AD/ADRD and cognitive resi	ience, but identifies speci	fic areas that build on co	urrent efforts suppor	



SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
		biology that have not been adequately acresearch and analytical tools and to integ			·	
108114 <u>T</u>		Genetic Underpinnings of Endosomal in Alzheimer's Disease and Alzheimer's ADRD)	National Institute on Aging/NIH/DHHS	NOT-AG-21-034 1	1-Mar-2024	Not Specified
	Contact Telephone Contact Email	millerm@nia.nih.gov				
	· ·	Link to program URL 11-Mar-2024, 09-Jul-2024, 12-Nov-2024				
	Synopsis	The goals of this Notice of Special Interest molecular, cellular, and physiological prorelated dementias (ADRD). Studies funde enhancing our understanding of how the pathophysiological changes associated w	cesses associated with the d under this topic will sup genetic underpinnings o	e endosomal compartmen pport research into AD/AD	t in AD and Alzhei RD pathogenesis r	imer's disease related to
111X / /X	Notice of Special Interest (NOSI): n Aging and Alzheimer's Disease	Selective Cell and Network Vulnerability	National Institute on Aging/NIH/DHHS	NOT-AG-21-040 1	1-Mar-2024	Not Specified
	Contact Telephone	Bradley C. Wise, Ph.D. 301-496-9350 WiseB@mail.nih.gov				
	_	Link to program URL				
	Deadline Dates (ALL) Synopsis	11-Mar-2024, 09-Jul-2024, 12-Nov-2024 The goal of this Notice of Special Interest (e.g., neurons and glia), neural activity ar (or resistant) in brain aging and AD and t	(NOSI) is to stimulate res	functional networks, and b	rain regions that	are vulnerabl



signatures of different types of neurons and glial cells across the adult lifespan, in AD compared to other dementias of aging,

SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
		and in different stages of AD will implicate types by physiological measures such as networks will provide a functional index generate sophisticated data on molecula networks. Understanding the mechanism define the disease process and to develo	electrophysiology and co of selective vulnerability or signatures of brain cells ors underlying selective vu	nnectivity and manipula Applicants are encoura and on structure and fu	iting neural activity in ged to use new appro unction of brain circu	n circuits and paches to its and
	Notice of Special Interest (NOSI): Studying Clinical Alzheimer's Dise	Novel Approaches to Diagnosing and ase and Related Dementias	National Institute on Aging/NIH/DHHS	NOT-AG-21-036	11-Mar-2024	Not Specified
	Contact Name	John Hsiao, M.D.				
	Contact Telephone	301-496-9350				
	Contact Email	jhsiao@mail.nih.gov				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	11-Mar-2024 , 09-Jul-2024 , 12-Nov-2024	4			
	Synopsis	The goal of this NOSI is to encourage the outcomes in AD and ADRD.	development of novel a	oproaches to characteriz	zing, diagnosing, and	predicting
111X /X/I	Notice of Special Interest (NOSI): Services for Persons with Dement	Dementia Care Research: Programs and iia	National Institute on Aging/NIH/DHHS	NOT-AG-21-046	11-Mar-2024	Not Specified
	Contact Name	Elena Fazio, Ph.D.				
	Contact Telephone	301-496-3136				
	Contact Email	elena.fazio@nih.gov				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	11-Mar-2024 , 09-Jul-2024 , 12-Nov-2024	1			
	Synopsis	This NOSI invites applications on high-pri areas as set forth by the National Institut discussions from the NIH 2020 Dementia on AD/ADRD, and is aligned with AD/ADI	te on Aging's Division of I Care Summit, the NASEI	Behavioral and Social Re M Decadal Survey of Beh	search. The NOSI is b	ased on exper



SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
	Notice of Special Interest (NOSI): Predictors of Preclinical Alzheime	Sensory and Motor System Changes as r's Disease	National Institute on Aging/NIH/DHHS	NOT-AG-21-044	11-Mar-2024	Not Specified
	Contact Name	Coryse St. Hillaire-Clarke, Ph.D.				
	Contact Telephone	301-827-6944				
	Contact Email	sthillaireclacn@mail.nih.gov				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	11-Mar-2024 , 09-Jul-2024 , 12-Nov-202	4			
	Synopsis	The purpose of this Notice of Special Int combination of basic and clinical studies impact the development and progression	that investigate how fund	•		
ווצל צווו	Notice of Special Interest (NOSI): Alzheimer's Disease	Deciphering the Glycosylation Code of	National Institute on Aging/NIH/DHHS	NOT-AG-21-042	11-Mar-2024	Not Specified
	Contact Name	Austin Yang, Ph.D.				
	Contact Telephone	301-496-9350				
	Contact Email	yangj13@mail.nih.gov				
	Sponsor Website					
	Program URL	Link to program URL				
	· ·	Link to program URL 11-Mar-2024, 09-Jul-2024, 12-Nov-202	4			
	· ·		st (NOSI) is to invite resear			
108315 L	Deadline Dates (ALL) Synopsis	11-Mar-2024, 09-Jul-2024, 12-Nov-202 The goal of this Notice of Special Interes carbohydrate analyses to understand th  Dementia Care Workforce for Those	st (NOSI) is to invite resear			
108315 L	Deadline Dates (ALL)  Synopsis  Notice of Special Interest (NOSI): Living with Alzheimer's Disease and Dementias (AD/ADRD)	11-Mar-2024, 09-Jul-2024, 12-Nov-202 The goal of this Notice of Special Interest carbohydrate analyses to understand the Dementia Care Workforce for Those and Alzheimer's Disease-Related	et (NOSI) is to invite resear e potential impact of glyco National Institute on	osylation on the etiolo	gy of AD and biomark	er discovery.
108315 L	Deadline Dates (ALL)  Synopsis  Notice of Special Interest (NOSI): Living with Alzheimer's Disease and Dementias (AD/ADRD)	11-Mar-2024, 09-Jul-2024, 12-Nov-202 The goal of this Notice of Special Interest carbohydrate analyses to understand the Dementia Care Workforce for Those and Alzheimer's Disease-Related  John W. R. Phillips, Ph.D.	et (NOSI) is to invite resear e potential impact of glyco National Institute on	osylation on the etiolo	gy of AD and biomark	er discovery.



SPIN ID Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
Sponsor Websit	e				
Program UR	L Link to program URL				
Deadline Dates (ALL	11-Mar-2024 , 09-Jul-2024 , 12-	-Nov-2024			
Synopsi	and the impact of workforce factorized dementia (AD/ADRD) and their provide care may cite NOT-AG-2 cite NOT-AG-21-047 in the Agernot be considered a high priorit explore whether PAR-21-307 Definition of the considered and	NOSI) is intended to promote beh ctors on outcomes for persons livi families. Applications focused on 21-046, and applications focused ncy Routing Identifier field (box 48 ty for this NOSI. Studies proposing ementia Care and Caregiver Supplifor Dementia Care and Caregiver	ing with Alzheimer's dise n care of persons living w solely on unpaid demen B). PLEASE NOTE: Applic g dementia care interver ort intervention Researc	ease or Alzheimer's di vith dementia and the tia care partners/care ations proposing clini ution research are enc h (R01 – Clinical Trial	sease-related systems that egivers may cal trials will couraged to Required)
108373 Notice of Special Interest (NOSI)	: Infectious Etiology of Alzheimer	's Disease National Institute on Aging/NIH/DHHS	NOT-AG-21-043	11-Mar-2024	Not Specified
Contact Nam	e Miroslaw 'Mack' Mackiewicz, Pł	h.D.			
Contact Telephon	e 301-496-9350				
Contact Ema	il mirolsaw.mackiewicz@nih.gov				
Sponsor Websit	е				
Program UR	L Link to program URL				
Deadline Dates (ALL	.) 11-Mar-2024 , 09-Jul-2024 , 12-	-Nov-2024			
Synopsi		leveraging existing cohorts with averaging address the possible links			luid (CSF), and
108321 Notice of Special Interest (NOSI)  Disease Genetic Variants	: Human Cell Biology of Alzheimer	r's National Institute on Aging/NIH/DHHS	NOT-AG-21-052	11-Mar-2024	Not Specified
Contact Nam	e Bradley Wise, Ph.D.				
Contact Telephon	e 301-496-9350				
	il wiseb@mail.nih.gov				
Sponsor Websit	е				



SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
	Program URL	Link to program URL				
	Deadline Dates (ALL)	11-Mar-2024 , 09-Jul-2024 , 12-Nov-2024	4			
	Synopsis	The goal of this Notice of Special Interest and other age- and disease-modifying fa and genomic editing approaches.				
	Notice of Special Interest (NOSI): and Monitoring of Alzheimer's Dis	Digital Technology for Early Detection sease and Related Dementias	National Institute on Aging/NIH/DHHS	NOT-AG-21-048 1	.1-Mar-2024	Not Specified
	Contact Name	Yuan Luo, Ph.D.				
	Contact Telephone	301-496-9350				
	Contact Email	yuan.luo@nih.gov				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	11-Mar-2024 , 09-Jul-2024 , 12-Nov-2024	4			
	Synopsis	This Notice of Special Interest (NOSI) end monitoring of cognitive and functional d				
108309	Notice of Special Interest (NOSI):	Behavioral and Social Science Priority	National Institute on	NOT-AG-21-047 1	.1-Mar-2024	Not
108309	Areas in Dementia Care Partner/C	Caregiver Research	Aging/NIH/DHHS	NOT-AU-21-047 1	.1-10101-2024	Specified
	Contact Name	Melissa S. Gerald, Ph.D.				
	Contact Telephone	301-496-3136				
	Contact Email	melissa.gerald@nih.gov				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	11-Mar-2024 , 09-Jul-2024 , 12-Nov-2024	4			
	Synopsis	This NOSI solicits high-priority Alzheimer areas as set forth by the National Institution AD/ADRD research implementation Summit and recommendations from the	te on Aging's Division of B milestones and are based	ehavioral and Social Resea on expert discussions fron	arch. Priority areas on the NIH 2020 De	are guided by mentia Care



SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
1112211	Notice of Special Interest (NOSI): Changes in Alzheimer's Disease	Role of Age-Associated Metabolic	National Institute on Aging/NIH/DHHS	NOT-AG-21-053	11-Mar-2024	Not Specified
	Contact Name	Yih-Woei Fridell, Ph.D.				
	Contact Telephone	01-496-7847				
	Contact Email	<u>yih-woei.fridell@nih.gov</u>				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	11-Mar-2024 , 09-Jul-2024 , 12-Nov-2024	1			
	Synopsis	This Notice of Special Interest (NOSI) is a peripheral tissues or in the brain affect t				ic changes in
108307	Notice of Special Interest (NOSI):	In vivo Synaptic Function in Alzheimer's	National Institute on	NOT-AG-21-038	11-Mar-2024	Not
[	Disease and Related Dementias		Aging/NIH/DHHS	NOT-AG-21-036	11-10101-2024	Specified
	Contact Name	John Hsiao, M.D.				
	Contact Telephone	301-496-9350				
	Contact Email	jhsiao@mail.nih.gov				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	11-Mar-2024 , 09-Jul-2024 , 12-Nov-2024	1			
	Synopsis	This Notice of Special Interest (NOSI) has (AD) and Alzheimer's disease-related der vivo, in humans.		•		
/	Aging Research Dissertation Awar Not Allowed)	rds to Promote Diversity (R36 Clinical Tria	National Institute on Aging/NIH/DHHS	PAR-24-052	16-Feb-2024	Not Specified
	Not Allowed)		•			
		Jamie Lahvic, Ph.D.				
		·				
	Contact Name Contact Telephone	·				



SPIN ID Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
Program URL	Link to program URL				
Deadline Dates (ALL)	16-Feb-2024 , 16-Mar-2024 , 16-Jun-2024 2025 , 16-Jul-2025 , 16-Oct-2025 , 16-Nov Nov-2026			•	•
Synopsis	This Notice of Funding Opportunity (NOF engaged in research on aging and aging-rwithin NIA's strategic priorities.				
121943 RFA-AA-23-004 Comprehensive Clinical Trial Optional)	e Alcohol-HIV/AIDS Research Center (P60	National Institute on Alcohol Abuse and Alcoholism/NIH/DHHS	RFA-AA-23-004 [	L6-Mar-2024 Optional][LOI/Pre- App]	6,000,000 USD
Contact Name	Kendall Bryant, Ph.D				
Contact Telephone	301-402-0332				
Contact Emai	kbryant@mail.nih.gov				
Sponsor Website					
Program URL	Link to program URL				
Deadline Dates (ALL)	16-Mar-2024 [Optional][LOI/Pre-App], 18	3-Apr-2024			
Synopsis	NIAAA seeks applications aimed to addre pandemic. This NOFO uses the NIH Comp conduct a range of basic and behavioral of	orehensive Research Cent	er (P60) mechanism to sup	oport research cent	er grants to
	nabling and Early-Stage Development of	National Institute on			Not
108556 Medications to Treat Alcohol Use Damage (UT1/UT2 Clinical Trial C	-	Alcohol Abuse and Alcoholism/NIH/DHHS	PAR-22-103 2	27-Mar-2024	Specified
Contact Name	Jenica Patterson, Ph.D.				
Contact Telephone	301-827-6166				
Contact Emai	jenica.patterson@nih.gov				
Sponsor Website					
Program URL	Link to program URL				
Deadline Dates (ALL)	27-Mar-2024 , 04-Dec-2024				



SPIN ID Program Title Sponsor Name Spo	oonsor Number	Deadline Date	Funding Amount
--	---------------	---------------	-------------------

This Funding Opportunity Announcement (FOA) supports Small Business Technology Transfer (STTR) applications from small business concerns (SBCs) that propose the development of therapeutic agents for the treatment of alcohol use disorder (AUD) and/or alcohol associated organ damage (AAOD). As a starting point, eligible applicants must identify a therapeutic candidate with a robust body of background data in the basic science and early discovery phases to be ready for transition to the preclinical and clinical phases of development. Data may include having sufficient bioactivity, stability, manufacturability, bioavailability, in vivo efficacy and/or target engagement, and other favorable properties that are consistent with the desired clinical application. Projects responsive to this announcement could be undertaken at any point along the drug development continuum, from late discovery (i.e., lead optimization/early safety) up to early-stage clinical trials. For small molecules, the earliest stage of eligibility for this Award is already having small-molecule compounds with proof of desired pharmacological activity. For biologics, the profiling of promising product candidates in animal models of AUD or AAOD will be allowed as the earliest entry point. The ultimate purpose and goal of this FOA is to advance molecules closer to U.S. Food and Drug Administration (FDA) approval. Milestones will be commensurate with the project proposed and the purpose of this FOA. This FOA supports early-phase clinical trials, although these are not required. Women-owned and socially or economically disadvantaged small businessesare encouraged to apply.

Investigational New Drug (IND)-enabling and Early-Stage Development of

Medications to Treat Alcohol Use disorder and Alcohol-Associated Organ

Damage (U43/U44 Clinical Trial Optional)

Synopsis

National Institute on Alcohol Abuse and Alcoholism/NIH/DHHS

PAR-22-102

27-Mar-2024

Not Specified

Contact Name Jenica Patterson, Ph.D.

Contact Telephone 301-827-6166

Contact Email jenica.patterson@nih.gov

Sponsor Website

Program URL Link to program URL

Deadline Dates (ALL) 27-Mar-2024, 04-Dec-2024

This Funding Opportunity Announcement (FOA) supports Small Business Innovation Research (SBIR) applications from small business concerns (SBCs) that propose the development of therapeutic agents for the treatment of alcohol use disorder (AUD) and/or alcohol associated organ damage (AAOD). As a starting point, eligible applicants must identify a therapeutic candidate with a robust body of background data in the basic science and early discovery phases to be ready for transition to the preclinical and clinical phases of development. Data may include having sufficient bioactivity, stability, manufacturability, bioavailability, in vivo efficacy and/or target engagement, and other favorable properties that are consistent with the desired clinical application. Projects responsive to this announcement could be undertaken at any point along the drug

development continuum, from late discovery (i.e., lead optimization/early safety) up to early-stage clinical trials. For small

Synopsis

	1					
SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
		molecules, the earliest stage of eligibility pharmacological activity. For biologics, be allowed as the earliest entry point. The and Drug Administration (FDA) approvathis FOA. This FOA supports early-phase economically disadvantaged small busing	the profiling of promising p The ultimate purpose and go II. Milestones will be commo e clinical trials, although the	roduct candidates in anima oal of this FOA is to advanc ensurate with the project p se are not required. Wome	al models of AUD e molecules close proposed and the	or AAOD will er to U.S. Food purpose of
104639 <u>N</u> I	IDA Animal Genomics Program (	(U01 – Clinical Trial Not Allowed)	National Institute on Drug Abuse/NIH/DHHS	PAR-21-244 04	1-Mar-2024	Not Specified
	Contact Name	Amy C. Lossie, PhD				
	Contact Telephone	301-827-6092				
	Contact Email	lossieac@mail.nih.gov				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	04-Mar-2024				
	Synopsis	The purpose of the NIDA Animal Genetic underlie: 1. Phenotypes associated with disorder (SUD) trajectory (e.g. initial/ac abstinence and relapse or recovery); 2. discounting, and other genetically-assophenotypes and behaviors linked with SApplications may examine any type of variants, and all types of mobile DNA. Napproaches that integrate multi-level of discovered genetic or epigenetic variant and facilitate the discovery of targets for these different aspects of SUD.	n addictive behaviors and/o ute use, escalation of use, a Behaviors associated with S ciated phenotypes); and 3. ( SUD (e.g. anxiety, stress, po- variant, including single nucl IIDA encourages application omics data, delineate gene r ts. NIDA expects these stud	r vulnerability to distinct standard requisition of tolerance, de SUD (e.g. impulsivity, novel Comorbidities that demonstor maternal care, social defectide variants (SNVs), industrial take genomics, multipletworks, and/or uncover the tourcover to the stourcover to	tages along the supendence, uncon lty seeking, delayestrate genetic corfeat, and other palels, large and smiti-omics, and/or delayestrate genetic corfeat, and other palels, large and smiti-omics, and/or delayestrates that contraction of knanisms that contractions.	ubstance use atrolled use, ed relations with aradigms). all structural data-based nown or newly ribute to SUD
11345/		racterization of Genes or Variants rders (R21/R33 Clinical Trial Not Allowed	National Institute on Drug Abuse/NIH/DHHS	PAR-23-041 04	1-Mar-2024	Not Specified
	Contact Name Contact Telephone	John Satterlee Ph.D. 301-435-1020				

SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
	Contact Email satterle	ej@nida.nih.gov				
	Sponsor Website					
	Program URL Link to	orogram URL				
	• • •	-2024 , 26-Jul-2024 , 03-Mar-202	•			
	Synopsis The purpose of this initiative is to support projects that functionally validate and/or characterize genes or variants involved in substance use disorder-relevant phenotypes.					
111018 Behavioral & Integrative Treatment Development Program (R34 Clinical Trial Optional)			National Institute on Drug Abuse/NIH/DHHS	PAR-22-183 2	1-Mar-2024	450,000 USD

Contact Name Will M. Aklin, Ph.D.

Contact Telephone 301-827-5909

Contact Email aklinwm@mail.nih.gov

Sponsor Website

Program URL Link to program URL

Deadline Dates (ALL) 21-Mar-2024, 09-Aug-2024, 21-Mar-2025

The purpose of this Funding Opportunity Announcement (FOA) is to encourage research grant applications on the development and testing of behavioral and integrative treatments for substance use and dependence. This FOA reaffirms the continued commitment of NIDA to major programs of research on behavioral and integrative treatments. The term behavioral treatments" is used here in a broad sense and includes but is not limited to psychotherapies, cognitive, relapse" prevention, remediative, rehabilitative, skills training, counseling, family, and exercise therapies. Screening, brief, computerized, adherence, prevention interventions for HIV risk behaviors, and interventions that target therapist training and fidelity also are included. Integrative refers to combinations with other treatments, including pharmacotherapies or other complementary approaches. The development and testing of putative targets and mechanisms of behavior change, as well as the use and development of valid and reliable assessment tools are crucial to the three stages of treatment research supported under this initiative: Stage I (treatment generation, refinement) encompasses all activities related to the creation of a new behavioral intervention. This stage also includes the modification, adaptation, or refinement of an existing intervention (Stage IA). Stage I culminates in feasibility and pilot testing (Stage 1B). For example, one can conduct Stage I studies in research settings, with research therapists and research subjects, or in community settings with community providers. Stage II ("Efficacy") research consists of experimental testing of promising behavioral interventions in research settings, with research-based therapists/providers. Stage III ("Efficacy in Real-World") research consists of experimental testing of promising behavioral interventions in community settings, with community-based therapists/providers and

Synopsis

	SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
--	---------	------------------	--------------	----------------	---------------	-------------------

patients, while maintaining a high level of control necessary to establish internal validity. Stages I, II, and III all include a focus on theory-derived, targets/putative moderators, mediators, and change mechanisms that underlie the treatment, and studies that optimize combined, sequential, or integrated behavioral/pharmacological treatments.

111016

Behavioral & Integrative Treatment Development Program (R01 Clinical Trial Optional)

National Institute on Drug Abuse/NIH/DHHS

PAR-22-182

21-Mar-2024

Not Specified

Contact Name Will M. Aklin, Ph.D.

Contact Telephone 301-827-5909

Contact Email aklinwm@mail.nih.gov

Sponsor Websitel

Program URL Link to program URL

Deadline Dates (ALL) 21-Mar-2024, 09-Aug-2024, 21-Mar-2025

The purpose of this Funding Opportunity Announcement (FOA) is to encourage research grant applications on the development and testing of behavioral and integrative treatments for drug and alcohol use, abuse, and dependence. This FOA reaffirms the continued commitment of NIDA to major programs of research on behavioral and integrative treatments. The term "behavioral treatments" is used here in a broad sense and includes but is not limited to psychotherapies, cognitive, relapse prevention, remediative, rehabilitative, skills training, counseling, family, and exercise therapies. Screening, brief, computerized, adherence, prevention interventions for HIV risk behaviors, and interventions that target therapist training and fidelity are included. Integrative refers to combinations with other treatments, including pharmacotherapies or other complementary approaches. The development and testing of putative targets and mechanisms of behavior change, as well as the use and development of valid and reliable assessment tools are crucial to the three stages of treatment research Synopsis supported under this initiative: Stage I (treatment generation, refinement) encompasses all activities related to the creation of a new behavioral intervention. This stage also includes the modification, adaptation, or refinement of an existing intervention (Stage IA). Stage I culminates in feasibility and pilot testing (Stage 1B). For example, one can conduct Stage I studies in research settings, with research therapists and research subjects, or in community settings with community providers. Stage II ("Efficacy") research consists of experimental testing of promising behavioral interventions in research settings, with research-based therapists/providers. Stage III ("Efficacy in Real-World") research consists of experimental testing of promising behavioral interventions in community settings, with community-based therapists/providers and patients, while maintaining a high level of control necessary to establish internal validity. Stages I, II, and III all include a focus on theory-derived, targets/putative moderators, mediators, and change mechanisms that underlie the treatment, and studies that optimize combined, sequential, or integrated behavioral/pharmacological treatments.

SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
103052 <u>C</u>	Cutting-Edge Basic Research Awa	rds (CEBRA) (R21 Clinical Trial Optional)	National Institute on Drug Abuse/NIH/DHHS	PAR-21-208	08-Mar-2024	275,000 USD
	Contact Name	Amy C. Lossie, Ph.D.				
	Contact Telephone	301-827-6092				
	Contact Email	lossieac@mail.nih.gov				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	08-Mar-2024				
		innovative or conceptually creative reseause disorders (SUDs). It supports high-ris NIDA's current portfolio that has the pot adapt, revolutionary techniques or meth research; and /or 2. test an innovative and which, if confirmed, would transform	sk and potentially high-imp cential to transform SUD re nods for addiction research nd significant hypothesis fo m current thinking.	act research that is unde search. The proposed re or that show promising	errepresented or no search should: 1. do future applicability	ot included in evelop, and/or to SUD ninary data
11/5X4 <del>-</del>		Research on Substance Use Disorders dies with Humans (BESH) Required)	National Institute on Drug Abuse/NIH/DHHS	PAR-23-158	13-Mar-2024	Not Specified
	Contact Name	Vani Pariyadath, Ph.D.				
	Contact Telephone	301-443-3209				
	Contact Email	vani.pariyadath@nih.gov				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	13-Mar-2024 , 20-Jun-2024 , 09-Oct-202	4 , 13-Mar-2025 , 20-Jun-2	025 , 09-Oct-2025 , 13-N	1ar-2026	
	Synopsis	This Notice of Funding Opportunity (NOF research applications that are explorator mechanisms underlying substance use duse. This NOFO is for basic science experbasic science studies involving human pameet the definition of basic research. Ty	ry and developmental in na isorders (SUD), including fu imental studies involving h articipants." These studies	nture and focus on under undamental circuitry and numans, referred to in No fall within the NIH defini	rstanding the neuro behavior relevant OT-OD-18-212 as "p tion of a clinical tria	bbiological to substance prospective al and also



	Рисаном					Funding
SPIN ID	Program Title	Sponsor Name	Sponsor Number		<b>Deadline Date</b>	Amount
		prospectively assign human participants that assess biomedical or behavioral out phenomena without specific application toward processes or products in mind sh Research on Substance Use Disorders (R research approach, applicants are encoudrant (Parent R01 Basic Experimental St	comes in humans for the p towards processes or prod ould submit under the cor 61/R33 Clinical Trial Option raged to apply under a dif	ourpose of understanding ducts in mind. Studies con mpanion NOFO - Explorato nal) PAR-23-157. For proje ferent activity code (e.g., I	the fundamental a ducted with speci- ory Clinical Neuros ects not requiring a	aspects of fic applications science a phased
11/5x/	xploratory Clinical Neuroscience R61/R33 Clinical Trial Optional)	Research on Substance Use Disorders	National Institute on Drug Abuse/NIH/DHHS	PAR-23-157 1	.3-Mar-2024	Not Specified
	Contact Name	Vani Pariyadath, Ph.D.				
	Contact Telephone	301-443-3209				
	Contact Email	vani.pariyadath@nih.gov				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	13-Mar-2024 , 20-Jun-2024 , 09-Oct-202	4 , 13-Mar-2025 , 20-Jun-2	.025 , 09-Oct-2025 , 13-Ma	ar-2026	
	Synopsis	This Notice of Funding Opportunity (NOI research applications that are explorator mechanisms underlying substance use duse. Note: For basic science experiments science studies involving human particip on Substance Use Disorders (R61/R33 Barequiring a phased research approach, a 20-183 "Research Project Grant (Parent	ry and developmental in national in nation	ature and focus on unders undamental circuitry and l s, referred to in NOT-OD-1 panion NOFO - Exploratory with Humans (BESH)) PAR- to apply under a different	tanding the neuro behavior relevant .8-212 as "prospec Clinical Neuroscie 23-282 For projec	obiological to substance ctive basic ence Research ts not
	Notice of Special Interest (NOSI): Pharmacology of Addictive Drugs		National Institute on Drug Abuse/NIH/DHHS	NOT-DA-23-002 0	7-Jan-2024	Not Specified
	Contact Name	Kiran Vemuri, Ph.D.				
	Contact Telephone	301-435-4446				
	Contact Email	kiran.vemuri@nih.gov				
	Sponsor Website					



SPIN ID	Program Title		Sponsor Name	Sponsor Number	Deadline Date	Funding Amount	
	Program URL Deadline Dates (ALL)	07_lan_20	<del></del>	, 08-Mar-2024 , 07-May-2024 , 05-Jun-2024 , 16	-Jun-2024 , 07-Sep-20	24 , 12-Feb-	
	The mission of the Division of Neuroscience and Behavior of NIDA is to discover, facilitate and promote outstanding basic animal and human research aimed at identifying the causes and consequences of drug addiction across the lifespan and to guide treatment strategies. As a component of the Division, the Chemistry and Pharmacology Branch supports research or all aspects of the chemistry and pharmacology of addictive drugs. The Branch develops and oversees a broad portfolio encompassing research on substance use disorders (SUD) and overdose designed to: 1) elucidate mechanisms of action, synthetic and biosynthetic methodologies, structure-activity relationships, pharmacology and toxicity of addictive drugs, a determination of 3D structures of ligands bound to biological targets, 2) develop new receptor type and subtype specific agents, and 3) discover and advance the pre-clinical development of new pharmacotherapies for the treatment of SUD and overdose, emphasizing the pre-clinical stages of target identification through hit-to-lead.						
1719511	FA-DA-25-013Targeting Inflam	nmasomes	in HIV and Substance Use (R21	National Institute on Drug Abuse/NIH/DHHS RFA-DA-25-013	13-Feb-2024 [Optional][LOI/Pre- App]	275,000 USD	
	Contact Name	Shang-Yi A	Anne Tsai, PhD				
	Contact Telephone	301-827-5	5842				
	Contact Email	stsai@nih	.gov				
	Sponsor Website						
	Program URL	Link to pr	ogram URL				
	Deadline Dates (ALL)	13-Feb-20	024 [Optional][LOI/Pre-App], 13	-Mar-2024 , 13-Mar-2025			
	Synopsis	activation disorders virus and	and their link to neurocognitiv (SUDs). This NOFO supports stu drug-induced immune activation	unity (NOFO) is to encourage research to explore e disorder (NCD) and immune function in people udies to (1) elucidate the role and the underlying on, (2) identify molecular markers associated with microenvironments that influence inflammasome	with HIV and substan mechanisms of inflam inflammasome pathy	nce use nmasomes in ways in NCD	

findings into therapeutic tools that improve clinical outcomes in people with HIV.

progression among individuals with SUD. Overall goal of this program is to facilitate translation of inflammasome research

		3				
SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
	RFA-DA-25-012Targeting Inflam Clinical Trial Not Allowed)	nmasomes in HIV and Substance Use (R01	National Institute on Drug Abuse/NIH/DHHS	RFA-DA-25-012	13-Feb-2024 [Optional][LOI/Pre- App]	2,500,000 USD
	Contact Name	Shang-Yi Anne Tsai, PhD				
	Contact Telephone	301-827-5842				
	Contact Email	stsai@nih.gov				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	13-Feb-2024 [Optional][LOI/Pre-App], 13	3-Mar-2024 , 13-Mar-2025			
	Synopsis	activation and their link to neurocognitive disorders (SUDs). This NOFO supports state of the supports and drug-induced immune activation and 3) illuminate the cellular and tissue a progression among individuals with SUD findings into therapeutic tools that impression among individuals with support of the	udies to (1) elucidate the ron, (2) identify molecular ronicroenvironments that in .  Overall goal of this progr	ole and the underlying n narkers associated with Ifluence inflammasomes am is to facilitate transla	nechanisms of inflan inflammasome path in HIV-1 infection o	nmasomes in ways in NCD r disease
1//1114	RFA-DA-25-052 Tools for Decer Disorder (R43/R44 Clinical Trials (	ntralized Clinical Trials for Substance Use Optional)	National Institute on Drug Abuse/NIH/DHHS	RFA-DA-25-052	14-Mar-2024	Not Specified
	Contact Name	Yordan Kostov, PhD				
	Contact Telephone	301-435-5650				
	Contact Email	yordan.kostov@nih.gov				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	14-Mar-2024				
	Synopsis	This notice of funding opportunity (NOFO small business concerns (SBCs) proposing use disorders (SUD). Applicants are enco	g research projects for dev	eloping tools for distribu	uted clinical trials fo	substance

transfer, handling and storage of relevant clinical data with the purpose of supporting distributed clinical trials for SUD.

SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
	RFA-DA-25-051 Tools for Decen Disorder (R41/R42 Clinical Trials C	tralized Clinical Trials for Substance Use Optional)	National Institute on Drug Abuse/NIH/DHHS	RFA-DA-25-051	14-Mar-2024	Not Specified
	Contact Name	Yordan Kostov, PhD				
	Contact Telephone	301-435-5650				
	Contact Email	yordan.kostov@nih.gov				
	Sponsor Website					
	Program URL	Link to program URL				
	Deadline Dates (ALL)	14-Mar-2024				
	Synopsis	This notice of funding opportunity (NOFosmall business concerns (SBCs) proposinuse disorders (SUD). Applicants are encotransfer, handling and storage of relevants	g research projects for devouraged to develop tools a	veloping tools for distrib nd/or software solution:	outed clinical trials for sthat facilitate remo	r substance te collection,
	Notice of Special Interest (NOSI): Medical/Psychosocial Consequen		National Institute on Drug Abuse/NIH/DHHS	NOT-DA-24-002	07-Jan-2024	Not Specified
	Contact Name	Raul Mandler, MD				
	Contact Telephone	240-281-0569				
	Contact Email	mandlerr@nih.gov				
	Sponsor Website					
	Sportsor Website					
	·	Link to program URL				
	·		ct-2024 , 16-Oct-2024 , 07	-Jan-2025 , 05-Feb-2025	5 , 12-Feb-2025 , 16-	eb-2025 , 07-
	Program URL  Deadline Dates (ALL)	Link to program URL 07-Jan-2024, 05-Feb-2024, 12-Feb-2024 2024, 07-Sep-2024, 05-Oct-2024, 12-O May-2025, 07-May-2025, 05-Jun-2025,	ct-2024 , 16-Oct-2024 , 07 , 12-Jun-2025 , 16-Jun-202 research on the epidemiol	-Jan-2025 , 05-Feb-2025 5 , 07-Sep-2025 , 05-Oct ogy, medical/psychosoc	5 , 12-Feb-2025 , 16- t-2025 , 12-Oct-2025 ial impact, and prev	entive and

			-	•			
SPIN ID	Program Title		Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
	Contact Name	Shang-Yi A	Anne Tsai, Ph.D.				
	Contact Telephone		•				
	Contact Email						
	Sponsor Website						
	Program URL		ogram URI				
07-Jan-2024 , 05-Feb-2024 , 12-Feb-2024 , 16-Feb-2024 , 08-Mar-2024 , 07-May-2024 , 05-Jun-2024 , 12-Jun-2024 , 16-Jun-2025 , 05-Feb-2025 , 12-Feb-2025 , 16-Feb-2025 , 05-Feb-2025 , 12-Feb-2025 , 16-Feb-2025 , 05-Jun-2025 , 05-Jun-2025 , 07-Jan-2025 , 07-Jan-2025 , 07-Jan-2025 , 18-Oct-2025 , 18-Oct-2025 , 07-Jan-2026 , 05-Feb-2026 , 12-Feb-2026 , 12-Feb-2026 , 12-Feb-2026 , 12-Feb-2026 , 07-May-2026 , 05-Jun-2026 , 12-Jun-2026 , 16-Jun-2026 , 07-Sep-2026   This Notice of Special Interest (NOSI) encourages studies to exploit the unique properties and functions of glial cells and							
		develop s substance	trategies to mitigate Central Nes or therapeutic avenues for a	ervous System (CNS) dama ddiction treatments.		_	ctive
111673	Notice of Special Interest (NOSI): Neuroscience Branch in the Divis			National Institute on Drug Abuse/NIH/DHHS	NOT-DA-22-058 0	7-Jan-2024	Not Specified
	Contact Name	Olivier Be	rton, Ph.D.				
	Contact Telephone	301-827-7	7771				
	Contact Email	Olivier.be	rton@nih.gov				
	Sponsor Website						
	Program URL	Link to pr	ogram URL				
	07-Jan-2024, 05-Feb-2024, 12-Feb-2024, 16-Feb-2024, 08-Mar-2024, 07-May-2024, 05-Jun-2024, 12-Jun-2024, 16-Jun- Deadline Dates (ALL) May-2025, 07-May-2025, 05-Jun-2025, 12-Jun-2025, 16-Jun-2025, 07-Sep-2025, 12-Oct-2025, 16-Oct-2026						
, 07-Jan-2026  The mission of the Division of Neuroscience and Behavior (DNB) is to facilitate and promote outstanding basic animal and human research aimed at identifying the causes and consequences of substance use and substance use disorders (SUD) synopsis across the lifespan and to guide treatment strategies. The Integrative Neuroscience (IN) Branch within DNB supports research on the cellular mechanisms and circuitry that underlie substance use and SUD. Research supported by the Bra covers: 1) the regulation and plasticity of neurotransmitter and neuromoduatory systems induced by chronic or intermitation.							ers (SUD) oports y the Branch



SPIN ID Program Title		Sponsor Name	Sponsor Number		סדבנו סמווחבסנוו	Funding Amount
	interacti substance	e to, and/or withdrawal from, acons and their modification by subsequent and SUD, and 5) neuroim neuroinflammation.	ubstance use and SUD 4) ne	euroendocrine modulation	on of neural systems	in relation to
1083/10	celerating the Pace of linical Trial Optional)	Drug Abuse Research Using	National Institute on Drug Abuse/NIH/DHHS	RFA-DA-22-037	04-Mar-2024	Not Specified
	ontact Name Marsha	F. Lopez, Ph.D., M.H.S.				
Conta	ct Telephone 301-443	-6504				
(	Contact Email <u>marsha.</u>	lopez@nih.gov				
Spo	nsor Website					
	Program URL Link to p	orogram URL				
Deadlin	e Dates (ALL) 04-Mar-	2024 , 05-Aug-2024 , 15-Nov-20	24			
	existing substant preventi other ex trajector develops	cose of this Funding Opportunity social science, behavioral, admit the using behaviors (defined as a son of substance use and HIV, artant community-based or clinicaties of substance using behavior ment of psychopathology, strate effective and efficient services for is not allowed for applications	nistrative, and neuroimaging loohol, tobacco, prescription and health service utilization all datasets to their full potes and their consequences in the green and treater the prevention and treater the prevention and treater to guide the development or the prevention and treater to guide the development the prevention and treater the preventio	ng data to study the etio on, and other substances . This FOA encourages the ential in order to increase ncluding morbidity and re ment, testing, implement	logy and epidemiolo ) and related disordene ne analyses of public e our knowledge of e mortality, risk and re tation, and delivery o	gy of ers, use and etiology, silience in the of high
	dolescent Overdose Proceed Trial Not Allowed)	evention and SUD Treatment	National Institute on Drug Abuse/NIH/DHHS	RFA-DA-25-030	13-Feb-2024 [Optional][LOI/Pre- App]	275,000 USD
	ontact Name Sean Lyr	nch, PhD, LCSW				
Conta	ct Telephone 301-594	-4596				
(	Contact Email <u>sean.lyn</u>	ch@nih.gov				
Spo	nsor Website					
	Program URL Link to p	rogram LIPI				



SPIN ID	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount	
	Deadline Dates (ALL)	13-Feb-2024 [Optional][LOI/Pre-App], 13	3-Mar-2024				
This notice of funding opportunity (NOFO) encourages exploratory and developmental research to better under adolescent illicit fentanyl use and overdose patterns among adolescents at high risk for overdose (i.e., intention unintentional, fatal, and/or non-fatal). Research studies should identify targets for overdose prevention and sudisorder (SUD) treatment and recovery. Research studies may use a variety of approaches (e.g., leveraging exists sources, survey research, social network analysis, development of new methods, feasibility research). Outcome include, but are not limited to, prevalence of overdose and reduction in substance use, particularly fentanyl us substances that are commonly laced with fentanyl; unintentional use/overdose, use/overdose by risk group, st and environmental risk and protective factors, treatment engagement, adolescents' perceptions of substance optimistic bias. Research studies involving services delivery or interventions are encouraged to consider the consideration of the							
177413	FA-DA-25-029 National Drug E U01 Clinical Trial Not Allowed)	arly Warning System Coordinating Cente	r National Institute on Drug Abuse/NIH/DHHS	RFA-DA-25-029 [	0-Feb-2024 Optional][LOI/Pre- .pp]	Not Specified	
	Contact Name	MeLisa R. Creamer, PhD, MPH					
	Contact Telephone	301-402-1933					
	Contact Email	melisa.creamer@mail.nih.gov					
	Sponsor Website						
	Program URL	Link to program URL					
	Deadline Dates (ALL)	20-Feb-2024 [Optional][LOI/Pre-App], 20	0-Mar-2024				
		This notice of funding opportunity (NOF the identification and dissemination of s Coordinating Center will provide operati	ignals of emerging drug us	se patterns in communities	across the United	States. The	

Synopsis

the identification and dissemination of signals of emerging drug use patterns in communities across the United States. The Coordinating Center will provide operational, administrative, and logistical support by executing the following: Establish a Scientific Advisory Group to provide guidance and direction. Engage an Early Warning Network composed of two components: local health experts on drug use from selected communities (Sentinel Sites) and a broader network of community-based health researchers, to support the bi-directional sharing of information and insights into drug use patterns in their communities and to support the ongoing monitoring, interpretation, and dissemination of data. Identify, compile, analyze, and triangulate research data and resources from multiple sources to assess and contextualize emerging drug threats. Disseminate contextualized research findings, data, and resources to key audiences who can use the data to inform their response.

SPIN II	Program Title	Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
106250	NIDA Research Education Program for Clinic (R25 Clinical Trial Not Allowed)	cal Researchers and Clinicians	National Institute on Drug Abuse/NIH/DHHS	PAR-21-320 15	5-Mar-2024	1,750,000 USD

Contact Name Aria Davis Crump, Sc.D.

Contact Telephone 301-435-0881

Contact Email acrump@nida.nih.gov

Sponsor Website

Program URL Link to program URL

Deadline Dates (ALL) 15-Mar-2024, 09-Aug-2024

The NIH Research Education Program (R25) supports research education activities in the mission areas of the NIH. The overarching goal of this NIDA R25 program is to support educational activities that complement and/or enhance the training of a workforce to meet the nation's biomedical, behavioral and clinical research needs. This FOA is intended to support research education activities that enhance the knowledge of substance use (SU) and substance use disorder (SUD) research. The program is intended for those in clinically focused careers and/or those training for careers as clinicians/health service providers, clinical researchers, or optimally a combination of the two. This mechanism may not be used to support non-research-related clinical training. To accomplish the stated over-arching goal, this FOA will support creative educational activities with a primary focus on Courses for Skills Development and Research Experiences. The proposed research education programs must include both courses for skills development and research experiences with primary emphasis on research experiences. Proposed courses should be developed in conjunction with and support research experiences to enhance skills development.

SPIN ID Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
122558 <u>Prevention and SUD Treatment Initiative (R34 - Clinical Trial Optional)</u>	National Institute on Drug Abuse/NIH/DHHS	RFA-DA-25-031	13-Feb-2024 [Optional][LOI/Pre- App]	225,000 USD

Contact Name Sean Lynch, PhD, LCSW

Contact Telephone 301-594-4596

Contact Email sean.lynch@nih.gov

Sponsor Website

Program URL Link to program URL

Deadline Dates (ALL) 13-Feb-2024 [Optional][LOI/Pre-App], 13-Mar-2024



				I.			
SPIN ID	Program Title	Sp	oonsor Name	Sponsor Number		Deadline Date	Funding Amount
		for large-scale, is substance use of are not limited to centered outcook interventions for are effective, processing whose purpose risk in order to it consider the consideration that the consideration tha	unding opportunity (NOFO) or rigorous trials that will guide lisorder (SUD) treatment, an to, harm reduction, recovery mes, and implementation factor ar adolescents at high risk of factical, cost-effective, scalate is to better understand adol dentify targets for overdose mpanion NOFO, RFA-DA-25- rial Not Allowed).	the expansion of effective d recovery services for add treatment retention and ctors. The goal of this NOF overdose (i.e., intentional, ble, and sustainable. Development illicit fentanyl use a prevention and SUD treat	e, non-stigmatizing overdo plescents. Outcomes of int effectiveness, quality of c O is to improve the availal unintentional, fatal, and/ opmental and exploratory and overdose patterns ame ment and recovery are en	see prevention, terest include, but are, patient-bility of for non-fatal) that research studies ong youth at high couraged to	
114003	Notice of Special Interest (NOS Epigenetic Regulators for Trea and Substance Use Disorders		National Institute on Drug Abuse/NIH/DHHS	NOT-DA-24-004	07-Jan-2024 N	ot Specified	
	Contact Name	Sam Ananthan,	Ph.D.				
	Contact Telephone	301-435-2199					
	Contact Email	sam.ananthan@	Onih.gov				
	Sponsor Website						
	Program URL	Link to program	URL				
	Deadline Dates (ALL)	12-Jun-2024 , 10 07-Jan-2025 , 0	5-Feb-2024 , 12-Feb-2024 , 1 6-Jun-2024 , 08-Aug-2024 , 0 5-Feb-2025 , 12-Feb-2025 , 1 8-Aug-2025 , 07-Sep-2025 , 0	7-Sep-2024 , 05-Oct-2024 6-Feb-2025 , 08-Apr-2025	, 12-Oct-2024 , 16-Oct-20 , 07-May-2025 , 05-Jun-20	24 , 08-Dec-2024 , 025 , 12-Jun-2025 ,	
	Synopsis	The National Ins	stitute on Drug Abuse (NIDA ecial interest in innovative r enetic regulators and mecha	) is issuing this Notice of Spesearch that uses chemica	pecial Interest (NOSI) to in I and pharmacological app	form applicants proaches to identif	
114048	Notice of Special Interest (NOS Chemoproteomic Approaches Targets and Therapeutics to Truse Disorders	for Discovery of	National Institute on Drug Abuse/NIH/DHHS	NOT-DA-24-005	07-Jan-2024 N	ot Specified	-



SPIN ID	Program Title	Sp	onsor Name	Sponsor Number		<b>Deadline Date</b>	Fundin Amour
	Contact Name	Sam Ananthan, I	Ph.D.				
	Contact Telephone	301-435-2199					
	Contact Email	sam.ananthan@	nih.gov				
	Sponsor Website						
	Program URL	Link to program	<u>URL</u>				
	Deadline Dates (ALL)	12-Jun-2024 , 16 07-Jan-2025 , 05	5-Feb-2024 , 12-Feb-2024 , 1 5-Jun-2024 , 08-Aug-2024 , 0 5-Feb-2025 , 12-Feb-2025 , 1 3-Aug-2025 , 07-Sep-2025 , 0	7-Sep-2024 , 05-Oct-2024 6-Feb-2025 , 08-Apr-2025	, 12-Oct-2024 , 16-Oct-20 , 07-May-2025 , 05-Jun-2	024 , 08-Dec-2024 2025 , 12-Jun-2025	,
	Synopsis	special interest i	this Notice is to inform poter in supporting basic research development of drugs to trea	on the application of chen	noproteomic approaches	•	
122412	RFA-DA-25-027 The Nationa Treatment Clinical Trials Netw Trial Required)		National Institute on Drug Abuse/NIH/DHHS	RFA-DA-25-027	13-Feb-2024 [Optional][LOI/Pre-App]	2,500,000 USD	
	Contact Name	Betty Tai, Ph.D.					
	Contact Telephone	301-443-2397					
	Contact Email	btai@nida.nih.g	<u>ov</u>				
	Sponsor Website						
	Program URL	Link to program	<u>URL</u>				
	Deadline Dates (ALL)	13-Feb-2024 [Օր	otional][LOI/Pre-App], 13-Ma	ar-2024			
	Synopsis	Drug Abuse Trea public health ne of substance use providers, and h	te on Drug Abuse (NIDA) invision of the control of the continuation of the control of the contro	k (CTN) and contribute to ue to develop and test inte partnerships among NIDA	the network's capacity to erventions for addressing , clinical research investig	respond to urgen the wide spectrum gators, healthcare	t 1
104059	Summer Research Education E Program (R25 Clinical Trial Not		National Institutes of Health/DHHS	PAR-21-168	19-Mar-2024 6	525,000 USD	



				•			
SPIN ID	Program Title	Spe	onsor Name	Sponsor Number		<b>Deadline Date</b>	Funding Amount
	Title						Amount
	Contact Name	Laura E. Kwako,	Ph.D.				
	Contact Telephone	301-451-8507					
		laura.kwako@nil	h.gov				
	Sponsor Website						
	Program URL	Link to program	UR <u>L</u>				
	Deadline Dates (ALL)	19-Mar-2024 , 07	7-May-2024				
	Synopsis	NIH. The overare enhance the train accomplish the s	ching goal of this R25 prograining of a workforce to mee tated over-arching goal, the periences for high school st	ram is to support education to the nation's biomedical is FOA will support creati	ition activities in the mission onal activities that complem I, behavioral and clinical rese ve educational activities wit tudents, and/or science tead	nent and/or earch needs. To th a primary focus	
109426	Notice of Special Interest (NOS Administrative Supplement for Science to Synergize Chemical Countermeasures Discovery and Development	Collaborative Medical	National Institutes of Health/DHHS	NOT-AI-22-029	01-Mar-2024 10	00,000 USD	
	Contact Name	Dave Yeung, Ph.I	D.				
	Contact Telephone	301-796-7237					
	Contact Email	dy70v@nih.gov					
	Sponsor Website						
	Program URL	Link to program	<u>URL</u>				
	Deadline Dates (ALL)	01-Mar-2024					
	Synopsis	funded Chemical These funds are opportunities to	Countermeasures Researd Intended to stimulate ongo	th Program (CCRP) grants oing research by providing	nents to a subset of existing and cooperative agreement g CCRP-supported researche not anticipated at the time	ts across the NIH. ers the	-



SPIN ID	Program Title	Sp	oonsor Name	Sponsor Number		Deadline Date	Funding Amount
108508	RFA-HL-23-006 Stimulating A Research in Residency (StARR) Independent Clinical Trial Not	(R38	National Institutes of Health/DHHS	RFA-HL-23-006	15-Mar-2024	Not Specified	
	Contact Name	David Schopfer					
	Contact Telephone	301-402-3833					
	Contact Email	david.schopfer@	@nih.gov				
	Sponsor Website						
	Program URL	Link to program	<u>URL</u>				
	Deadline Dates (ALL)	15-Mar-2024 , 1	L6-May-2024				
	Synopsis	demonstrated p this critical com programs that c ability to transit provide support	this program is to recruit are potential and interest in pur ponent of the research work an provide outstanding me tion to individual career develor up to 2 years of research gators with defined program	suing careers as clinician- kforce, this funding oppo ntored research opportur elopment research award ch conducted by Resident	investigators. To address rtunity seeks application nities for Resident-Invest ds. The program will supp	s the growing need for s from institutional sigators and foster the port institutions to	or
117361	RFA-MH-23-110 BRAIN Initia Ruth L. Kirschstein National Re Award (NRSA) Individual Posto Fellowship (F32)	search Service	National Institutes of Health/DHHS	RFA-MH-23-110	10-Mar-2024 [Optional][LOI/Pre- App]	Not Specified	
	Contact Name	Ashlee Van't Ve	er, PhD				
	Contact Telephone	301-443-3107					
	Contact Email	Brain.Initiative.	Training@nih.gov				
	Sponsor Website						
	Program URL	Link to program	<u>URL</u>				
	Deadline Dates (ALL)		Optional][LOI/Pre-App], 09- <i>A</i> [LOI/Pre-App], 11-Aug-2025		Optional][LOI/Pre-App], 1	LO-Dec-2024 , 12-Jul-	
	Synopsis		the Brain Research through s to enhance the research t				;



SPIN ID	Program Title	S	ponsor Name	Sponsor Number		Deadline Date	Funding Amount
		the BRAIN Initioneuroethics. Appredoctoral resintegral comportant encountries and the second expect to do so have complete does not allow	ve the potential to become pative. Applications are encounted policiants are expected to property of the applications from a policial from the research training rages applications from indivipation within 12 months of the applicants to propose to lead tence in a clinical trial led by a particular trial and the applicants.	raged in any research area pose research training in lytical tools appropriate f plan. In order to maximiz iduals who have not yet o lication due date. On the stdoctoral training. This F I an independent clinical t	a aligned with the BRAIN In an area that clearly comple for the proposed research is the training potential of the completed their terminal do application due date, cand	itiative, including ments their s expected to be a the F32 award, thi octoral degree and idates may not incement (FOA)	n s
I /UX IX -	Planning for Product Develops R34 Clinical Trial Not Allowed		National Institutes of Health/DHHS	PAR-24-029	13-Mar-2024 22	25,000 USD	
	Contact Name	Marina Protopo	ppova, Ph.D.				
	Contact Telephone	301-761-7653					
	Contact Email	marina.protopo	ppova@nih.gov				
	Sponsor Website						
	Program URL	Link to progran	<u>ı URL</u>				
	Deadline Dates (ALL)	13-Mar-2024 ,	04-Dec-2024 , 13-Mar-2025 ,	04-Dec-2025 , 13-Mar-20	)26 , 04-Dec-2026		
	Synopsis	well-defined pr	this Notice of Funding Opportude oduct development strategy coinfections and complication	for next-generation treat	ments for HIV and HIV-asso	ociated	I

103986 Notice of Special Interest (NOSI): Early-life
Factors and Cancer Development Later in Life

National Institutes of Health/DHHS

application to the FDA.

NOT-CA-21-074

translation of research findings into drug products that enables submission of an Investigational New Drug (IND)

07-Jan-2024

**Not Specified** 

Contact Name
Contact Telephone
Contact Email
Sponsor Website

SPIN ID	Program Title	Sp	onsor Name	Sponsor Number		Deadline Date	Funding Amount
	Program URL	Link to program	<u>URL</u>				
	Deadline Dates (ALL)	07-Jan-2024 , 05	5-Feb-2024 , 16-Feb-2024 , 0	7-Mar-2024			
	Synopsis		this Notice of Special Interestal- al-paternal, in utero, birth a cer in life.			•	
107763	Notice of Special Interest (NOS Nicotine Delivery Systems (EN Alternative Nicotine and Tobac Systems: Population, Clinical a Prevention Mechanisms of He	DS) and cco Delivery nd Applied	National Institutes of Health/DHHS	NOT-OD-22-023	07-Jan-2024 N	ot Specified	
	Contact Name	Rachel Grana Ma	ayne, PhD, MPH				
	Contact Telephone	240-276-5899					
	Contact Email	rachel.mayne@i	nih.gov				
	Sponsor Website						
	Program URL	Link to program	<u>URL</u>				
	Deadline Dates (ALL)	07-Jan-2024 , 05	5-Feb-2024 , 16-Feb-2024 , 0	07-Mar-2024 , 07-May-202	24		
	Synopsis	research on elect systems [e.g., he on other non-co examine popular potential risks, b	sease Prevention and particition in the control of	tems (ENDS). Research on called heat-not-burn)] wacco products will be consolied prevention of disease tobacco use behavior and	alternative nicotine and to fill also be considered. Reso idered on a case-by-case b e, including etiology and ep mong different population	obacco delivery earch with a focus asis. Studies shou oidemiology of use s. Studies	ld
107248	Notice of Special Interest (NOS Outcomes in Cancer Treatment Cardiotoxicity		National Institutes of Health/DHHS	NOT-CA-22-001	07-Jan-2024 N	ot Specified	
	Contact Name Contact Telephone	Crystal Wolfrey 240-276-6277					



SPIN ID Program Title		Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
	l wolfreyc@mai	l.nih.gov				
Sponsor Website		··· LIDI				
Deadline Dates (ALL	Link to program 07-Jan-2024, ( 07-Sep-2024,	 05-Feb-2024 , 16-Feb-2024 , 0	7-Mar-2024 , 07-May-202	4 , 05-Jun-2024 , 07-Jun-2	024 , 16-Jun-2024	,
Synopsi	mitigate cardio	f this Notice of Special Interestovascular dysfunction while operated cardiotoxicity and transland management.	otimizing cancer outcomes	s by understanding the me	chanisms of cance	er
Notice of Special Interest (NOSI): Preventive Interventions to Address Cardiometabolic Risk Factors in Populations that Experience Health Disparities  National Institutes of Health/DHHS NOT-OD-22-154 O7-Jan-2024 Not Specified						
Contact Name	Jennifer Alvidr	ez, PhD				
Contact Telephone	301-827-0071					
Contact Emai	Jennifer.alvidr	ez@nih.gov				
Sponsor Website	9					
Program UR	Link to program	m URL				
Deadline Dates (ALL		05-Feb-2024 , 06-Feb-2024 , 1 07-Sep-2024 , 05-Oct-2024 , 0		•		
Synopsi		f this NOSI is to solicit projects that experience health dispar		ons that address cardiome	etabolic risk factors	5
Notice of Special Interest (NC 112420 Uptake of Evidence-Based Scr Populations Across the Lifesp	eening in Divers	National Institutes of Health/DHHS	NOT-OD-22-178	07-Jan-2024 N	lot Specified	_
Contact Name	Melissa C. Gre	en Parker, PhD				
Contact Telephone	301-480-1161					



	Program						Funding
SPIN ID	Title	Sp	onsor Name	Sponsor Number		<b>Deadline Date</b>	Amount
		•					
	Contact Email	melissa.greenpa	rker@nih.gov				
	Sponsor Website						
	Program URL	Link to program	<u>URL</u>				
	Deadline Dates (ALL)		-Jun-2024 , 07-Sep-2024 ,		4 , 07-Mar-2024 , 07-May-2 4 , 16-Oct-2024 , 07-Jan-202		',
	Synopsis	Offices (ICs) are strategies and in populations inclustudies addressing	issuing this Notice of Speci terventions to improve the uding, but not limited to, th	al Interest (NOSI) to encou e uptake of evidence-base nose experiencing health of dissemination and implem	stitutes of Health (NIH) Instiurage applications proposind screening services across disparities and those that are tentation research, as well a	g to test multileve the lifespan and ir e underserved.	el n
112421	Notice of Special Interest (NOS Evidence Gaps in Screening	SI): Addressing	National Institutes of Health/DHHS	NOT-OD-22-179	07-Jan-2024 N	ot Specified	
	Contact Name	Melissa C. Green	Parker, PhD				
	Contact Telephone	301-480-1161					
	Contact Email	melissa.greenpa	rker@nih.gov				
	Sponsor Website						
	Program URL	Link to program	<u>URL</u>				
	Deadline Dates (ALL)	-	-Jun-2024 , 07-Sep-2024 , (	·	4 , 07-Mar-2024 , 07-May-2 4 , 16-Oct-2024 , 07-Jan-202	•	٠,
	Synopsis	Offices (ICs) are evidence base for balance of benefined and rigorous me	issuing this Notice of Speci or preventive screening ser fits and harms cannot be d	al Interest (NOSI) to solicit vices where the evidence etermined. This NOSI enco lose high priority evidence	stitutes of Health (NIH) Instit t applications proposing to s is lacking, of poor quality, c purages the development ar e gaps to elevate screening	strengthen the onflicting, or the nd use of innovativ	



SPIN ID	Program Title	Sp	onsor Name	Sponsor Number		Deadline Date	Funding Amount
11 /un/	Notice of Special Interest (NOS he Health of Bisexual and Bise		National Institutes of Health/DHHS	NOT-OD-22-166	07-Jan-2024	Not Specified	
	Contact Name	Christopher Bar	nhart, PhD				
	Contact Telephone	301-594-8983					
	Contact Email	christopher.barr	nhart@nih.gov				
	Sponsor Website						
	Program URL	Link to program	<u>URL</u>				
	Deadline Dates (ALL)	07-May-2024 , 0	5-Feb-2024 , 06-Feb-2024 , 05-Jun-2024 , 12-Jun-2024 , 5-Oct-2024 , 25-Oct-2024 ,	16-Jun-2024 , 21-Jun-20	024 , 25-Jun-2024 , 09-J	ul-2024 , 07-Sep-2024 ,	
	Synopsis	health and well- those with the p not necessarily a "Bisexual+" or "	pecial Interest (NOSI) solicity being of people who ident betential to be attracted, roset the same time, not necestial; in this NOSI is an umbit limited to bisexual, panse	fy as bisexual or bisexual mantically and/or sexual sarily in the same way, rella term that is intender	al+. "Bisexual" or "bi" in ally, to people of more to and not necessarily to to ed to encompass non-m	n this NOSI may describe than one sex or gender, the same degree.	
112325	Notice of Special Interest (NOS Addressing Violence to Improv Outcomes		National Institutes of Health/DHHS	NOT-OD-22-167	07-Jan-2024	Not Specified	
	Contact Name	Dara R. Blachma	ın, Ph.D.				
	Contact Telephone	301-496-8522					
	Contact Email	Dara.blachman-	demner@nih.gov				
	Sponsor Website						
	Program URL	Link to program	URL				
	Deadline Dates (ALL)	09-Jul-2024 , 07	5-Feb-2024 , 06-Feb-2024 , -Sep-2024 , 05-Oct-2024 , 1 )5-Jun-2025 , 16-Jun-2025 ,	.6-Oct-2024 , 12-Nov-20	24 , 07-Jan-2025 , 05-F	-	-
	Synopsis		this Notice is to highlight in ence-related screening and	_			




SPIN ID	Program Title	Sp	ponsor Name	Sponsor Number		Deadline Date	Funding Amount
		intimate partne	r violence/teen dating vio	sing exposure to violence - plence, elder mistreatment alth processes and outcom	t, peer violence/bullyin		nt,
108660 <u>f</u>	Notice of Special Interest (NOS Digital Health and Artificial Int or Improved Assessment in E Clinical, and Intervention Rese	elligence Tools pidemiological,	National Institutes of Health/DHHS	NOT-CA-22-037	28-Dec-2023	Not Specified	
	Contact Name	Dana Wolff-Hug	ghes, PhD				
	Contact Telephone	240-620-0673					
	Contact Email	dana.wolff@nih	n.gov				
	Sponsor Website	2					
	Program URL	Link to program URL					
	Deadline Dates (ALL)	) 05-Jan-2024 , 07-Jan-2024 , 05-Feb-2024 , 15-Feb-2024 , 16-Feb-2024 , 07-Mar-2024					
	The purpose of this Notice of Special Interest (NOSI) is to encourage grant applications to support the evaluation of the utility and validity of digital health and artificial intelligence (AI) tools and technologies in epidemiological, Synopsis clinical, and intervention research. The intent is to support the addition of new measurement modalities to evaluate existing and recently developed but not yet validated digital health and AI tools such as sensor technologies, smartphone applications, software as a medical device (SaMD), and AI algorithms.						
114/65	Notice of Special Interest (NO: and Mortality Prevention Rese		y National Institutes of Health/DHHS	NOT-OD-23-039	28-Dec-2023	Not Specified	
	Contact Name	Dara R. Blachma	an, Ph.D.				
	Contact Telephone	2					
	Contact Email	Dara.blachman-	-demner@nih.gov				
	Sponsor Website						
	Program URL	-					
	Deadline Dates (ALL)	024 , 09-Jul-2024 , 07-9	// // // // // // // // // // // // //	,			



	Program						Funding		
SPIN ID	Title	Sp	onsor Name	Sponsor Number		Deadline Date	Amount		
	Synopsis	firearm injury, the perpetrators, according to the firearm injury are	this Notice is to highlight int ne identification of those at cidental injury), the develop nd mortality, and the examin interventions to prevent fire	risk of firearm injury (inclument, piloting, and testing nation of approaches to im	uding self- and other-dired g of innovative intervention oprove the implementation	cted, victims and ons to prevent			
114589	Notice of Special Interest (NOS Address 'Ending the HIV Epide Goals Relevant to Substance U At-Risk for or Living with HIV	mic' Initiative	National Institutes of Health/DHHS	NOT-DA-23-013	07-Jan-2024 N	Not Specified			
	Contact Name Vasundhara Varthakavi, PhD								
	Contact Telephone	301-443-2146							
	Contact Email	vasundhara.vart	hakavi@nih.gov						
	Sponsor Website								
	Program URL	Link to program	<u>URL</u>						
	Deadline Dates (ALL)	07-Sep-2024 , 05 07-May-2025 , 0	-Feb-2024 , 16-Feb-2024 , 2 5-Oct-2024 , 16-Oct-2024 , 1 5-Jun-2025 , 16-Jun-2025 , ( 7-May-2026 , 05-Jun-2026 ,	4-Nov-2024 , 07-Jan-2025 07-Sep-2025 , 05-Oct-2025	, 05-Feb-2025 , 16-Feb-2 5 , 16-Oct-2025 , 07-Jan-20	025 , 21-Mar-2025 026 , 05-Feb-2026	,		
	The purpose of this NOSI is to support a broad spectrum of multi-disciplinary, substance use research to address the goals of the four pillars, including Diagnose, Treat, Prevent, and Respond of the 'Ending the HIV Epidemic in the U.S. (EHE)' initiative. Projects proposed in response to this NOSI are required to meet the needs of the substance using populations who are at high risk for contracting HIV or living with HIV in the geographically defined EHE priority areas within the U.S.								
117360	Notice of Special Interest (NOS Address Vaccine Uptake and Ir among Populations Experienci Disparities	nplementation	National Institutes of Health/DHHS	NOT-MD-23-008	05-Feb-2024 N	Not Specified			
	Contact Name	Deborah E. Linar	es, Ph.D., M.A.						
	Contact Telephone	301-402-2516							



SPIN ID Program Title		Sponsor Name	Sponsor Number		Deadline Date	Funding Amount
	act Email <u>deborah.linar</u> Website	res@nih.gov				
·	gram URL Link to progra	am URL				
_	05-Feb-2024 tes (ALL) 16-Oct-2024	, 16-Feb-2024 , 07-Mar-2024 , , 07-Nov-2024 , 05-Feb-2025 , , 16-Feb-2026 , 05-Jun-2026				
	vaccine uptal and its territo hesitancy reg virus (HPV), v especially in p social inequit all ages). The reach, access organizations access, uptak	se and implementation among the and implementation among the arises. Research is needed to unarding uptake of vaccines (e.g. aricella, tetanus, diphtheria, and appulations at increased risk foies, as well as chronic medical purpose of this NOSI is to solic, and uptake of vaccinations are, and series completion, and and series completion, and anosocial barriers, and social defity contexts.	populations experiencing derstand and address mis , SARS-CoV-2, pneumocod nd pertussis [Tdap]) amonor morbidity and mortality conditions. This NOSI is four research that will: 1) ur mong populations experies and initiatives that miss evaluate community-er	shealth disparities in the United States in the United States in the United States in the U.S. and the U.S. a	nited States (U.S.) distrust, and human papilloma d its territories, emic health and s the life span (i.e. riers to increasing evaluate rities in vaccine expand reach,	
122129 RFA-AT-24-006 Reso and Cannabinoid Reso Not Allowed)	ource Center for Canna earch (U24 Clinical Tria	National Institutos of	RFA-AT-24-006	16-Mar-2024 [Optional][LOI/Pre- 4 App]	,250,000 USD	
Conta	ect Name Patrick C. Stil	, PhD, Program Director				
Contact Te	elephone 301-682-189	5				
Conta	act Email patrickstill@r	nih.gov				
Sponsor	Website					
Prog	ram URL Link to progra	am URL				
Deadline Da		[Optional][LOI/Pre-App], 16-A				
	Synoncial	of this notice of funding oppor of a Resource Center for Cann	* *		•	



SPIN ID	Program Title	Sp	oonsor Name	Sponsor Number		Deadline Date	Funding Amount
		and its constitue across a variety for researchers research tools a Overall, the Cen	nism (U24). Such a Center wi ents as well as to enable res of research domains in both entering the cannabis resea and studies that will improve ater will facilitate research a sic science, clinical, and regul munity.	earchers to successfully gone basic and clinical researd rch space and to support upon and eventually chad dvances through synergis	enerate more rigorous scie ch. The Center is expected t the development and estab inge the landscape of canna tic interactions among expe	ntific evidence o be a focal point blishment of bis research. erts in relevant	
108050 D	esearch on Current Topics in visease and Its Related Demer rial Optional)		National Institutes of Health/DHHS	PAR-22-094	11-Mar-2024 2 <sup>°</sup>	75,000 USD	
	Contact Name	Sanoj K. Suneja,	Ph.D				
	Contact Telephone	301-402-7710					
	Contact Email	sanoj.suneja@n	iih.gov				
	Sponsor Website						
	Program URL	Link to program	URL				
	Deadline Dates (ALL)	11-Mar-2024 , 0	9-Jul-2024 , 12-Nov-2024				
	Synopsis	models, techniq need additional	this Funding Opportunity Ar Jues, etc. to advance researd preliminary data with broad The priority topics will be and	ch on Alzheimer's disease der dissemination to esta	(AD) and its related demen blish them for more genera	tias (ADRD) that I use in this	
108049 D	esearch on Current Topics in visease and Its Related Demer rial Optional)		National Institutes of Health/DHHS	PAR-22-093	11-Mar-2024 N	ot Specified	
	Contact Name	Sanoj K. Suneja,	Ph.D				
	Contact Telephone	301-402-7710					
	Contact Email	sanoj.suneja@n	iih.gov				
	Sponsor Website						
	Program URL	Link to program	URL				



SPIN ID	Program Title	Spo	onsor Name	Sponsor Number		Deadline Date	Funding Amount
	Synopsis	The purpose of the current topics in	9-Jul-2024 , 12-Nov-2024 his Funding Opportunity An Alzheimer's disease (AD) ar interest will be announced	nd its related dementias (A	DRD). Further information	on the high-	
112871	RFA-NS-22-070 HEAL Initiative and Validation of Non-Rodent Models of Pain (R01 Clinical Tri	<u>Mammalian</u>	National Institutes of Health/DHHS	RFA-NS-22-070	05-Feb-2024 [Optional][LOI/Pre- 3, App]	750,000 USD	
	Sponsor Website	<u>HEALanimalmod</u>	-				
	_	Link to program U 05-Feb-2024 [On		ar-2024			
Deadline Dates (ALL) 05-Feb-2024 [Optional][LOI/Pre-App], 06-Mar-2024  This funding opportunity announcement (FOA) invites research to develop, characterize, and rigorously validate non-rodent mammalian models of pain, associated outcome measures and/or endpoints that will significantly advance translational research for effective pain management. These models are expected to recapitulate molecular, cellular, pathological, behavioral, and/or cognitive aspects of human pain disorders and conditions. Research supported under this FOA is expected to provide well-validated models and measures that facilitate the development of non-opioid analgesic therapeutic interventions with little or no addiction liability.						ill significantly capitulate nd conditions. that facilitate the	
122638	Career Enhancement Award to Research on Firearm Injury and Prevention (K18 Independent ( Allowed)	l Mortality	National Institutes of Health/DHHS	PAR-24-070	15-Mar-2024 N	ot Specified	
	Contact Telephone Contact Email Sponsor Website	Dara Blachman-E 301-496-8522 dara.blachman-d Link to program I	emner@nih.gov				



SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
---------	------------------	--------------	----------------	---------------	-------------------

Deadline Dates (ALL) 15-Mar-2024

This NIH Research Career Enhancement Award (K18) program invites applications from experienced investigators seeking to redirect or expand their research programs through the acquisition of new skills and knowledge in the area of firearm mortality and injury prevention research, which is beyond and complementary to their current areas of expertise. The program will support research training and career development experiences and a smallscale research project that will provide experienced investigators with the scientific competencies required to conduct research relevant to firearm morality and injury prevention research. Eligible candidates are independent investigators at any faculty rank or level. The proposed project must be related to the programmatic interests of one or more of the participating NIH Institutes and Centers (ICs) based on their scientific missions. This Notice of Funding Opportunity (NOFO) is designed specifically for applicants proposing research that does not involve leading an independent clinical trial, a clinical trial feasibility study, or an ancillary clinical trial. Under this NOFO applicants are permitted to propose a research experience in a clinical trial led by a mentor or co-mentor. Those proposing a clinical trial or an ancillary clinical trial as lead investigator, should apply to the companion NOFO PAR-24-073.

Synopsis

Notice of Special Interest (NOSI): HEAL 112750 Initiative: Workforce Interventions to Improve Addiction Care Quality and Patient Outcomes

National Institutes of Health/DHHS

NOT-DA-23-008

20-Mar-2024

Not Specified

Contact Name Julia Zur, Ph.D.

Contact Telephone 301-443-2261

Contact Email julia.zur@nih.gov

Sponsor Website

Program URL Link to program URL

Deadline Dates (ALL) 20-Mar-2024

This opportunity addresses a critical barrier to addressing the overdose crisis: ensuring a robust workforce to deliver interventions and services to people with substance use disorders and related comorbidities. Recruiting, training, and retaining a robust and highly qualified behavioral health workforce is essential to delivering effective services that address opioid misuse and addiction. However, workforce shortages and high rates of turnover among Synopsis behavioral health services staff and increases in demand for care have substantially impacted access to, cost of, and quality of services. Further, these barriers undermine efforts to implement innovative approaches to care. In 2018, the Health Resources and Services Administration (HRSA) projected that demand for addiction counselors will exceed supply by approximately 38% in 2030; this trend has likely worsened in response to the COVID-19

pandemic. Workforce challenges were highlighted as one of the top priorities listed in the Office of National Drug



				1			
SPIN ID	Program Title	Sį	oonsor Name	Sponsor Number		Deadline Date	Funding Amount
		(primary prever Prevention Stra training, and red develop and eva must focus on in	ONDCP) 2022 Drug Control Solution, harm reduction, evidentegy. There are numerous itaining behavioral health properties to addressing the strategies to addressing the strategies and the strategies are strategies and the strategies and the strategies and the strategies and the strategies are strategies and the strategies and the strategies and the strategies are strategies and the strategies and the strategies are strategies are strategies and the strategies are strategies are strategies are strategies are strategies are strategies and the strategies are stra	nce-based treatment, recondividual, organizational of signification of the second of t	overy support) of the HHS -, and system-level challer , little research has been efore, research funded the s to recruiting, training, a	Overdose nges to recruiting, conducted to rough this initiative nd retaining a highl	
112749	Notice of Special Interest (NOS Initiative: Opioid Use Disorder for Individuals with Histories o Violence	Care Pathways	National Institutes of Health/DHHS	NOT-DA-23-007	12-Feb-2024	Not Specified	
	Contact Name	Carrie Mulford					
	Contact Telephone	301-827-6473					
	Contact Email	Carrie.Mulford@	<u>@nih.gov</u>				
	Sponsor Website						
	Program URL	Link to program	URL				
	Deadline Dates (ALL)	12-Feb-2024 , 2	0-Mar-2024 , 12-Jun-2024 , :	12-Oct-2024 , 12-Feb-202	5 , 12-Jun-2025		
	Synopsis		nitiative seeks to test innova es for individuals who have a			e use and mental	
122693	RFA-MH-24-106 Early Psycho Network (EPINET) Data Coordi (U24 Clinical Trial Not Allowed	inating Center	National Institutes of Health/DHHS	RFA-MH-24-106	29-Feb-2024 [Optional][LOI/Pre- App]	5,000,000 USD	
	Contact Name	Robert K. Heins	sen, Ph.D.				
	Contact Telephone	301-435-0371					
	Contact Email	rheinsse@mail.	nih.gov				
	Sponsor Website	·					
	Program URL	Link to program	URL				
	Deadline Dates (ALL)	29-Feb-2024 [O	ptional][LOI/Pre-App], 29-M	ar-2024			



SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount

The purpose of this Notice of Funding Opportunity (NOFO) is to solicit Resource-Related Research (U24)

applications for an Early Psychosis Intervention Network (EPINET) National Data Coordinating Center (ENDCC). The ENDCC will develop infrastructure to facilitate large-scale, practice-oriented research across clinics offering evidence-based Coordinated Specialty Care (CSC) to persons experiencing a first episode of psychosis. This NOFO focuses on research tools and resources directed at (1) optimizing the EPINET Core Assessment Battery (CAB) to support learning health care studies within and across CSC research networks; (2) adapting and implementing the CAB for use in publicly funded CSC programs that aspire to measurement-based care; (3) developing the informatics infrastructure and pipelines necessary to gather, store, and upload de-identified, person-level data collected across participating research networks to the NIMH Data Archive (NDA); and (4) assembling individual network datasets into a national repository of early psychosis clinical features, interventions, and treatment outcomes to be shared with qualified investigators via the NDA. In addition, the ENDCC will provide operational and technical support to the EPINET research consortium described in companion announcement RFA-MH-24-105. This NOFO requires a Plan for Enhancing Diverse Perspectives (PEDP), which will be assessed as part of the scientific and technical peer review evaluation. Applications that fail to include a PEDP will be considered incomplete and will be withdrawn. Applicants should carefully read the NOFO instructions and review the available PEDP guidance

RFA-MH-25-115 -- BRAIN Initiative: Marmoset 122695 Colonies for Neuroscience Research (U24 Clinical Trials Not Allowed)

National Institutes of Health/DHHS

RFA-MH-25-115

01-Feb-2024 [Optional][LOI/Pre-

App]

Not Specified

Contact Name Abigail Soyombo, Ph.D., MBA

Contact Telephone 301-827-7329

Synopsis

Contact Email abigail.soyombo@nih.gov

Sponsor Website

Program URL Link to program URL

material.

Deadline Dates (ALL) 01-Feb-2024 [Optional] [LOI/Pre-App], 01-Mar-2024

Synopsis

The common marmoset (Callithrix jacchus) has emerged as a promising nonhuman primate model system to understand the primate brain. This has come about both from the realization that the behavior of the common marmoset is similar in some ways to human behavior and from recent demonstration of germline transmission of exogenous genetic information. This Notice of Funding Opportunity (NOFO) solicits applications to expand existing colonies of the common marmoset for neuroscience research in the United States, and to support the care, breeding and distribution of genetically modified marmosets, and cryopreserved embryos and gametes created by



SPIN ID	Program	Sponsor Name	Sponsor Number	Deadline Date	Funding
SPIN ID	Title	Sponsor warne	Sponsor Number	Deadine Date	Amount

NIH-funded research programs such as the NIH BRAIN Initiative Tools for Germline Gene Editing in Marmosets research consortium. Recipients under this NOFO are expected to expand their current marmoset colonies to provide healthy, well-characterized animals that will be made available to the neuroscience research community, and to include a plan to accept genetically modified marmosets, and cryopreserved embryos and gametes for distribution to the research community. Recipients are also expected to participate in and provide health and genetic information to an NIH-Funded Marmoset Coordination Center to help the community understand the pedigree of individuals in the captive marmoset population and improve the genetic diversity of that population across multiple colonies. This NOFO requires a Plan for Enhancing Diverse Perspectives (PEDP), which will be assessed as part of the scientific and technical peer review evaluation. Applications that fail to include a PEDP will be considered incomplete and will be withdrawn. Applicants are strongly encouraged to read the NOFO instructions carefully and view the available PEDP guidance material.

RFA-MH-24-105 -- Early Psychosis Intervention

Network (EPINET): Learning Health Care Research to Improve Mental Health Services and Outcomes (P01 Clinical Trial Optional)

National Institutes of Health/DHHS

RFA-MH-24-105

29-Feb-2024 [Optional][LOI/Pre-

5,000,000 USD

App]

Contact Name Robert K. Heinssen, Ph.D.

Contact Telephone 301-435-0371

Contact Email rheinsse@mail.nih.gov

Sponsor Website

Program URL Link to program URL

Deadline Dates (ALL) 29-Feb-2024 [Optional] [LOI/Pre-App], 29-Mar-2024

The purpose of this NOFO is to solicit Program Project (P01) applications from scientific hubs to support learning health care research in clinics offering evidence-based Coordinated Specialty Care (CSC) to persons in the early stages of psychotic illness. For this NOFO, "early psychosis" is defined as the period spanning the onset of an affective or non-affective psychotic disorder and up to 5 years following the first episode of psychosis. Each scientific hub will link multiple early psychosis service programs through (1) the EPINET Core Assessment Battery (CAB) of early psychosis clinical features, CSC services, and treatment outcomes; (2) informatics tools to collect deidentified, person-level data across sites; and (3) a unified approach for analyzing pooled data and disseminating promising findings rapidly across the network. The P01 activity code supports research that has multiple distinct but synergistic projects built around a clearly defined unifying central theme or well-defined overall objective. This

NOFO requires a Plan for Enhancing Diverse Perspectives (PEDP), which will be assessed as part of the scientific and

Synopsis

122692

SPIN ID	Program Title	S	ponsor Name	Sponsor Number		Deadline Date	Funding Amount
		·	review evaluation. Applicatio olicants should carefully read			•	e
122696	RFA-MH-25-116 BRAIN Initia Coordination Center (U24 Clin Allowed)		National Institutes of Health/DHHS	RFA-MH-25-116	01-Feb-2024 [Optional][LOI/Pre- N App]	ot Specified	
	Contact Name	Abigail Soyomb	o, Ph.D., MBA				
	Contact Telephone	301-827-7329					
	Contact Email	abigail.soyomb	o@nih.gov				
	Sponsor Website						
	Program URL	Link to program	ı URL				
	Deadline Dates (ALL)	01-Feb-2024 [O	ptional][LOI/Pre-App], 01-M	ar-2024			
Deadline Dates (ALL) 01-Feb-2024 [Optional][LOI/Pre-App], 01-Mar-2024  This Notice of Funding Opportunity Announcement (NOFO) solicits applications to create a Marmoset Coord Center. The recipient will be responsible for two separate but related activities. The first activity will be to be the data coordinating center for genomic, pedigree, and event records (date of birth, medical, reproductive for captive marmosets. The recipient recipient will also coordinate with marmoset breeding centers and pe genome sequencing of marmosets that are yet to be sequenced. The recipient is expected to use available of help make breeding recommendations to maximize the health and genetic diversity of marmosets in the procionies. Applicants are encouraged to adopt the model used by the Association of Zoos and Aquariums. The Synopsis second major activity of the recipient will be to maintain a website and an information support center to as neuroscience researchers who are used to working with other animal models so that they may assess the utincluding marmosets in their scientific research program. In cases where the neuroscientists want to move for the Coordination Center will link the investigators to marmoset colonies that may be able to facilitate their solutions. This NOFO requires a Plan for Enhancing Diverse Perspectives (PEDP), which will be assessed as part of the sand technical peer review evaluation. Applications that fail to include a PEDP will be considered incomplete will be withdrawn. Applicants are strongly encouraged to read the NOFO instructions carefully and view the available PEDP guidance material.						will be to become productive historiaters and perform the available data to ets in the programmariums. The center to assist assess the utility on to move forwarilitate their science part of the scientincomplete and	ne ry) o n o f rd,
121852	RFA-DK-23-004 Human Islet Network - Consortium on Moo		National Institutes of Health/DHHS	RFA-DK-23-004	20-Feb-2024 [Optional][LOI/Pre- 3, App]	.750,000 USD	

SPIN ID Program Title		Sponsor Name	Sponsor Number		Deadline Date	Funding Amount		
Autoimmune Diabe								
		Dh D						
	ntact Name Albert Hwa, Telephone 301-451-15:							
	,							
	ntact Email <u>albert.hwa@</u>	<u>ynın.gov</u>						
·	or Website	mana LIDI						
	ogram URL Link to prog		4 2024					
Deadline		4 [Optional][LOI/Pre-App], 20-N						
	This Notice of Funding Opportunity (NOFO) welcomes applications for the Consortium on Modeling Autoimmune Diabetes (CMAD) that supports the development of in vitro and in vivo models of type 1 diabetes (T1D) to enable studies of human T1D pathophysiology and to serve as platforms for preclinical assessments of new T1D interventions. CMAD is part of the Human Islet Research Network (HIRN).							
108113 Notice of Special In Disparities and Alzh	terest (NOSI): Health neimer's Disease	National Institutes of Health/DHHS	NOT-AG-21-033	11-Mar-2024	Not Specified			
Cor	ntact Name Damali Mar	tin, Ph.D.						
Contact	Telephone 301-402-83	10						
Co	ntact Email <u>martinda@ı</u>	mail.nih.gov						
Spons	or Website							
Pr	ogram URL Link to prog	ram URL						
Deadline	Dates (ALL) 11-Mar-202	4 , 09-Jul-2024 , 12-Nov-2024						
	Synonsis This Notice	of Special Interest (NOSI) encon AD/ADRD, using diverse coho		examine mediators and	moderators of			
RFA-DA-24-037 A  115841 Abuse Research Us  Clinical Trial Option		Drug National Institutes of Health/DHHS	RFA-DA-24-037	04-Mar-2024	275,000 USD			
Cor	ntact Name Marsha F. Lo	opez, Ph.D., M.H.S.						
	Telephone 301-443-650	•						
Со	ntact Email marsha.lope	ez@nih.gov						



SPIN ID	Program	Sn.	oncor Namo	Spansor Number		Deadline Date	Funding
SPIN ID	Title	Sp	onsor wame	Sponsor Number		Deadline Date	Amount
	Sponsor Website						
	Program URL	Link to program	<u>URL</u>				
	Deadline Dates (ALL)	04-Mar-2024 , 05	4 , 05-Aug-2024 , 15-Nov-2024 e of this Funding Opportunity Announcement (FOA) is existing social science, behavioral, administrative, and by of substance using behaviors (defined as alcohol, to orders, prevention of substance use and HIV, and health oublic use and other extant community-based or clinic knowledge of etiology, trajectories of substance using mortality, risk and resilience in the development of the testing, implementation, and delivery of high quality and treatment of substance use disorder and HIV. Printo this FOA.  National Institutes of Health/DHHS  Ph.D.  Ph				
analysis of existing social science, behavioral, administrative, and neuroimaging data to study the etiology and epidemiology of substance using behaviors (defined as alcohol, tobacco, prescription, and other substances) and related disorders, prevention of substance use and HIV, and health service utilization. This FOA encourages the analyses of public use and other extant community-based or clinical datasets to their full potential in order to increase our knowledge of etiology, trajectories of substance using behaviors and their consequences including morbidity and mortality, risk and resilience in the development of psychopathology, strategies to guide the development, testing, implementation, and delivery of high quality, effective and efficient services for the prevention and treatment of substance use disorder and HIV. Primary data collection is not allowed for applications in response to this FOA.  114250 Trailblazer Award for New and Early Stage Investigators (R21 Clinical Trial Optional)  Randy King, Ph.D.  Randy King, Ph.D.							ns
114750 -				PAR-24-022	07-Jan-2024	400,000 USD	
	Contact Name	Randy King, Ph.D	).				
	Contact Telephone	301-451-0707					
epidemiology of substance using behaviors (defined as alcohol, tobacco, prescription, and other substances) and related disorders, prevention of substance use and HIV, and health service utilization. This FOA encourages the analyses of public use and other extant community-based or clinical datasets to their full potential in order to increase our knowledge of etiology, trajectories of substance using behaviors and their consequences including morbidity and mortality, risk and resilience in the development of psychopathology, strategies to guide the development, testing, implementation, and delivery of high quality, effective and efficient services for the prevention and treatment of substance use disorder and HIV. Primary data collection is not allowed for applications in response to this FOA.  114250 Trailblazer Award for New and Early Stage Investigators (R21 Clinical Trial Optional)  National Institutes of Health/DHHS  PAR-24-022  07-Jan-2024  400,000 USD							
	Deadline Dates (ALL)	16-Nov-2024, 07	7-Jan-2025 , 16-Feb-2025 ,	-			
	Synopsis	(https://grants.n NIBIB that integr project may be e design-directed, for which there a	nih.gov/policy/early-invest rate engineering and the p exploratory, developmenta discovery-driven, or hypo are minimal or no prelimin	igators/index.htm) to purs hysical sciences with the I II, proof of concept, or hig thesis-driven. Importantly ary data. A distinct featur	sue research programs ife and/or biomedical shrisk-high impact, and applicants must propose for this FOA is that no	ciences. A Trailblazer may be technology ose research approach o preliminary data are	



SPIN ID	Program Title	Sp	onsor Name	Sponsor Number		Deadline Date	Funding Amount		
		journal.All prelin figure. Application	naterial which the applicant ninary data should be clear ons including data more tha ith the FOA instructions and	y marked and limited to o n one-half page or more t	ne-half page, which ma han one figure will be co	y include one	d		
122740	RFA-DK-23-021 Cardiovascu Type 1 Diabetes (CARE-T1D) C Clinical Trial Not Allowed).		National Institutes of Health/DHHS	RFA-DK-23-021	11-Mar-2024 [Optional][LOI/Pre- App]	1,800,000 USD			
	Contact Name	Teresa L. Z. Jone	s, M.D.						
	Contact Telephone	301-435-2996							
	Contact Email	teresa.jones@ni	h.gov						
	Sponsor Website								
	<del>-</del>	Link to program							
	Deadline Dates (ALL)	11-Mar-2024 [Optional][LOI/Pre-App], 11-Apr-2024							
Cardiovascular complications are the leading cause of death for individuals with type 1 diabetes (T1D) and significantly shorten their lives. Cardiovascular disease (CVD) progression in people with T1D differs from that observed in people with type 2 diabetes (T2D) and residual increased risk of CVD remains after treatment of standard risk factors, such as hyperglycemia, hypertension, and hyperlipidemia. The NIH Cardiovascular Repostor T1D (CaRe-T1D) was initiated with the goal of establishing a biorepository of human CV tissue and a scient consortium to advance and support discovery and mechanistic research that increase the understanding of CV T1D. The first phase launched the biorepository and now in the second phase investigative teams will be added form a consortium with the biorepository serving as the Coordinating Center (CC). CaRe-T1D is currently collected hearts, kidneys, carotid and peripheral arteries, and blood from organ donors with T1D, T2D and without diabetes. The goal of this NOFO is to attract investigative teams with complementary interests and expertise will leverage these resources through individual and collaborative studies to advance our knowledge of the pathogenesis of CVD in T1D.							n o ng		
108318	Notice of Special Interest (NOS Gender Differences in Alzheim Alzheimer's Disease-Related D (AD/ADRD)	ner's Disease and Dementias	National Institutes of Health/DHHS	NOT-AG-21-050	11-Mar-2024	Not Specified			
	Contact Name	Amelia Karraker,	Ph.D.						



SPIN ID	Program Title	Sp	oonsor Name	Sponsor Number		Deadline Date	Funding Amount	
	Contact Telephone	301-496-3131						
	·	amelia.karraker	@nih.gov					
	Sponsor Website		-					
	Program URL	Link to program	<u>URL</u>					
	Deadline Dates (ALL)	11-Mar-2024 , 0	9-Jul-2024 , 12-Nov-2024					
	Synopsis	This NOSI promotes multidisciplinary research to clarify sex and gender differences in the risk, development, progression, diagnosis, and clinical presentation of Alzheimer's disease (AD) and Alzheimer's disease-related dementias (ADRD). Studies that examine sex and gender differences in outcomes (e.g., clinical, functional, well-being) among people living with AD/ADRD as well as AD/ADRD caregiving-related outcomes are also relevant. Broad areas of interest include biological (e.g., hormonal, genetic, metabolic, comorbidity-related), neuroscienti (e.g., neural systems and functions), behavioral (e.g., physical activity, substance use, social engagement), social (e.g., history of maltreatment or adversity, parenthood, marital status, educational attainment, socioeconomic amployment status), psychological (e.g., depression, cognitive functioning, socio-emotional functioning and self-regulation, stress reactivity, personality), healthcare profession (e.g., provider knowledge and attitudes about dementia) and healthcare system-level (e.g., access to care) factors and processes that separately, or together, adrive observed differences by sex and gender and/or may operate differently by sex and gender. Studies that account for methodological and measurement issues that may drive sex and gender differences are also of interest.						
	Notice of Special Interest (NOS							
111847/	Disorders and Circadian Clock Alzheimer's Disease and other		National Institutes of Health/DHHS	NOT-AG-21-051	11-Mar-2024 N	ot Specified		
	Aging							
	Contact Name	Miroslaw 'Mack	' Mackiewicz, Ph.D.					
	Contact Telephone	301-496-9350						
		mirolsaw.macki	ewicz@nih.gov					
	Sponsor Website							
	_	Link to program						
	Deadline Dates (ALL)	11-Mar-2024 , 0	9-Jul-2024 , 12-Nov-2024					

SPIN ID	Program Title	Sp	onsor Name	Sponsor Number		Deadline Date	Funding Amount
	Synopsis	and circadian clo	NOSI is to advance basic and ock dysfunction in AD/ADRE of neurodegeneration.		•	· · · · · · · · · · · · · · · · · · ·	
122639	Career Enhancement Award to Research on Firearm Injury an Prevention (K18 Independent Required)	d Mortality	National Institutes of Health/DHHS	PAR-24-073	15-Mar-2024	Not Specified	
	Contact Name	Dara Blachman-l	Demner				
	Contact Telephone						
			demner@nih.gov				
	Sponsor Website						
	-	Link to program	<u>URL</u>				
	Deadline Dates (ALL)						
This NIH Research Career Enhancement Award (K18) program invites applications from experienced investigators seeking to redirect or expand their research programs through the acquisition of new skills and knowledge in the area of firearm mortality and injury prevention research, which is beyond and complementary to their current areas of expertise. The program will support research training and career development experiences and a small-scale research project that will provide experienced investigators with the scientific competencies required to conduct research relevant to firearm morality and injury prevention research. Eligible candidates are independent investigators at any faculty rank or level. The proposed project must be related to the programmatic interests of one or more of the participating NIH Institutes and Centers (ICs) based on their scientific missions. This Notice of Funding Opportunity (NOFO) is designed specifically for applicants proposing to serve as the lead investigator of a independent clinical trial, a clinical trial feasibility study, or a separate ancillary study to an existing trial, as part of their research and career development. Applicants not planning an independent clinical trial, or proposing to gain research experience in a clinical trial led by another investigator, must apply to companion NOFO (TEMP 24098).							t an f
111641	Notice of Special Interest (NOS Change and Health	SI): Climate	National Institutes of Health/DHHS	NOT-ES-22-006	07-Jan-2024	Not Specified	
	Contact Name Contact Telephone	Claudia L. Thom 984-287-3330	pson				



SPIN II)	Program Title	S	ponsor Name	Sponsor Number		Deadline Date	Funding Amount			
		thompso1@nie	ehs.nih.gov							
	Sponsor Website									
	Program URL	Link to program	<del></del>							
		07-May-2024 , 08-Aug-2024 , ( 15-Nov-2024 , (	5-Jan-2024 , 05-Feb-2024 , 1: 25-May-2024 , 05-Jun-2024 , 07-Sep-2024 , 25-Sep-2024 , ( 08-Dec-2024 , 09-Dec-2024 , 08-Apr-2025 , 07-May-2025	12-Jun-2024 , 16-Jun-202 05-Oct-2024 , 12-Oct-2024	24 , 19-Jun-2024 , 09-Jul-202 4 , 16-Oct-2024 , 21-Oct-20	24 , 15-Jul-2024 , 24 , 12-Nov-2024	,			
	Synopsis	The National Institute of Environmental Health Science (NIEHS), in partnership with Fogarty International Center (FIC), National Institute of Minority Health and Health Disparities (NIMHD), Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), National Institute of Mental Health (NIMH), National Institute of Nursing Research (NINR), National Heart Blood and Lung Institute (NHBLI) and National Institute of Allergy and Infectious Disease (NIAID) is leading an NIH-wide Climate Change and Health Initiative (CCHI) with the goals of: reducing the health threats posed by climate change across the lifespan; improving the health of people who are at increased risk from or disparately affected by climate change impacts; and building health resilience among individuals, communities, nations around the world, thereby increasing health equity. As a part of this CCHI, this NOSI encourages applications that address the impact of climate change on health and well-being over the life course, including the health implications of climate change in the United States and globally.								
111986 Re	otice of Special Interest (NOS esearch to Understand and A ood and Nutrition Insecurity		National Institutes of Health/DHHS	NOT-OD-22-135	07-Jan-2024 No	ot Specified				
	Contact Name	Marya Levintov	va, PhD							
	Contact Telephone	301-496-9535								
	Contact Email	marya.levintov	a@nih.gov							
	Sponsor Website									
	Program URL	Link to program	<u>ı URL</u>							
	Deadline Dates (ALL)		5-Feb-2024 , 06-Feb-2024 , 1 .6-Jun-2024 , 07-Sep-2024 , 0		•	024 <i>,</i> 05-Jun-2024	• ,			
	Synopsis		purpose of this NOSI is to encourage research on the efficacy of interventions that address nutrition security the mechanisms of food insecurity on a variety of health outcomes. It also calls for the development of new							



SPIN ID	Program Title	Spo	onsor Name	Sponsor Number		Deadline Date	Funding Amount
		the Office of Nut	trition security and assessn crition Research (ONR) Impl th NIH Institutes and Cente rition Research.	ementation Working Grou	p on Nutrition and Health	n Disparities in	
122869	Mobile Health: Technology and Low and Middle Income Count Clinical Trial Optional)		National Institutes of Health/DHHS	PAR-23-318	22-Mar-2024	Not Specified	
	Contact Name	Brad Newsome,	Ph.D				
	Contact Telephone	301-480-8389					
	Contact Email	brad.newsome@	nih.gov				
	Sponsor Website						
	_	Link to program					
	Deadline Dates (ALL)	22-Mar-2024 , 21	1-Mar-2025 , 20-Mar-2026				
	The purpose of this Funding Opportunity Announcement (FOA) is to encourage exploratory/developmental research applications that propose to study the development, validation, feasibility, and effectiveness of innovative mobile health (mHealth) interventions or tools specifically suited for low- and middle-income countries (LMICs) that utilize new or emerging technology, platforms, systems, or analytics. The overall goal of the program is to catalyze innovation through multidisciplinary research that addresses global health problems, develop an evidence base for Synopsis the use of mHealth technology to improve clinical and public health outcomes, and strengthen mHealth research capacity in LMICs. This FOA provides support for up to two years (R21 phase) for technology development and feasibility studies, followed by a possible transition to expanded research support (R33 phase) for validation, larger-scale feasibility, and effectiveness studies. Transition to the R33 depends on the completion of applicant-defined milestones, as well as program priorities and the availability of funds. All applicants must address both the R21 and R33 phases.						
105957	Time-Sensitive Obesity Policy a Evaluation (R01 Clinical Trial N		National Institutes of Health/DHHS	PAR-21-305	09-Jan-2024	Not Specified	
	Contact Name	Mary Evans, Ph.[	Э.				
	Contact Telephone	301-594-4578					
	Contact Email	evansmary@mai	il.nih.gov				



SPIN ID	Program Title	Sp	onsor Name	Sponsor Number		<b>Deadline Date</b>	Funding Amount
	Sponsor Website Program URL	Link to program	<u>URL</u>				
	Deadline Dates (ALL) 09-Jan-2024 , 09-Feb-2024 , 08-Mar-2024 , 09-Apr-2024 , 10-Jun-2024 , 09-Aug-2024 , 10-Sep-2024  This Funding Opportunity Announcement (FOA) establishes an accelerated review/award process to support time-sensitive research to evaluate a new policy or program that is likely to influence obesity related behaviors (e.g., dietary intake, physical activity, sedentary behavior, and/or sleep) and/or weight outcomes in an effort to prevent or reduce obesity. This FOA is intended to support research where opportunities for empirical study are, by their very nature, only available through expedited review and funding. All applications submitted to this FOA must demonstrate that the evaluation of an obesity-related policy or program offers an uncommon and scientifically-compelling research opportunity that will only be available if the research is initiated with minimum delay. For these reasons, applications submitted to this time-sensitive FOA are not eligible for re-submission. It is intended that eligible applications selected for funding will be awarded within 4 months of the application due date; however, administrative requirements and other unforeseen circumstances may delay issuance dates beyond that timeline.						
122741	RFA-DK-25-001 Addressing t Syndemics on the Health of Pe and Diseases and Conditions w Missions of NIDDK and NHLBI ( Optional)	ople with HIV vithin the	National Institutes of Health/DHHS	RFA-DK-25-001	19-Feb-2024 [Optional][LOI/Pre- 2 App]	2,500,000 USD	
	Contact Name	Peter Perrin, Ph.	D.				
	Contact Telephone						
		Peter.Perrin@ni	h.gov				
	Sponsor Website		LIDI				
	Program URL	Link to program	UKL				



Deadline Dates (ALL) 19-Feb-2024 [Optional][LOI/Pre-App], 20-Mar-2024, 18-Feb-2025 [Optional][LOI/Pre-App], 20-Mar-2025

This Notice of Funding Opportunity (NOFO) invites research projects that seek solutions to the development, exacerbation, and ineffective management of co-occurring conditions in marginalized communities of People with

racism, marginalization, discrimination, and/or stigma and their inter-relationships with social and structural risks. Projects may use mechanistic interventional approaches, policy/program evaluation studies, or epidemiology

Synopsis HIV (PWH). Projects must be based on a syndemics (synergistic epidemic) framework with a focus on the impact of

	Drogram						Funding
SPIN ID	Program Title	Spo	onsor Name	Sponsor Number		Deadline Date	Amount
		be within the mis which will be ass a PEDP will be co	d the evidence base to supp ssion of NIDDK or NHLBI. Th essed as part of the scientif insidered incomplete and w fully and view the available	is NOFO requires a Plan fo ic and technical peer revie ill be withdrawn. Applican	or Enhancing Diverse Perspew evaluation.	ectives (PEDP), s that fail to includ	le
112755	RFA-DA-23-053 HEAL Initiati Research to Practice to End th (R61/R33 Clinical Trial Optional	e Overdose Crisis	National Institutes of Health/DHHS	RFA-DA-23-053	19-Feb-2024 [Optional][LOI/Pre- N App]	ot Specified	_
	Contact Name	Carrie Mulford, P	Ph.D.				
	Contact Telephone						
		carrie.mulford@	nih.gov				
	Sponsor Website						
	_	Link to program I					
	Deadline Dates (ALL)		tional][LOI/Pre-App], 20-Ma				
The goal of this initiative is to support action-oriented research that accelerates the translation of resear practice to address the overdose crisis. There remains an urgent need for research that advances the destigma-free patient-centered systems of care such that people who experience addiction can recover are their recovery over the long-term. This FOA solicits applications that address understudied areas of opporticularly those that focus on fundamental barriers or facilitators to reducing overdose deaths at the provider, organizational, community, or system levels. Projects should be in alignment with the overall HEAL Initiative, and should focus on replicable, scalable, equitable approaches for accelerating the move evidence-based and promising treatments into routine use. This FOA invites phased applications to supprojects for which preliminary or feasibility data is not available at the time of submission. This FOA is a to RFA-DA-23-054, which solicits applications for which pilot data is available.						s the design of cover and sustain of opportunity, at the individual, overall goals of the movement of to support	
112756	RFA-DA-23-054 HEAL Initiati Research to Practice to End th (R33 Clinical Trial Optional)		National Institutes of Health/DHHS	RFA-DA-23-054	19-Feb-2024 [Optional][LOI/Pre- 3, App]	750,000 USD	
	Contact Name	Carrie Mulford, P	h.D.				
	Contact Telephone	301827-6473					



SPIN ID Pro	ogram le	Spo	onsor Name	Sponsor Number		Deadline Date	Funding Amount			
		carrie.mulford@	nih.gov							
	Sponsor Website									
	_	Link to program (		2024						
	Deadline Dates (ALL)		tional][LOI/Pre-App], 20-M nitiative is to support actior			-f				
	Synopsis	practice to addrestigma-free paties their recovery ovunderstudied are overdose deaths alignment with the approaches for a This FOA invites process.	ce to address the overdose crisis. There remains an urgent need for research that advances the design of a-free patient-centered systems of care such that people who experience addiction can recover and sustain recovery over the long-term. This Funding Opportunity Announcement (FOA) solicits applications that address studied areas of opportunity, particularly those that focus on fundamental barriers or facilitators to reducing ose deaths at the individual, provider, organizational, community, or system levels. Projects should be innent with the overall goals of the HEAL Initiative, and should focus on replicable, scalable, equitable aches for accelerating the movement of moving evidence-based and promising treatments into routine use. OA invites projects for which preliminary or feasibility data is available. This FOA is a companion to RFA-DA-3, which solicits applications for which pilot data is unavailable.							
	s Phenotypes Related to le e INCLUDE Project (X01 C ed)		National Institutes of Health/DHHS	PAR-24-081	13-Mar-2024 N	ot Specified				
	Contact Name	Huiqing Li, PhD								
	Contact Telephone	301-435-0554								
	Contact Email	huiqing.li@nih.go	<u>ov</u>							
	Sponsor Website									
	Program URL	Link to program l	<u>URL</u>							
	Deadline Dates (ALL)	13-Mar-2024 , 13	3-Mar-2025 , 13-Mar-2026							
		(INvestigation of to generate a larg molecular mecha and phenotypic of funding will be po	Notice of Funding Opportunity (NOFO) invites applications to submit samples to NIH INCLUDE Project vestigation of Co-occurring conditions across the Lifespan to Understand Down syndromE)-supported resources generate a large volume of integrated genomic and multi-omics data that will facilitate discovery of the lecular mechanisms of health conditions related to Down syndrome. The resulting data, and associated clinical phenotypic data, will become part of the INCLUDE Data Hub for sharing with the research community. No ding will be provided directly to applicants under this NOFO. Applicants are encouraged to propose omics assays existing biospecimens collected from individuals with Down syndrome and controls. The program will accept							



SPIN ID	Program	Sponsor Name	Sponsor Number	Deadline Date	Funding
SFIN ID	Title	Sponsor Warne	Sponsor Number	Deadine Date	Amount

applications that propose whole genome sequencing, including both short-read and long-read, exome, epigenome, and transcriptome sequencing, as well as proteomic, metabolomic, and single-cell RNA sequencing and ATAC sequencing, when justified. Applicants are encouraged to propose cohorts of underrepresented racial and ethnic groups or to increase racial and ethnic representation of existing collections.

Notice of Special Interest (NOSI):

Administrative Supplements to Support

123020 Extramural Collaborators for Notified Applicants for the Bench-to-Bedside and Back

Program (BtB) (Clinical Trial Optional)

National Institutes of Health/DHHS

NOT-OD-24-027

02-Mar-2024

300,000 USD

Contact Name Hana Smith, M.Sc.

Contact Telephone 301-402-6313

Contact Email BenchtoBedside@nih.gov

Sponsor Website

Program URL Link to program URL

Deadline Dates (ALL) 02-Mar-2024

Aiming to improve human health, the NIH Bench-to-Bedside and Back Program (BtB) Program ( https://ocreco.od.nih.gov/btb/btb program.html) supports innovative small/pilot research projects designed to translate basic scientific findings into therapeutic interventions for patients and to increase understanding of important clinical observations of disease processes. It promotes robust multi-directional collaborations among laboratory ("bench") and patient-focused ("bedside") investigators. Through the NIH BtB Program, this funding opportunity will invite two-year administrative supplement applications for collaborations between the NIH intramural research investigators, who conduct translational and clinical research and extramural NIH recipients. Every project must include an NIH intramural investigator who is responsible for submitting the BtB Letter of Intent (LOI) and application online (Proposal Central; PC; https://proposalcentral.com/). This NOSI is intended for the extramural collaborators of awarded Bench to Bedside (BtB) proposals. Selected Applicants will be notified by the

**Synopsis** 

Intramural partners may consult: NIH's database of all current intramural research at http://intramural.nih.gov/search/index.tml; Intramural Principal Investigator Directory at http://irp.nih.gov/ourresearch/principal-investigators; "Search the Studies" website to identify investigators on relevant protocols

BtB Program Officer to apply for an administrative supplement in response to this NOSI. Projects may have single or multiple Principal Investigator(s). Extramural investigators may initiate or lead projects, though the extramural investigator must still have an intramural collaborator. Extramural investigators who need assistance identifying

SPIN ID	Program Title	Sp	oonsor Name	Sponsor Number		Deadline Date	Funding Amount				
		at https://clinica	alstudies.info.nih.gov/; or B mural partners.	tB Program Office (Bench	ntoBedside@mail.nih.gov	for assistance in					
121638	RFA-DA-25-047 Seeking Pro Social Needs impacting Substa Disorders (SUD) (R41/R42 Clin Optional)	ance Use	National Institutes of Health/DHHS	RFA-DA-25-047	13-Feb-2024 [Optional][LOI/Pre- App]	Not Specified					
	Contact Name	Morris Flood, DI	HSc								
	Contact Telephone	301-496-6144									
	Contact Email	morris.flood@n	<u>ih.gov</u>								
	Sponsor Website										
	Program URL	Link to program	URL								
	Deadline Dates (ALL)	II	ptional][LOI/Pre-App], 13-N [LOI/Pre-App], 13-Mar-202		Optional][LOI/Pre-App], 1	3-Mar-2025 , 12-Feb	-				
	Synopsis	(SBCs) to develo	this notice of funding oppo p technologies for commer UD), excluding alcohol use	cialization to address hea							
121634	RFA-DA-25-048 Seeking Pro Social Needs impacting Substa Disorders (SUD) (R43/R44 Clin Optional)	ance Use	National Institutes of Health/DHHS	RFA-DA-25-048	13-Feb-2024 [Optional][LOI/Pre- App]	Not Specified					
	Contact Name	Morris Flood, DI	HSc								
	Contact Telephone	301-496-6144									
	Contact Email	morris.flood@n	ih.gov								
	Sponsor Website										
	Program URL	Link to program	Link to program URL								
	Deadline Dates (ALL)	II	ptional][LOI/Pre-App], 13-N [LOI/Pre-App], 13-Mar-202		Optional][LOI/Pre-App], 1	3-Mar-2025 , 12-Feb	-				



SPIN ID	Program Title	Sp	oonsor Name	Sponsor Number		Deadline Date	Funding Amount			
	Synopsis	(SBC) to develop	this notice of funding oppo technologies for commen UD), excluding alcohol use	cialization to address h						
123077	Intramural Loan Repayment P General Research (GR-LRP) (D		National Institutes of Health/DHHS	NOT-OD-24-035	15-Mar-2024	150,000 USD				
	Contact Name Contact Telephone Contact Email	866-849-4047								
	Sponsor Website Program URL	Link to sponsor Link to program								
	Deadline Dates (ALL)	15-Mar-2024								
	NIH invites applications for the Intramural Loan Repayment Program for General Research. The NIH Loan  Synopsis Repayment Programs (LRPs) are a set of programs established by Congress and designed to recruit and retain highly qualified health professionals into biomedical or biobehavioral research careers.									
123143	Limited Competition: Revision Existing NIH Centers for AIDS I and Developmental Centers for (D-CFAR) Grants (P30 Clinical	Research (CFAR) or AIDS Research	National Institutes of Health/DHHS	PAR-24-080	01-Mar-2024	Not Specified				
	Contact Name	Eric Refsland, Ph	n.D.							
	Contact Telephone	301-761-7193								
		eric.refsland@n	ih.gov							
	Sponsor Website									
	Program URL	Link to program	<u>URL</u>							
	Deadline Dates (ALL)	01-Mar-2024 , 0	9-Oct-2024 , 09-Oct-2025							
	Synopsis	AIDS Research ( additional suppo	Inding opportunity (NOFO) CFAR) and Developmental ort and infrastructure for t e United States and global	CFARs (D-CFAR) to expraining, mentoring, and	and the role of the CFARs dresearch related to HIV a	and D-CFARs to include and HIV-related health	е			



SPIN ID Program Title	s	ponsor Name	Sponsor Number		Deadline Date	Funding Amount	
	goals. This NOF		ing Diverse Perspective	of diverse perspectives into the state of th		<b>λ</b> R	
123075 Intramural Loan Repayment Clinical Researchers from Dis Backgrounds (CR-LRP)		National Institutes of Health/DHHS	NOT-OD-24-034	15-Mar-2024 1	00,000 USD		
Contact Nam	e						
Contact Telephon	e 866-849-4047						
Contact Ema	il <u>lrp@nih.gov</u>						
Sponsor Websit	e Link to sponsor	website					
Program UF	L Link to progran	<u>ı URL</u>					
Deadline Dates (AL	_) 15-Mar-2024						
Synops	Backgrounds. T	he NIH Loan Repayment Pro	grams (LRPs) are a set o	m for Clinical Researchers fro f programs established by Co into biomedical or biobehavi	ongress and		
123074 Intramural Loan Repayment Research (AIDS-LRP)	Program for AIDS	National Institutes of Health/DHHS	NOT-OD-24-033	15-Mar-2024 1	00,000 USD		
Contact Nam	e						
Contact Telephon	e 866-849-4047						
Contact Ema	il <u>lrp@nih.gov</u>						
Sponsor Websit	e Link to sponsor	website					
Program UF	L Link to progran	n URL					
Deadline Dates (AL	_) 15-Mar-2024						
Synops	Deadline Dates (ALL)  NIH invites applications for the Intramural Loan Repayment Program for AIDSResearch. The NIH Loan Repayment  Synopsis Programs (LRPs) are a set of programs established by Congress and designed to recruit and retain highly qualified health professionals into biomedical or biobehavioral research careers.						



SPIN ID	Program Title	Sp	onsor Name	Sponsor Number		Deadline Date	Funding Amount
122970	Implementation Research on Noncommunicable Disease Risk Low- and Middle-Income Countr Populations Living in City Enviror Clinical Trial Optional)	ry and Tribal	National Institutes of Health/DHHS	PAR-23-319	11-Mar-2024	Not Specified	
	Contact Name B Contact Telephone 3 Contact Email <u>F</u>	01-480-8389					
	Sponsor Website Program URL L Deadline Dates (ALL) 1	• •	<u>URL</u>				
Deadline Dates (ALL)  The National Institutes of Health (NIH) participating Institutes and Centers (ICs), in collaboration with the Glo Alliance for Chronic Diseases (GACD), invite applications for implementation research focused on addressing factors for common noncommunicable diseases (NCDs) in World Bank-defined low- and middle-income countries (LMICs) and American Indian/Alaska Native (Al/AN) populations in the United States (US). Air, wate soil pollution; lack of greenspace; urban heat islands; lack of safe infrastructure for walking, cycling, and active living; lack of access to healthcare facilities, lack of health insurance, and cost of medications; housing condition and wide availability of tobacco, alcohol, and unhealthy foods and beverages contribute to the NCD epidemic environments. In the context of this Notice of Funding Opportunity (NOFO), "cities" include urban centers, in Synopsis settlements, slums, and periurban areas. This NOFO supports applications that propose implementation rese reduce the risks of NCDs in the context of cities in LMICs and/or among Al/AN populations in US cities, with the potential to equip policymakers and practitioners with evidence-based strategies for prevention and/or management of NCDs among disadvantaged populations globally. NIH defines implementation research as the scientific study of the use of strategies to adopt and integrate evidence-based health interventions into clinic community settings to improve individual outcomes and benefit population health. All applications must be wears the scope of the mission of one of the Institutes/Centers listed above (see "Components of Participating Organizations," excluding the Fogarty International Center which manages this program but does not support							ity al to
113256	Notice of Special Interest (NOSI) and Preliminary Testing of Healt Behavioral Interventions		Office of Behavioral and Social Sciences Research/NIH/DHHS	NOT-OD-22-203	07-Jan-2024	Not Specified	

SPIN ID Title Sponsor Name Sponsor Number Deadline Date Amount
--

Contact Name William Elwood, PhD

Contact Telephone 301-402-0116

**Synopsis** 

Contact Email william.elwood@nih.gov

Sponsor Website

Program URL Link to program URL

07-Jan-2024, 16-Jan-2024, 01-Feb-2024, 05-Feb-2024, 06-Feb-2024, 13-Feb-2024, 15-Feb-2024, 16-Feb-2024,

Deadline Dates (ALL) 20-Feb-2024 , 07-Mar-2024 , 11-Mar-2024 , 07-May-2024 , 13-May-2024 , 05-Jun-2024 , 07-Jun-2024 , 16-Jun-2024

, 18-Jun-2024 , 09-Jul-2024 , 07-Sep-2024 , 13-Sep-2024

To achieve more potent strategies to promote sustained health-related behavior change, there is a need for intentional and methodical translation of foundational behavioral and social science discoveries into new or improved interventions. The Office of Behavioral and Social Sciences Research (OBSSR) and participating ICOs are issuing this Notice to highlight interest in the systematic development of original health-related behavioral interventions that test hypotheses that draw on basic behavioral and social sciences research (bBSSR) findings that posit causal or processual mechanisms of action of healthier behavior change. This includes research that focuses

on use-inspired bBSSR, understanding of mechanisms of action underlying initial and sustained behavior change, and systematic development and testing of health-related behavioral interventions and their components.

SPIN ID	Program Title		Sponsor Name		Sponsor Number	Deadline Date	Funding Amount
109414	Industry-University Cooperative	Research Centers Program		ional Science ndation	20-570	13-Mar-2024 [LOI/Pre-App]	Not Specified
	Contact Name	Prakash G. Balan					
	Contact Telephone	703-292-5341					
	Contact Email	pbalan@nsf.gov					
	Sponsor Website	Link to sponsor website					
	Program URL	Link to program URL					
	Deadline Dates (ALL)	13-Mar-2024 [LOI/Pre-App], 12-Jun-20	24				
	Synopsis	The IUCRC program catalyzes breakthr industry innovators, world-class acade agencies connect directly and efficient impact research to meet shared and criving innovative technology developengineering workforce.	mic teams, and govern ly with university resea itical industrial needs i	ment agencies. In archers to achieve in companies of a	UCRCs help three prim Il sizes; 2) E	industry partners a nary objectives: 1) C inhance U.S. global	and government Conduct high- leadership in
108144	Long-Term Ecological Research (	LTER) - Renewal		ional Science Indation	22-543	07-Mar-2024	Not Specified
	Contact Name	Roberto Delgado					
	Contact Telephone	703-292-2397					
	Contact Email	robdelga@nsf.gov					
	Sponsor Website	Link to sponsor website					
	Program URL	Link to program URL					
	Deadline Dates (ALL)	07-Mar-2024					
	Synopsis	To address ecological questions that call Long-Term Ecological Research Programs supported by other NSF programs: the natural biomes, and it emphasizes the five core areas. Long-term studies are interact as well as to test ecological the	m (LTER) in 1980. Two research is located at study of ecological phe critical to achieve an in	components diffe specific sites chos enomena over lor stegrated underst	erentiate LT sen to repre ng periods o anding of h	ER research from pesent major ecosystof time based on da low components of	rojects em types or ta collected in ecosystems



SPIN ID	Program Title		Sponsor Name		Sponsor Number	Deadline Date	Funding Amount
		testing of fundamental ecological theocommunities and ecosystems. It often patterns or processes over broad spati individual site, NSF requires that data sites. The program is on-going and proor when funding opportunities arise to solicitations. This solicitation governs s	integrates multip al scales. Recogn collected by all LT posals are period support new LTE	ole disciplines and, thro izing that the value of FER sites be made publ lically invited when a n ERs. These opportuniti	ough cross-s long-term d icly accessib leed is ident es are annoi	ite interactions ma ata extends beyond ble. NSF currently so ified to balance the unced through sepa	y examine d use at any upports 28 LTER LTER portfolio
111866	Mid-Career Advancement (MCA)	1		National Science Foundation	22-603	01-Mar-2024	Not Specified
	Contact Name	Leslie J. Rissler					
	Contact Telephone	703-292-4628					
	Contact Email	<u>lrissler@nsf.gov</u>					
	Sponsor Website	Link to sponsor website					
	Program URL	Link to program URL					
	Deadline Dates (ALL)	01-Mar-2024					
	Synopsis	The MCA program offers an opportuni advance their research program and cathey need to advance their research program service, teaching, or other activities these constraints to reduce workload in disabilities, and individuals from group	areer trajectory. I rograms to ensure at limit the amou nequities and ena	Mid-career scientists a e long-term productivi int of time devoted to able a more diverse sc	re at a critic ty and creat research. M ientific work	al career transition civity but are often CA support is expe cforce (more wome	stage where constrained by cted to help lift
113761	Expanding Al Innovation through	n Capacity Building and Partnerships		National Science Foundation	23-506	11-Mar-2024	Not Specified
	Contact Name						
	Contact Telephone	703-292-5111					
	Contact Email	ExpandAlProgram@nsf.gov					
	Sponsor Website	Link to sponsor website					
	Program URL	Link to program URL					



SPIN ID	Program Title		Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Deadline Dates (ALL)	11-Mar-2024 , 24-Jun-2024 , 18-Oct-20	024 , 10-Mar-2025 , 23-Jun-2025			
	Synopsis	research community for the advancem promote the NSF vision and core value Building and Partnerships (ExpandAI) p	ts partners support the continued grow lent of AI and AI-powered innovation, p s, especially inclusion and collaboration program aims to significantly broaden posity city development projects and through	roviding a unic	que opportunity t ng Al Innovation t Al research, educ	o broadly through Capacity ation, and
114947	Biodiversity on a Changing Plane	<u>et</u>	National Science Foundation	23-542 2	1-Mar-2024	Not Specified
	Contact Name	Matthew D. Carling				
	Contact Telephone	703-292-2134				
	Contact Email	biodiversity@nsf.gov				
	Sponsor Website	<u>Link to sponsor website</u>				
	Program URL	Link to program URL				
	Deadline Dates (ALL)	21-Mar-2024				
	Synopsis	proposals addressing grand challenges including climate change. Successful Be connections to shifting biodiversity dyncomplex intersections among climatic, combine multiple perspectivesincluding paleontological approaches at various biodiversity across temporal and spatial climatic, and geological processes are aby requiring an integrative approach to under changing environmental condition international partnerships with the National Research	also encouraged. While this focus compounderstanding functional biodiversity ons. The program supports both US-onlitional Natural Science Foundation of Chasearch Foundation (NRF) of South Africulating to NSF and the collaborating (	ext of unpreceds about function phasis on intercell processes. utionary, phyloper predictive capases, predictive capases, predictive several it relates to y collaborative ina (NSFC), the a. International	dented environmental biodiversity and biodiversity agrative research Integrative research ability about functions, and future all core programs shifting biodivers proposals and presearch and page São Paulo Research collaborative proposative presearch and page São Paulo Research And	ental change, and its into the rch is likely to cal, and/or actional biological, at NSF, it differs sity dynamics roposals with arch Foundation oposals are to

	1						
SPIN ID	Program Title	s	Sponsor Name		Sponsor Number	Deadline Date	Funding Amount
					Trumber .	Dutc	/ Induit
118691	Expanding TRIPODS through Part	tnerships		National Science Foundation	23-591 01	-Mar-2024	200,000 USD
	Contact Name	Eyad Abed					
	Contact Telephone	703-292-2303					
	Contact Email	nsftripodsworkgrp@nsf.gov					
	Sponsor Website	<u>Link to sponsor website</u>					
	Program URL	Link to program URL					
	Deadline Dates (ALL)	01-Mar-2024					
	Synopsis	and Information Science and Engineering Mathematical and Physical Sciences (MF Directorate for Engineering (ENG) of the diverse interdisciplinary research commpromote the NSF vision and core values, Principles of Data Science through Partn broaden participation in data science resthe current TRIPODS Phase II Institutes a amounts of NSF funding.	PS), and the Divi e National Sciend unity for the ad , especially inclu nerships (XTRIPC search, education	sion of Electrical, Com te Foundation (NSF) wancement of data sci- sion and collaboration DS) program, which lean, and workforce dev	munications and ill support the cence, providing the Expanding everages the exicelopment by su	d Cyber Systems ontinued growt a unique oppor g Transdisciplina sting TRIPODS p pporting partne	s (ECCS) in the h of a broad and tunity to broadly ary Research in rogram, aims to rships between
122261	<u>Transport Phenomena Research</u> <u>Earth</u>	at the International Space Station to Ben	nefit Life on	National Science Foundation	24-501 04	-Mar-2024	3,600,000 USD
	Contact Name	Ronald D. Joslin					
	Contact Telephone	703-292-7030					
	Contact Email	rjoslin@nsf.gov					
	Sponsor Website	Link to sponsor website					
	Program URL	Link to program URL					
	Deadline Dates (ALL)	04-Mar-2024					
	Synopsis	The Division of Chemical, Bioengineering National Science Foundation (NSF) is part					



SPIN ID	Program Title		Sponsor Name		Sponsor Number	Deadline Date	Funding Amount
		solicit research projects in the general systems, thermal transport processes National Lab to conduct research that §6010, including academic investigate eligible to apply.	, and nanoscale interact will benefit life on Earth	ions that can utilized.  Only entities the	e the Inte at qualify a	rnational Space Stat as "U.S. Persons" un	ion (ISS) der 22 U.S. Code
122134	NSF/CASIS Collaboration on Tiss Space Station (ISS) to Benefit Life	ue Engineering and Mechanobiology o e on Earth		onal Science ndation	24-502	15-Mar-2024	400,000 USD
	Contact Telephone						
		shisharm@nsf.gov					
	•	Link to sponsor website					
	Deadline Dates (ALL)	Link to program URL					
		The Divisions of Chemical, Bioenginee Infrastructure (CMMI) in the Enginee for the Advancement of Science in Spand mechanobiology that can utilize tile on Earth. For utilization of the ISS U.S. Code §6010: "United States per United States, and any corporation, p	ring Directorate of the Nace, Inc. (CASIS) to solicithe International Space Sational Lab through the son' means any United S	ational Science Fo t research project tation (ISS) Natio is solicitation, ent tates citizen or ali	undation ( s in the ge hal Lab to ( ities must en admitte	(NSF) are partnering neral fields of tissue conduct research th qualify as "U.S. Pers ed for permanent re	with the Center e engineering at will benefit sons" under 22 esidence in the
122951	Collaborative Research in Comp	utational Neuroscience		onal Science ndation	24-510	07-Mar-2024	Not Specified
	Contact Name	Kenneth Whang					
	Contact Telephone	703-292-5149					
	Contact Email	kwhang@nsf.gov					
		<u>Link to sponsor website</u>					
	-	<u>Link to program URL</u>					
	Deadline Dates (ALL)	07-Mar-2024 , 13-Nov-2024 , 12-Nov	2025				



SPIN ID	Program Title		Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Synopsis	Computational neuroscience provides nervous system at all levels, building or other disciplines to accelerate the undesystem disorders, and computational sfunding organizations support collabor appropriate to the missions and strates to this solicitation: Research Proposals sharing of data and other resources.	n the theory, methods, and findings of erstanding of nervous system structu trategies used by the nervous system ative activities that span a broad spec gic objectives of each agency. Two cla	of computer so re and function. Through the ctrum of complesses of propo	cience, neuroscience on, mechanisms und e CRCNS program, the putational neurosciens osals will be conside	e, and numerous lerlying nervous e participating ence research, as red in response
123047	Strengthening American Infrastr	<u>ucture</u>	National Science Foundation	24-519	12-Mar-2024	750,000 USD
	Contact Name	Steven Breckler				
	Contact Telephone	703-292-7369				
	Contact Email	sbreckle@nsf.gov				
	Sponsor Website	Link to sponsor website				
	Program URL	Link to program URL				
	Deadline Dates (ALL)	12-Mar-2024				
	Synopsis	Strengthening American Infrastructure potentially transformative research ain strong foundation for socioeconomic vinfrastructure spurs private-sector innomefficient, strengthens communities, prosecurity and fuels American leadership science and engineering disciplines. SA making, governance, and social and cuimproves lives and society and builds of convergence of expertise in one or mo support substantial and potentially patinfrastructure.	ned at strengthening America's infrastitality and broad improvement in quadration, grows the economy, creates omotes equal opportunity, protects the Achieving these objectives requires I focuses on how fundamental knowletural processes enables the building an advances in technology and engine are social, behavioral or economic scie	tructure. Effe dity of life. Str jobs, makes p he natural en- the integration edge about he and maintena ering. Success nces, deeply	ective infrastructure rong, reliable and efoublic-sector service vironment, enhance on of expertise from uman reasoning and ince of effective infraful projects will registed with other	provides a fective provision more s national across all d decision- astructure that present a er disciplines to
123061	<u>Future of Semiconductors</u>		National Science Foundation	24-521	14-Mar-2024	2,000,000 USD

SPIN ID Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
-----------------------	--------------	-------------------	------------------	-------------------

Contact Name Nadia A. El-Masry

Contact Telephone 703-292-4975

Contact Email fuse1@nsf.gov

Sponsor Website Link to sponsor website

Program URL Link to program URL

Deadline Dates (ALL) 14-Mar-2024

The current state of semiconductor microelectronic systems is at a crossroads. Continued advances in the capabilities of many technologies as well as the cost of the applications of these technologies across computing, sensing, and communications are threatened. The technology has expanded following the trends in miniaturization long characterized by Moore's Law, underpinned by new materials, processes, devices, and architectures. The developments in these underpinning areas have often progressed independent of the application area, which has delayed their incorporation into the nextgeneration technologies. Closing that gap between the essential components in the technology chain is now required to ensure further progress. The materials, devices, and systems need to be co-designed, that is, they need to be designed with simultaneous consideration of elements of the technology chain. The benefits of a co-design approach as a principal methodology to advance semiconductor technology have been widely recognized in a variety of government and industry Synopsis studies. This holistic, co-design approach can more rapidly create high-performance, robust, secure, compact, energyefficient, and cost-effective solutions. The technological drivers include the need to: dramatically reduce the energy consumption of computation and communication technologies; reduce the impact of device and system manufacturing on the environment; increase performance speed and capacity; and develop new computing systems. The goal of this solicitation is to cultivate a broad coalition of researchers and educators from across science and engineering communities that utilizes a holistic, co-design approach to fundamental research and workforce education and training, to enable rapid progress in new semiconductor technologies. The future of semiconductor manufacturing will require the design and deployment of diverse new technologies in materials, chemical and materials processes, devices, and architectures through

Dear Colleague Letter: Mid-scale Research Infrastructure Incubators and Conferences for National Science STEM Education Research with a Focus on Education Equity

**Foundation** 

the development of application-driven systems. Partnerships between industry and academic institutions are essential to

spur innovation and technology transfer, to inform the research needs, and to train the future workforce.

NSF 24-027

15-Mar-2024

**Not Specified** 

Contact Name

Contact Telephone 703-292-5111

Contact Email edumidsc@nsf.gov



122782

SPIN ID	Program Title		Sponsor Name		Sponsor Number	Deadline Date	Funding Amount
	•	With this Dear Colleague Letter (DCL), the community of the continuing collar for Strategic Innovation (Schmidt Futur Network (RCN) proposal opportunities	boration with the res), and the Walt that support the ets and needs of the frastructure (RI) mmunity because entation. Improvinfrastructures. Thr	Bill & Melinda Gates For con Family Foundation of development of mid-some hose historically underroom is a relatively new concerns STEM education researches the speed and scale arough this DCL, NSF aim	oundation, to offer Incucale research represented cept for the arch has tracet which STE as to concept	the Eric and Wendy ubator Research Cohinfrastructure efform STEM and that Science Technology ditionally been disted and consolitualize and consoli	r Schmidt Fund ordination orts, especially lead to greater y Engineering ributed, arch advances,
122789	<u>Dear Colleague Letter: Planning</u> <u>and Technology (CREST Centers)</u>	Proposals for Centers of Research Excel in Chemistry Research	lence in Science	National Science Foundation		01-Mar-2024 [LOI/Pre-App]	200,000 USD
	Contact Name						
	Contact Telephone	703-292-5111					
	Contact Email	selshall@nsf.gov					
	Sponsor Website	Link to sponsor website					
	Drogram LIDI	Link to program LIDI					

Program URL Link to program URL

Deadline Dates (ALL) 01-Mar-2024 [LOI/Pre-App], 01-May-2024

The Division of Equity for Excellence in STEM (EES) and the Division of Chemistry (CHE) jointly encourage the submission of planning proposals for a future CREST center proposal with a focus on chemistry research. The CREST Program supports the creation of research centers that will lead to strong societal impacts through 5-year awards. The projects focus on the enhancement of the research capabilities of Minority-Serving Institutions (MSIs) through the establishment of centers that effectively integrate education and research. CREST Center awards promote the development of new knowledge, the increase in the research productivity of individual faculty, and the expanded engagement of students from backgrounds historically underrepresented in STEM disciplines.



SPIN ID	Program Title	Sponsor Name	•	Deadline	Funding
			Number	Date	Amount

# Other Federal Funding Opportunities

SPIN ID Prog	ram Title	Sponsor Name	Sponsor Number	Dea	dline Date	Fund	ling Amount
Program Title	Sponsor Name		Sponsor Number		Deadline D	ate	Funding Amount
117245	FCOAmendmentAdvanced Research Open-Office Broad Agency Announcem		Advanced Research Projects Agency for Health/NIH/DHHS	75N99223	20001	14-Mar- 2024	Not Specified
	6.102(d)(2), Fresultant away procurement everyone by will develop a health resear better health Cancer Moor technology, cadvance the Clinical Trial I Microbial Research excluded are proposals dir physical infra	ns@ARPA-H.gov or website am URL	uncement (BAA) as contemplations (CFR) § 200.203, and in a cent laws and regulations, and the FAR. The mission of ARPA impact solutions to society's realth-related challenges through to the societal, ARPA-H so, communities, diseases, and nnovative approaches to enapovations that are entirely no such as the Cancer Moonshot lunger, Nutrition, and Health; addressing mental health an anary or incremental advance conal education and training, ce ARPA-H mission. ARPA-H ha	accordance value of the National Market Propose the National deurs of the Currer or center cooks identified to the National sidentified to the Currer or center cooks identified to the National sidentified to the Currer or center cooks identified to the Currer or center cooks identified to the National curbing the Currer or center cooks identified to the Currer or center or center cooks identified to the Currer or center or cent	with Public Litions and/or elerate bette ging health pential, high-ials that aim ditions, incluonary advance froncept or the Americal Action Plane opioid epicat state of the contination ar four initial for	aw No: 1 awards er health problem impact b to rapid ding in s ces in sci contribu an Bioeco n for Cor demic. S he art. Ac nd consti	117-328. Any for outcomes for s. Awardees iomedical and y achieve upport of the ence, ate directly to phony; abatting Antipecifically ditionally, ruction of es that are a

# Other Federal Funding Opportunities

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Fundi	ing Amount
		health outcomes or prolong well-being, espec currently lacks effective treatment options. Af from foundational science to the introduction with ARPA-H's mission to accelerate better he within the health funding ecosystem due to the	RPA-H will foster innovations ac of new prototypes into the man alth outcomes and undertake re	ross the spectrum of tec rketplace. To receive fur	chnology rea	adiness – cs must align
122990	2024-25 EdUSA Opportu	nity Funds Program for Graduate Study	Department of State	FY2024VE005	01-Mar- 2024	75,000 USD
	Contact Name Contact Telephone					
	Sponsor Website					
	Program URL Deadline Dates (ALL)	Link to program URL				
	Synopsis	The Public Diplomacy Section at the Venezuela focused on promoting U.S. higher education of at the post-graduate level in the Agricultural Stand the United States and be directed at Venezuela.	pportunities for high-achieving, TEM and Public Health fields. Pi	financially disadvantage roject activities must tak	ed Venezuel ke place in V	lan students /enezuela
123073		focused on promoting U.S. higher education o at the post-graduate level in the Agricultural S	pportunities for high-achieving, TEM and Public Health fields. Pr zuelan audiences/participants.	financially disadvantage roject activities must tak	ed Venezuel ke place in V ) for one aw 23-Jan- 2024	lan students /enezuela
123073	Boosting Innovative GEO Announcement (BAA)  Contact Name	focused on promoting U.S. higher education of at the post-graduate level in the Agricultural S and the United States and be directed at Vene INT-Science and Technology (BIG-ST) Broad Age	pportunities for high-achieving, TEM and Public Health fields. Pr zuelan audiences/participants. ency National Geospatial-	financially disadvantage roject activities must tak Total funding is \$75,000	ed Venezuel se place in V ofor one aw 23-Jan- 2024 [LOI/Pre-	lan students /enezuela /ard.
123073	Boosting Innovative GEO Announcement (BAA)  Contact Name Contact Telephone	focused on promoting U.S. higher education of at the post-graduate level in the Agricultural S and the United States and be directed at Vene INT-Science and Technology (BIG-ST) Broad Age	pportunities for high-achieving, TEM and Public Health fields. Pr zuelan audiences/participants. ency National Geospatial-	financially disadvantage roject activities must tak Total funding is \$75,000	ed Venezuel se place in V ofor one aw 23-Jan- 2024 [LOI/Pre-	lan students /enezuela /ard.
123073	Boosting Innovative GEO Announcement (BAA)  Contact Name Contact Telephone Contact Email	focused on promoting U.S. higher education of at the post-graduate level in the Agricultural S and the United States and be directed at Vene INT-Science and Technology (BIG-ST) Broad Age	pportunities for high-achieving, TEM and Public Health fields. Pr zuelan audiences/participants. ency National Geospatial-	financially disadvantage roject activities must tak Total funding is \$75,000	ed Venezuel se place in V ofor one aw 23-Jan- 2024 [LOI/Pre-	lan students /enezuela /ard.
123073	Boosting Innovative GEO Announcement (BAA)  Contact Name Contact Telephone Contact Email Sponsor Website	focused on promoting U.S. higher education of at the post-graduate level in the Agricultural Stand the United States and be directed at Vene INT-Science and Technology (BIG-ST) Broad Age	pportunities for high-achieving, TEM and Public Health fields. Pr zuelan audiences/participants. ency National Geospatial-	financially disadvantage roject activities must tak Total funding is \$75,000	ed Venezuel se place in V ofor one aw 23-Jan- 2024 [LOI/Pre-	lan students /enezuela /ard.
123073	Boosting Innovative GEO Announcement (BAA)  Contact Name Contact Telephone Contact Email Sponsor Website Program URL	focused on promoting U.S. higher education of at the post-graduate level in the Agricultural S and the United States and be directed at Vene INT-Science and Technology (BIG-ST) Broad Age	pportunities for high-achieving, TEM and Public Health fields. Pr zuelan audiences/participants. ency National Geospatial-	financially disadvantage roject activities must tak Total funding is \$75,000	ed Venezuel se place in V ofor one aw 23-Jan- 2024 [LOI/Pre-	lan students /enezuela /ard.



# **Other Federal Funding Opportunities**

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
		submit innovative concepts to address hard GEOI (1) Foundational GEOINT, (2) Advanced Phenome Intelligence Foundational Model (GFM) is active.			_
121327	FY2024-2025 National Se	ea Grant BIL Marine Debris Challenge Competition	National Oceanic & Atmospheric Administration/Departmen of Commerce	NOAA-OAR-SG- t 2024-23706	31-Jan- 2024 [LOI/Pre- Not Specifie App]
	Contact Name				
	Contact Telephone				
	Contact Email	sg.grants@noaa.gov			
	Sponsor Website				
	Program URL	Link to program URL			
	Deadline Dates (ALL)	31-Jan-2024 [LOI/Pre-App], 27-Mar-2024			
	Synopsis	This competition will support innovative research removal of marine debris and provide the potential refers to research that transitions into tangible or prototypes, commercial products, specialized services and capacity building activities are allow result of these projects cannot be solely academic A strong application will clearly outline how the plandscape for marine debris prevention and/or restakeholders, industry, etc.) with the aim of address (but are not limited to) innovative or non-proven require additional research and development pricesystems, and/or the detection and mitigation of research and mitigation of respectives.	al for transformational behavious transformational behavious process. Example outputs includivices, or cutting-edge tools. Bigged but must accompany subsection of non-tangible outputs (e.g. project will produce new and elemoval. Projects will communicessing critical gaps with respectinterception and/or removal to to deployment, and/or need	or change. "Research de (but are not limited gideas and risk taking equent implementation, scientific publication ffective deliverables to to marine debris. Prechnologies (i.e. protest to be tested in new earth.)	to application" or R2A to) inventive are encouraged. on activities; the end s, awareness/training). that change the the public (communities oposals may address otype devices that
121949	Climate Resilience Cente	<u>rs</u>	Office of Science/Department of Energy	DE-FOA-0003181	07-Mar- 5,000,000 2024 USD
	Contact Name	Brian Benscoter			



#### **Other Federal Funding Opportunities**

**SPIN ID Program Title Sponsor Name Sponsor Number Deadline Date Funding Amount** 

Contact Telephone 630-252-4329

Contact Email Brian.Benscoter@science.doe.gov

Sponsor Website Link to sponsor website

Program URL Link to program URL

Deadline Dates (ALL) 07-Mar-2024

The DOE SC program in Biological and Environmental Research (BER) hereby announces its interest in applications from the scientific community for Climate Resilience Centers (CRCs) that will improve the availability and utility of BER research, data, Synopsis models, and capabilities to address climate resiliency, particularly by underrepresented or vulnerable communities. BER's mission is to support transformative science and scientific user facilities to achieve a predictive understanding of complex

biological, Earth, and environmental systems for energy and infrastructure security, independence, and prosperity.



SPIN ID	Program Title	Sponsor Name	Sponsor Number	<b>Deadline Date</b>	Funding Amount
121290	AHA/AV Collaborative Science	<u>Awards</u> Additional Ventures		21-Mar-2024	2,250,000 USD
	Contact Name				
	Contact Telephone				
	Contact Email	grants@additionalventures.org			
	Sponsor Website	<u>Link to sponsor website</u>			
	Program URL	Link to program URL			
	Deadline Dates (ALL)	21-Mar-2024			
	Synopsis	The AHA/AV CSAs are intended to foster innovative pairings of research teams from at least two broad teams of 2 to 4 labs each for projects lasting up to 1	y disparate disciplines – prov		
	Applicant Types				
	Funding Limit	2,250,000.00 maximum			
	Limited Submission	No			
093527	Innovation Grant	Alex's Lemonade Stand		19-Mar-2024	125,000 USD
	Contact Name				
	Contact Telephone	610-649-3034			
	Contact Email	Grants@AlexsLemonade.org			
	Sponsor Website	<u>Link to sponsor website</u>			
	Program URL	Link to program URL			



The Development Office offers assistance with many non profit opportunities. Please contact the Development Office's Corporate and Foundation Relations team by email at <a href="mailto:DevCorpFound@mountsinai.org">DevCorpFound@mountsinai.org</a> for assistance or questions.

SPIN ID	Program Title		Sponsor Name	Sponsor Number	Deadline Date	Funding Amount			
	Deadline Dates (ALL)	19-Mar-2024							
	Synopsis		e Innovation Grant is designed to provide critical and significant seed funding for experienced investigators with a vel and promising approach to finding causes and cures for childhood cancers. The award amount is \$250,000 ove o years.						
	Applicant Types								
	Funding Limit	125,000.00 max	kimum						
	Limited Submission	No							
104738	Lawrence and Isabel Barnett D	rug Developmei	nt Program ALS Association		07-Mar-2024	500,000 USD			
	Contact Name								
	Contact Telephone	1-800-782-4747	7						
	Contact Email	researchgrants	@alsa-national.org						
	Sponsor Website	Link to sponsor	website						
	Program URL	Link to program	<u>l URL</u>						
	Deadline Dates (ALL)	07-Mar-2024							
	Synopsis	The ALS Association offers the Lawrence and Isabel Barnett Drug Development Program provides support for preclinical assessment of therapeutics for ALS that have a high probability of reaching the clinic within three years. This program is open to industry and academic investigators proposing to develop novel or repositioning approaches for ALS.							
	Applicant Types								
	Funding Limit	500,000.00 max	kimum						
	Limited Submission	No							



Non Federal Funding Opportunities: March 2024

SPIN ID	Program Title	Sponsor Name		Sponsor Number	<b>Deadline Date</b>	Funding Amount		
119999	Zenith Fellows Award Program	(Zenith) Alzheir	ner's Association		15-Mar-2024	450,000 USD		
	Contact Name							
	Contact Telephone							
	Contact Email	grantsapp@alz.org						
	Sponsor Website	Link to sponsor website						
	Program URL	Link to program URL						
	Deadline Dates (ALL)	15-Mar-2024						
	Synopsis	The Zenith Fellows Award Program will support research that addresses fundamental problems related to eadetection, etiology, pathogenesis, treatment, or prevention of Alzheimer's and all other dementia. Each awalimited to \$450,000 total funding.						
	Applicant Types							
	Funding Limit	450,000.00 maximum						
	Limited Submission	No						
009054	Zenith Fellows Award Program	Alzheir	ner's Association		15-Mar-2024	450,000 USD		
	Contact Name							
	Contact Telephone	312-335-5747						
	Contact Email	grantsapp@alz.org						
	Sponsor Website	Link to sponsor website						
	Program URL	Link to program URL						
	Deadline Dates (ALL)	15-Mar-2024						



SPIN ID	Program Title	Sponsor Name		Sponsor Number	<b>Deadline Date</b>	Funding Amount
	Synopsis	The Zenith Fellows award was initiated personal commitment to the advance possible by the generosity of a group million to the Alzheimer's Association	ement of Alzheim of individuals an	ner's and all other dement ad organizations (Zenith So	ia research. The awa	ards are made
	Applicant Types					
	Funding Limit	450,000.00 maximum				
	Limited Submission	No				
115885	Global Program to Help Custor Solutions to Advance Health E	Δmazon V	Veb Services		31-Mar-2024	Not Specified
	Contact Name					
	Contact Telephone					
	Contact Email	aws-pr@amazon.com				
	Sponsor Website	Link to sponsor website				
	Program URL	Link to program URL				
	Deadline Dates (ALL)	31-Mar-2024 , 30-Jun-2024 , 15-Nov-	2024			
	Synopsis	AWS is committing \$40.0 million to h Services (AWS) is offering AWS Prom addressing health disparities that improgram will support applications the services, 2) reduce disparities by add and inclusive systems of care.	otional Credit and pact underserved at develop cultura	d technical expertise to se I or underrepresented com ally responsive solutions to	lected institutions an munities around th o: 1) increase access	nd companies e world. The to health



SPIN ID	Program Title	Sponsor N	lame	Sponsor Number	<b>Deadline Date</b>	Funding Amount	
	Applicant Types						
	Funding Limit	0.00 see detail					
	Limited Submission	No					
003686	Strategic Research Grant		American Academy of Slee Medicine Foundation	ρ	11-Mar-2024	250,000 USD	
	Contact Name						
	Contact Telephone	630-737-9724					
	Contact Email	foundation@aasm.org					
	Sponsor Website	<u>Link to sponsor website</u>					
	Program URL	Link to program URL					
	Deadline Dates (ALL)	11-Mar-2024					
The AASM Foundation is committed to improving patient-centered diagnosis and care for all peop disorders. To ensure that there is a continued advancement in effective diagnosis and care of peo disorders, the AASM Foundation provides research funding through the Strategic Research Grant. investigator-initiated and supports high-impact research projects aimed at addressing gaps in kno the ability to provide optimal, patient-centered, cost-effective diagnosis and care for people with						e with sleep nis grant is edge that impact	
	Applicant Types						
	Funding Limit	250,000.00 see detail					
	Limited Submission	No					
030860	Discovery Grants		American Brain Tumor Asso	ociation	27-Mar-2024	50,000 USD	



SPIN ID	Program Title		Sponsor Name	Sponsor Number	<b>Deadline Date</b>	Funding Amount			
	Contact Name								
	Contact Telephone	773-577-8742							
	Contact Email	grants@abta.or	g						
	Sponsor Website	Link to sponsor	nk to sponsor website						
	Program URL	Link to program	ink to program URL						
	Deadline Dates (ALL)	27-Mar-2024							
	Synopsis	with the potent	The American Brain Tumor Association seeks applications from faculty who propose highrisk/high-impact projects with the potential to change current diagnostic or treatment paradigms for adult and pediatric brain tumor care. ABTA Discovery Grants provide up to \$50,000 in support over a one-year period.						
	Applicant Types								
	Funding Limit	50,000.00 maxi	mum						
	Limited Submission	No							
001811	Basic Research Fellowships		American Brain Tumor A	ssociation	27-Mar-2024	100,000 USD			
	Contact Name								
	Contact Telephone	773-577-8750							
	Contact Email	grants@abta.or	g						
	Sponsor Website	Link to sponsor	<u>website</u>						
	Program URL	Link to program	URL						
	Deadline Dates (ALL)	27-Mar-2024							



SPIN ID	Program Title		Sponsor Name	Sponsor Number	<b>Deadline Date</b>	Funding Amount
	Synopsis	to brain tumor r Grants support effects, diagnos	research. ABTA Basic Resea basic research projects tha	eks applications from postdoctoral fell arch Fellowships provide up to \$100,00 at have significant potential to advance tumors. The funding mechanism is app ed research projects.	00 in support over a e our understanding	two-year period. g of the causes,
	Applicant Types					
	Funding Limit	100,000.00 max	kimum			
	Limited Submission	No				
043444	Research Grants		American Colle Animal Medici	ege of Laboratory ne Foundation	08-Mar-2024	Not Specified
	Contact Name	Jennifer Pullium	n, MVB, DACLAM			
	Contact Telephone	212-263-6532				
	Contact Email	jennifer.pullium	n@nyumc.org			
	Sponsor Website	Link to sponsor	<u>website</u>			
	Program URL	Link to program	ı URL			
	Deadline Dates (ALL)	08-Mar-2024				
	Synopsis		the ACLAM Foundation is t nrough funding research g	o expand the body of knowledge in th rants.	e fields of laborator	ry Animal Science
	Applicant Types					
	Funding Limit	0.00 not provide	ed			
	Limited Submission	No				



SPIN ID	Program Title		Sponsor Nar	ne	Sponsor Number	<b>Deadline Date</b>	Funding Amount
057836	Medical Toxicology Foundation Teaching, & Practice Grants	n Innovative Rese		merican College of Medio oxicology	cal	01-Mar-2024	20,000 USD
	Contact Name	Alison Meyn					
	Contact Telephone	844-226-8333					
	Contact Email	foundation@acr	mt.net				
	Sponsor Website	Link to sponsor	<u>website</u>				
	Program URL	Link to program	URL				
	Deadline Dates (ALL)	01-Mar-2024					
	Synopsis			•	projects that support the Fent of patients adversely in		
	Applicant Types						
	Funding Limit	20,000.00 maxir	mum				
	Limited Submission	No					
021763	AMS-Simons Travel Grants		А	merican Mathematical Sc	ociety	31-Mar-2024	6,000 USD
	Contact Name						
	Contact Telephone	401-455-4189					
	Contact Email						
	Sponsor Website	Link to sponsor	website				
	Program URL	Link to program	<u>URL</u>				
	'	•					



SPIN ID	Program Title		Sponsor Name	Sponsor Number	Deadline Date	Funding Amount			
	Deadline Dates (ALL)	31-Mar-2024							
		mathematics ar	AMS-Simons Travel Grant program acknowledges the importance of research interaction and collaboration in the shearth interaction and collaboration in the shearth and aims to facilitate these activities for recent PhD recipients. These grants provide support for a difficant number of committed researchers who have limited opportunities for travel and conferences and for aborative work.						
	Applicant Types								
	Funding Limit	3,000.00 per ye	ar						
	Limited Submission	No							
051613	President's Research Initiative	<u>Awards</u>	American Neuromuscular Foundation		15-Mar-2024	500 USD			
	Contact Name								
	Contact Telephone	507-288-0100							
	Contact Email	meeting@aane	m.org						
	Sponsor Website	Link to sponsor	<u>website</u>						
	Program URL	Link to program	<u>l URL</u>						
	Deadline Dates (ALL)	15-Mar-2024							
	Each year the AANEM President chooses a topic for research for the AANEM annual meeting. Up to 10 abstracts submitted to the annual meeting on this topic may receive the President's Research Initiative Award. Award winr must be the first and presenting author.								
	Applicant Types								
	Funding Limit	500.00 see deta	ail						



The Development Office offers assistance with many non profit opportunities. Please contact the Development Office's Corporate and Foundation Relations team by email at <a href="mailto:DevCorpFound@mountsinai.org">DevCorpFound@mountsinai.org</a> for assistance or questions.

SPIN ID	Program Title	Sponsor Name	Sponsor Number	<b>Deadline Date</b>	Funding Amount				
	Limited Submission	No							
055942	ANS Research Grant Award	American Neurotology	Society	01-Mar-2024	25,000 USD				
	Contact Name Dr. Ronna Hertzano, Chair of the American Neurotology Society Research Committee								
	Contact Telephone								
	Contact Email	ronna.hertzano@nih.gov							
	Sponsor Website	<u>Link to sponsor website</u>							
	Program URL	Link to program URL							
	Deadline Dates (ALL)	01-Mar-2024							
	Synopsis	research in sciences related to the investigation of diagnosis, management, and pathogenesis of diseaclinical gaps are especially encouraged. Grants may	The purpose of the American Neurotology Society (ANS) Research Grant is to encourage and support academic research in sciences related to the investigation of otology and neurotology. Appropriate areas of research include diagnosis, management, and pathogenesis of diseases of the ear and/or skull base. Grants that focus on addressing clinical gaps are especially encouraged. Grants may involve cell/molecular studies, animal research, or human subjects research. The maximum award request is \$25,000 per year (US dollars) and is annually renewable on a						
	Applicant Types								
	Funding Limit	25,000.00 maximum							
	Limited Submission	No							
059846	Research Grant	American SIDS Institute	2	01-Mar-2024 [LOI/Pre-App]	70,000 USD				
	Contact Name	Betty McEntire							



Non Federal Funding Opportunities: March 2024

SPIN ID	Program Title	Sponsor I	Name	Sponsor Number	<b>Deadline Date</b>	Funding Amount					
	Contact Telephone	239-431-5425									
	Contact Email	bmcentire@sids.org									
	Sponsor Website	<u>Link to sponsor website</u>									
	Program URL	Link to program URL									
	Deadline Dates (ALL)	01-Mar-2024 [LOI/Pre-Ap									
	The American SIDS Institute invites qualified investigators to submit a Letter of Intent (LOI) for a research grant related to sudden unexpected infant death (SUID). Applicants must have a faculty appointment or the equivalence of U.S. based university, hospital, research institution, or medical examiner office. Topics of interest include, but a limited to, pathology, physiology, neonatology, cardiology and epidemiology.										
	Applicant Types										
	Funding Limit	70,000.00 maximum									
	Limited Submission	No									
075275	Research Grants		American Society for Laser and Surgery, Inc.	Medicine	15-Jan-2024 [LOI/Pre-App]	70,000 USD					
	Contact Name										
	Contact Telephone	715-845-9283									
	Contact Email	information@aslms.org									
	Sponsor Website	Link to sponsor website									
	Program URL	Link to program URL									
	Deadline Dates (ALL)	15-Jan-2024 [LOI/Pre-App	], 11-Mar-2024								



SPIN ID	Program Title	Sponso	or Name	Sponsor Number	<b>Deadline Date</b>	Funding Amount
	Synopsis	The American Society f development and use of	or Laser Medicine and Surgery of lasers and other related tech	(ASLMS) supports researcl nologies in medical and su	n projects designed rgical applications.	to foster the
	Applicant Types					
	Funding Limit	70,000.00 maximum				
	Limited Submission	No				
071115	Kupfer Award		Association for Research in and Ophthalmology	Vision	01-Mar-2024	Not Specified
	Contact Name					
	Contact Telephone	240-221-2900				
	Contact Email	arvo@arvo.org				
	Sponsor Website	Link to sponsor website	<u>e</u>			
	Program URL	Link to program URL				
	Deadline Dates (ALL)	01-Mar-2024				
	Synopsis	on behalf of eye and vi	ors those who have demonstrat sion research. Recipients receiv ation, hotel, travel and per diem	e a plaque which is preser		-
	Applicant Types					
	Funding Limit	0.00 see detail				
	Limited Submission	No				



SPIN ID	Program Title	Sponsor Na	ıme	Sponsor Number	<b>Deadline Date</b>	<b>Funding Amount</b>
087365	Joanne G. Angle Award		Association for Research in and Ophthalmology	Vision	01-Mar-2024	Not Specified
	Contact Name					
	Contact Telephone	240-221-2900				
	Contact Email	arvo@arvo.org				
	Sponsor Website	<u>Link to sponsor website</u>				
	Program URL	Link to program URL				
	Deadline Dates (ALL)	01-Mar-2024				
	Synopsis	The Joanne G. Angle Award ARVO in support of its missi the ARVO Annual Meeting.	-			
	Applicant Types					
	Funding Limit	0.00 see detail				
	Limited Submission	No				
071113	Cogan Award		Association for Research in and Ophthalmology	Vision	01-Mar-2024	Not Specified
	Contact Name					
	Contact Telephone	240-221-2900				
	Contact Email	arvo@arvo.org				
	Sponsor Website	Link to sponsor website				



SPIN ID	Program Title		Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Program URL	Link to program	<u>URL</u>			
	Deadline Dates (ALL)	01-Mar-2024				
The Cogan Award is intended to recognize a young researcher who is 45 years of age or younger at the time nomination, and who has made important and worthwhile contributions to research in ophthalmology or viscience that are directly related to disorders of the human eye or visual system, and who show substantial properties for future contributions. The recipient presents the Cogan Award Lecture at the ARVO Annual Meeting and plaque, complimentary registration, hotel and travel, and per diem.						logy or visual stantial promise
	Applicant Types					
	Funding Limit	0.00 see detail				
	Limited Submission	No				
004923	Friedenwald Award		Association for Rese and Ophthalmology		01-Mar-2024	Not Specified
	Contact Name					
	Contact Telephone	240-221-2900				
	Contact Email	arvo@arvo.org				
	Sponsor Website	Link to sponsor v	<u>vebsite</u>			
	Program URL	Link to program	<u>URL</u>			
	Deadline Dates (ALL)	01-Mar-2024				
	Synopsis	Award recipient	Award honors outstanding respressents the Friedenwald Awa egistration, hotel and travel, a	rd Lecture at the ARVO Annua	• •	



SPIN ID	Program Title		Sponsor Name	Sponsor Number	<b>Deadline Date</b>	Funding Amount
	Applicant Types					
	Funding Limit	0.00 see detail				
	Limited Submission	No				
057909	Emerging Leader Award		Bay Area Lyme Foundatio	n	01-Mar-2024	150,000 USD
	Contact Name					
	Contact Telephone	650-530-2439				
	Contact Email	award@bayare	alyme.org			
	Sponsor Website	Link to sponsor	website			
	Program URL	Link to program	<u>ı URL</u>			
	Deadline Dates (ALL)	01-Mar-2024				
	Synopsis	researchers brid and innovative must include a 2023, the Foun- ELA grants to re	yme Foundation Emerging Leader Awanging new approaches and creative the projects and aim to attract aspiring new viable proposal for a proof-of-concept dation has increased our ELA award attended in academia or the private assor level or equivalent.	inking to the field of Lyme ew scientific talent to the fi t project to be funded, in pa mount to \$150,000. We wil	disease. These gran eld of Lyme. Candid art or in sum, by the I be offering at leas	ts support new ate applications grant award. For t two \$150,000
	Applicant Types					
	Funding Limit	150,000.00 max	ximum			
	Limited Submission	No				



SPIN ID	Program Title	Sponsor Name	Sponsor Number	<b>Deadline Date</b>	Funding Amount	
011220	BIRD Call for Proposals	Binational Industrial Re	esearch and	07-Mar-2024	1,000,000	
011230	bind call for Froposais	Development (BIRD) Fo	oundation	[LOI/Pre-App	] USD	
	Contact Name					
	Contact Telephone	972-3-6988300				
	Contact Email	See notes				
	Sponsor Website	<u>Link to sponsor website</u>				
	Program URL	Link to program URL				
	Deadline Dates (ALL)	07-Mar-2024 [LOI/Pre-App], 11-Apr-2024				
	Synopsis	The Binational Industrial Research and Development (BIRD) Foundation provides support for projects be and Israeli companies.				
	Applicant Types					
	Funding Limit	1,000,000.00 maximum				
	Limited Submission	No				
057952	Seed Grant Program	Brain Research Founda	ation	07-Mar-2024	80,000 USD	
	Contact Name					
	Contact Telephone	312-759-5150				
	Contact Email	info@thebrf.org				
	Sponsor Website	<u>Link to sponsor website</u>				
	Program URL	Link to program URL				
	Deadline Dates (ALL)	07-Mar-2024				



The Development Office offers assistance with many non profit opportunities. Please contact the Development Office's Corporate and Foundation Relations team by email at <a href="mailto:DevCorpFound@mountsinai.org">DevCorpFound@mountsinai.org</a> for assistance or questions.

SPIN ID	Program Title		Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Synopsis	the field of Neu	roscience that will likely lea	eed Grant Program provides start-und to extramural funding from the I grant is limited to \$80,000 (direct co	National Institutes of H	ealth (NIH) or
	Applicant Types					
	Funding Limit	80,000.00 maxi	imum			
	Limited Submission	Yes				
079141	Exceptional Project Grants		Breast Cancer A	Alliance, Inc.	01-Mar-2024 [LOI/Pre-App	250,000 USD
	Contact Name					
	Contact Telephone	203-861-0014				
	Contact Email	researchgrants	@breastcanceralliance.org			
	Sponsor Website	Link to sponsor	website			
	Program URL	Link to program	<u>n URL</u>			
	Deadline Dates (ALL)	01-Mar-2024 [L	OI/Pre-App], 19-Jul-2024			
	Synopsis	Synopsis  Breast Cancer Alliance invites clinical doctors and research scientists at any stage of their careers, including post docs, whose current proposal is focused on breast cancer, to apply for an Exceptional Project Grant. This award recognizes creative, unique and innovative research and is open to applicants at institutions throughout the contiguous United States. This is a two-year grant for a total of \$125,000.				
	Applicant Types					
	Funding Limit	125,000.00 per	year			
	Limited Submission	Yes				



Non Federal Funding Opportunities: March 2024

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount			
120864	Research Grants	Cancer Prevention	Initiative	15-Mar-2024	450,000 USD			
	Contact Name							
	Contact Telephone	844-437-4891						
	Contact Email	Grants@CancerPreventionInitiative.org						
	Sponsor Website	Link to sponsor website						
	Program URL	Link to program URL	program URL					
	Deadline Dates (ALL)	15-Mar-2024	ar-2024					
	Synopsis	he goal of CPI's research grant program is to identify and provide seed funding for innovative projects that have the otential to make substantial contributions to the development of therapeutic interventions for the prevention of therited cancers. The sponsor is open to considering both short-term pilot projects and long-term in-depth studie						
	Applicant Types							
	Funding Limit	150,000.00 per year						
	Limited Submission	No						
058489	Technology Impact Award	Cancer Research I	nstitute, Inc.	15-Mar-2024	200,000 USD			
	Contact Name							
	Contact Telephone	212-688-7515						
	Contact Email	grants@cancerresearch.org						
	Sponsor Website	Link to sponsor website						
	Program URL							
	Deadline Dates (ALL)	15-Mar-2024						



SPIN ID	Program Title	Sponsor	Name	Sponsor Number	<b>Deadline Date</b>	Funding Amount
	Synopsis		titute Technology Impact Awa the gap between technology	-		
	Applicant Types					
	Funding Limit	200,000.00 maximum				
	Limited Submission	No				
061149	Research Grants Program		Childhood Brain Tumor Fo	undation	15-Mar-2024	60,000 USD
	Contact Name					
	Contact Telephone	301-515-2900				
	Contact Email	cbtf@childhoodbraintun	nor.org			
	Sponsor Website	Link to sponsor website				
	Program URL	Link to program URL				
	Deadline Dates (ALL)	15-Mar-2024				
	Synopsis	The Childhood Brain Tun research on pediatric bra	nor Foundation (CBTF) is solic ain tumors.	iting grant applications for	the current calenda	ar year for
	Applicant Types					
	Funding Limit	30,000.00 per year				
	Limited Submission	No				
061423	CAMS Summer Research Fellow	wship Scholarship	Chinese American Medical	Society	01-Mar-2024	5,000 USD
	Contact Name					



SPIN ID	Program Title	Sponsor Name		Sponsor Number	<b>Deadline Date</b>	Funding Amount
	Contact Telephone	212-334-4760				
Contact Email scholarship@camsociety.org						
Sponsor Website Link to sponsor website						
	Program URL	Link to program URL				
	Deadline Dates (ALL)	01-Mar-2024				
	The Chinese American Medical Society (CAMS) offers scholarships for medical students working on summer resea projects. The research can be basic science or clinical in nature but must be completed in a ten week time frame. Preferences will be given to proposals studying problems related to health problems of the Chinese. At the conclusion of the project, a written report is expected.					
	Applicant Types					
	Funding Limit	5,000.00 maximum				
	Limited Submission	No				
054015	CURE Epilepsy Award		nited for Researd CURE Epilepsy)	ch in	09-Jan-2024 [LOI/Pre-App]	250,000 USD
	Contact Name					
	Contact Telephone	312-255-1801				
	Contact Email	Research@CUREepilepsy.org				
	Sponsor Website	Link to sponsor website				
	Program URL	Link to program URL				
	Deadline Dates (ALL)	09-Jan-2024 [LOI/Pre-App], 26-Mar-2	024			



SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Synopsis	The CURE Epilepsy Award will provide grants of umodifying breakthroughs for people living with e	up to \$250,000 paid over 2 year epilepsy.	rs for research leading	g to disease-
	Applicant Types				
	Funding Limit	250,000.00 maximum			
	Limited Submission	No			
024600	Taking Flight Awards	Citizens United for Re Epilepsy (CURE Epilep		09-Jan-2024 [LOI/Pre-App]	125,000 USD
	Contact Name				
	Contact Telephone	312-255-1801			
	Contact Email	Research@CUREepilepsy.org			
	Sponsor Website	<u>Link to sponsor website</u>			
	Program URL	Link to program URL			
	Deadline Dates (ALL)	09-Jan-2024 [LOI/Pre-App], 26-Mar-2024			
	Synopsis	The Taking Flight Award (1.5 years / \$125,000) so them to develop an independent research focus.	eeks to promote the careers of	early-career investiga	ators to allow
	Applicant Types				
	Funding Limit	125,000.00 maximum			
	Limited Submission	No			
009212	Congressional Internship Progr	Congressional Hispan Institute, Inc.	ic Caucus	01-Mar-2024	Not Specified



SPIN ID	Program Title	Sponsor	Name	Sponsor Number	<b>Deadline Date</b>	Funding Amount
		ı				
	Contact Name					
	Contact Telephone	202-543-1771				
	Contact Email					
	Sponsor Website	Link to sponsor website				
Program URL Link to program URL						
	Deadline Dates (ALL) 01-Mar-2024					
		The CHCI Congressional Internship Program (CIP) provides college students of any major with a paid placement in a congressional office for a period of 12 weeks (Spring/Fall) or 10 weeks (Summer). Promising Latino undergraduates from across the country are selected for this unmatched leadership training program. Students gain work experien participate in community service, and receive educational and professional programming provided by CHCI.				
	Applicant Types					
	Funding Limit	0.00 see detail				
	Limited Submission	No				
HYX53H	Dr. Jose Leis Endowed Young In Chronic Lymphocytic Leukemia		Conquer Cancer Foundatio ASCO	n of	14-Mar-2024	50,000 USD
	Contact Name					
	Contact Telephone	571-483-1700				
	Contact Email	grants@conquer.org				
	Sponsor Website	Link to sponsor website				
	Program URL	Link to program URL				
		•				



SPIN ID	Program Title	Sponso	or Name	Sponsor Number	<b>Deadline Date</b>	Funding Amount
	Deadline Dates (ALL)	14-Mar-2024				
	Synopsis	The Conquer Cancer – I provides funding to pro	Or. Jose Leis Endowed Young mising investigators to encouocytic leukemia. The purpose faculty appointment.	rage and promote quality	research in clinical o	oncology with a
	Applicant Types					
	Funding Limit	50,000.00 maximum				
	Limited Submission	No				
098496	Young Investigators Award for Breast Cancer Research	Diversity and Inclusion	n Conquer Cancer Foundat ASCO	ion of	14-Mar-202	4 50,000 USD
	Contact Name					
	Contact Telephone	703-299-0158				
	Contact Email	grants@conquer.org				
	Sponsor Website	Link to sponsor website	!			
	Program URL	Link to program URL				
	Deadline Dates (ALL)	14-Mar-2024				
	Synopsis	in Breast Cancer Resear breast cancer research. and/or ethnic groups tr	Breast Cancer Research Found rch is designed with the prima The YIA will provide funding aditionally excluded in acade ring the transition from a fell	ary goal of increasing diver to promising investigators mic medicine and biomedi	sity in the oncology who identify as mer cal research. The pu	workforce and mbers of racial rpose of this award



SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Applicant Types	50,000.00 maximum			
059521	Grants Program	Conservation, Foundation	ood and Health	01-Jan-2024 [LOI/Pre-App]	Not Specified
	Contact Name	Prentice Zinn			
	Contact Telephone	617-391-3091			
	Contact Email	pzinn@gmafoundations.com			
	Sponsor Website	<u>Link to sponsor website</u>			
	Program URL	Link to program URL			
	Deadline Dates (ALL)	01-Jan-2024 [LOI/Pre-App], 01-Mar-2024 , (	01-Jul-2024 [LOI/Pre-App], 01-Sep-	-2024	
		The Conservation, Food and Health Foundal promote public health in Africa, Asia, the Conservation and applied research that generate environment and human life; advance local agricultural, and health sciences; develop the field. The Foundation prefers to support Foundation funds applied research, pilot prongoing support for programs that are alrest	aribbean, Latin America, and the Ne local or regional solutions to proll leadership and promote profession he capacity of local organizations at projects that address under-functoriects, new initiatives, training, and	Middle East. The Foundate of the quant of th	ation supports ality of the e conservation, ress challenges in hic areas. The rather than



SPIN ID	Program Title		Sponsor Name	S	ponsor Number	<b>Deadline Date</b>	Funding Amount
			help promising projects, org on funding in the future.	anizations, a	nd individuals develop t	he track record they	need to attract
	Applicant Types						
	Funding Limit	0.00 see detail					
	Limited Submission	Yes					
089449	Research Grants		Daisy Foundatio	n		05-Feb-2024 [LOI/Pre-App]	7,500 USD
	Contact Name	Faith Thomas					
	Contact Telephone	707-996-7936					
	Contact Email	FaithThomas@	daisyfoundation.org				
	Sponsor Website	Link to sponsor	<u>website</u>				
	Program URL	Link to program	<u>url</u>				
	Deadline Dates (ALL)	05-Feb-2024 [L	OI/Pre-App], 24-Mar-2024				
	Synopsis	populations by	ndation is eager to support the funding nursing research an f health aimed at improving	d evidence-b	pased practice (EBP) proj	ects designed to add	ress social
	Applicant Types						
	Funding Limit	7,500.00 maxim	num				
	Limited Submission	No					



SPIN ID	Program Title	Spons	or Name	Sponsor Number	<b>Deadline Date</b>	Funding Amount
058648	Early-Career Investigator Progr	am.	Desmoid Tumor Research		11-Mar-2024	, 90,000 USD
	Early Career investigator Frogr	<u>um</u>	Foundation		[LOI/Pre-App]	] 30,000 032
	Contact Name					
	Contact Telephone					
	Contact Email	grants@dtrf.org				
	Sponsor Website	Link to sponsor websit	<u>e</u>			
	Program URL	Link to program URL				
	Deadline Dates (ALL)	11-Mar-2024 [LOI/Pre-	-App], 15-Apr-2024			
	Synopsis		nat will advance current scientif			toward the
		development of new ti	reatment options and bringing (	us closer to our ultimate go	oal of a cure.	
	Applicant Types					
	· ·	30,000.00 per year				
	Limited Submission	No				
070199	<u>Professional and Student Poste</u>	er Travel Awards	Drug Information Associati	ion	06-Mar-2024	Not Specified
	Contact Name					
	Contact Telephone	202-601-8900				
	Contact Email	annualmeetingprogran	n@diaglobal.org			
	Sponsor Website	Link to sponsor websit	<u>e</u>			
	Program URL	Link to program URL				
	Deadline Dates (ALL)	06-Mar-2024				



SPIN ID	Program Title	Spon	sor Name	Spons	sor Number	<b>Deadline Date</b>	Funding Amount
	Applicant Types Funding Limit	poster to be displayed Program is an opport scientific professional pharmaceuticals, biot 0.00 see detail	elds related to the mission d at the DIA 2024 Global A unity to present research Is who are actively involve echnology, medical device	Annual Meetin results, case sed in the disco	ng in San Diego, CA. study, and/or thoug very, development,	The Professional a ht leadership to a and lifecycle man	and Student Poster diverse group of
122247	Research Infrastructures New Destination Earth	I	European Commiss	ion	HORIZON-INFRA 2024-TECH-01-0	12-Mar-202	16,650,000 USD
	Contact Name						
	Contact Telephone						
	Contact Email	See notes for contact	information.				
	Sponsor Website						
	Program URL	Link to program URL					
	Deadline Dates (ALL)	12-Mar-2024					
	Synopsis	Earth The topic is pa digital solutions for RI and methods and adv	against the following top art of the call: Next gener Is (2024) This call is under ranced digital solutions (II ence, while paving the wa	ation of scient the Destination NFRATECH), to	ific instrumentation on: Next generation enable new discove	, tools, methods, of scientific instru eries and keep Eur	and advanced umentation, tools rope's RIs at the



SPIN ID	Program Title		Sponsor Name	Sponsor Number	<b>Deadline Date</b>	Funding Amount
		is structured are empower Europ	oducts and services. This is one cound. The overall objective of the oe through world-class and acces echnology infrastructures landsca	e Research Infrastructures Prog sible research infrastructures, a	ramme under Horiz	on Europe is to
	Applicant Types					
	Funding Limit	15,000,000.00	see detail			
	Limited Submission	No				
006588	Pilot Research Grant		Eye Bank Association	of America	18-Mar-2024	7,500 USD
	Contact Name	Stacey Gardner	, Director of Education			
	Contact Telephone	202-775-4999				
	Contact Email	stacey@restore	esight.org			
	Sponsor Website	Link to sponsor	<u>website</u>			
	Program URL	Link to program	<u>ı URL</u>			
	Deadline Dates (ALL)	18-Mar-2024				
	Synopsis	provide suppor	ssociation of America awards the t for proposals specifically concer . Each proposal may be funded u	ned with issues directly related	•	
	Applicant Types					
	Funding Limit	7,500.00 maxim	num			
	Limited Submission	Yes				



SPIN ID	Program Title	Sponsor Name	Sponsor Number	<b>Deadline Date</b>	Funding Amount
006584	Crystal Cornea Award	Eye Bank Associati	on of America	08-Mar-2024	Not Specified
	Contact Name				
	Contact Telephone	202-775-4999			
	Contact Email				
	Sponsor Website	<u>Link to sponsor website</u>			
	Program URL	Link to program URL			
	Deadline Dates (ALL)	08-Mar-2024			
	Synopsis	The Crystal Cornea Award is presented to indi	viduals or organizations from out	tside healthcare and e	eye banking.
	Applicant Types				
	Funding Limit	0.00 see detail			
	Limited Submission	No			
057307	Research Grants	Fibrolamellar Cand	er Foundation	01-Mar-2024	Not Specified
	Contact Name	Payal Ray			
	Contact Telephone	203-340-7800			
	Contact Email	pray@fibrofoundation.org			
	Sponsor Website	<u>Link to sponsor website</u>			
	Program URL	Link to program URL			
	Deadline Dates (ALL)	01-Mar-2024 , 01-Jul-2024 , 01-Nov-2024			
	Synopsis	The Fibrolamellar Cancer Foundation (FCF) is a understanding and curative treatments for fib			



The Development Office offers assistance with many non profit opportunities. Please contact the Development Office's Corporate and Foundation Relations team by email at <a href="mailto:DevCorpFound@mountsinai.org">DevCorpFound@mountsinai.org</a> for assistance or questions.

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
		hepatocellular carcinoma (FL-HCC), is an aggresearch must focus specifically on FLC. Studunderstanding, diagnosis, epidemiology, or path towards a novel therapy or clinical tria accept grant applications to support innovabelieves that collaboration engaging the best resources, often accelerates the path to a content of the second content of the secon	dies should be intended to advance I treatment of FLC. Of particular inter Is with the ultimate goal of achieving tive and promising research projects at talent across institutions, together	knowledge relevant t est are applications s g a cure for FLC. The I towards the listed g	o the showing a clear Foundation will oals. The FCF
	Applicant Types				
	Funding Limit	0.00 see detail			
	Limited Submission	No			
026130	Post-doctoral Study Grants	Fondation Fysse	n	29-Mar-2024	49,950 USD
	Contact Name				
	Contact Telephone	33 0 1 4297 5316			
	Contact Email	secretariat@fondationfyssen.fr			
	Sponsor Website	Link to sponsor website			
	Program URL	Link to program URL			
	Deadline Dates (ALL)	29-Mar-2024			
	Synopsis	Study Grants are meant for post-doctoral repaleontology, archaeology, anthropology, prants are awarded to French or foreign res	sychology, epistemology, logic and	sciences of nervous s	ystem. These



Non Federal Funding Opportunities: March 2024

in a Laboratory in France; or either French or foreign researchers holders of a French Phd who wish to achieve their

The Development Office offers assistance with many non profit opportunities. Please contact the Development Office's Corporate and Foundation Relations team by email at <a href="mailto:DevCorpFound@mountsinai.org">DevCorpFound@mountsinai.org</a> for assistance or questions.

SPIN ID	Program Title	Sponsor Name		Sponsor Number	Deadline Date	Funding Amount
		project in a Laboratory abroad (e	xcluded co-tutorship	country). These grants, of	an annual maximum	n amount of
		€45,000, intend to cover expense	es of hosting, stay and	l health insurance.		
	Applicant Types					
	Funding Limit	45,000.00 maximum				
	Limited Submission	No				
100345	Clinical Innovation Awards	Found	lation Fighting Blindn	ess	06-Mar-2024	300,000 USD
	Contact Name					
	Contact Telephone	410-423-0600				
	Contact Email	grants@fightblindness.org				
	Sponsor Website	Link to sponsor website				
	Program URL	Link to program URL				
	Deadline Dates (ALL)	06-Mar-2024				
	Synopsis	The Foundation Fighting Blindnes in IRD clinical trials that might be disease progression. Annual budg	accepted by regulato	ry agencies for improving	IRD patients' condit	ions or slowing
	Applicant Types					
	Funding Limit	100,000.00 per year				
	Limited Submission	No				
004010	Individual Investigator Research	<u>ch Awards</u> Found	lation Fighting Blindn	ess	06-Mar-2024	300,000 USD
	Contact Name					



Non Federal Funding Opportunities: March 2024

SPIN ID	Program Title	Sponsor Name	e	Sponsor Number	<b>Deadline Date</b>	Funding Amount
	Contact Telephone	800-683-5555				
	Contact Email	grants@FightingBlindness.org				
	Sponsor Website	<u>Link to sponsor website</u>				
	Program URL	Link to program URL				
	Deadline Dates (ALL)	06-Mar-2024				
	Synopsis	Individual Investigator Research move toward treatments and of macular degeneration. This aw	cures for the inherited o	rphan retinal degenerative	e diseases and dry a	
	Applicant Types					
	Funding Limit	100,000.00 per year				
	Limited Submission	No				
030560	Therapeutic Pipeline Program		(Michael J.) Foundation kinson's Research	n for	11-Jan-2024	2,000,000 USD
	Contact Name					
	Contact Telephone	212-509-0995				
	Contact Email	grants@michaeljfox.org				
	Sponsor Website	Link to sponsor website				
	Program URL	Link to program URL				
	Deadline Dates (ALL)	11-Jan-2024 , 14-Mar-2024 , 10	6-May-2024 , 18-Jul-202	4		



SPIN ID	Program Title		Sponsor Name	Sponsor Number	Deadline Date	Funding Amount
	Synopsis	clinical testing of	of approaches addressing unn opeutics with clear potential t	m seeks to advance therapeutic on the seeks to advance therapeutic on the seeks to advance th	on's disease (PD). The	program is set up
	Applicant Types					
	Funding Limit	2,000,000.00 se	e detail			
	Limited Submission	No				
063403	<u>Grant-In-Aid</u>		Glaucoma Founda	ition	01-Mar-2024	75,000 USD
	Contact Name	Andrea Steele,	Director of Operations			
	Contact Telephone	212-651-2509				
	Contact Email	asteele@glauco	omafoundation.org			
	Sponsor Website	Link to sponsor	<u>website</u>			
	Program URL	Link to program	ı URL			
	Deadline Dates (ALL)	01-Mar-2024 , (	04-Mar-2024			
	Synopsis	novel innovatio Exfoliation Synd	ns and scientific advances. Th	searchers striving to improve the e areas of current focus for TGF's ma, Pressure Independent Mecha e under the age of 40 years.	s Grant Research prog	ram are
	Applicant Types					
	Funding Limit	75,000.00 see d	letail			
	Limited Submission	No				



The Development Office offers assistance with many non profit opportunities. Please contact the Development Office's Corporate and Foundation Relations team by email at <a href="mailto:DevCorpFound@mountsinai.org">DevCorpFound@mountsinai.org</a> for assistance or questions.

SPIN ID	Program Title	Sponsor N	lame	Sponsor Number	Deadline Date	Funding Amount
001746	<u>Bioethics Grants Program - Makin</u> <u>World Bioethics Dilemmas</u>	ng a Difference in Real-	Greenwall Foundation		02-Jan-2024 [LOI/Pre-App]	Not Specified
	Contact Name Ky	le Ruempler				
	Contact Telephone					
	Contact Email <u>kr</u> ı	uempler@greenwall.org				
	Sponsor Website <u>Lir</u>	nk to sponsor website				
	Program URL <u>Lir</u>	nk to program URL				
	Deadline Dates (ALL) 02	-Jan-2024 [LOI/Pre-App]	], 11-Mar-2024			
	Di im Synopsis or mi an	fference in Real-World Baportant emerging or una practice. The Foundation ission is to expand bioet and practice. Projects fund	is requesting proposals for Bioethics Dilemmas. The Ma answered bioethics probler in's vision is to make bioeth hics knowledge to improve ded under the Making a Diff e bioethics research that wi	king a Difference program n in clinical, biomedical, or ics integral to decisions in l clinical, biomedical, and pu erence program should pro	supports research to public health decision nealth care, policy, a ablic health decision promote the Foundation	o help resolve an on-making, policy, and research. Its -making, policy,
	Applicant Types					
	Funding Limit 0.0	00 see detail				
	Limited Submission No	)				
081191	SWOG Coltman Fellowship Progra	a <u>m</u>	Hope Foundation for Cano Research	er	15-Mar-2024	100,000 USD
	Contact Name Jo	hanna Horn				



Non Federal Funding Opportunities: March 2024

SPIN ID	Program Title	Sponsor N	lame	Sponsor Number	<b>Deadline Date</b>	Funding Amount			
	Contact Telephone	734-998-7150							
	Contact Email	jo@thehopefoundation.or	g						
	Sponsor Website	<u>Link to sponsor website</u>							
	Program URL	Link to program URL							
	Deadline Dates (ALL)	15-Mar-2024							
	Synopsis	The SWOG Cancer Research Network Dr. Charles A. Coltman, Jr. Fellowship Program protects time for clinical or ranslational research on SWOG-associated projects. The funding encourages investigators from SWOG member institutions to engage either in learning clinical trial methodology or in expanding current research interests within ooperative group environment. Each award provides \$100,000 over two years to successful candidates, as well as ey travel support.							
	Applicant Types								
	Funding Limit	100,000.00 maximum							
	Limited Submission	No							
019865	ICIS-Pfizer Award for Excellence Research	e in Cytokine & Interferon	International Cytokine and Interferon Society		04-Mar-2024	10,000 USD			
	Contact Name								
	Contact Telephone	800-947-1960							
	Contact Email								
Sponsor Website Link to sponsor website									
	Program URL	Link to program URL							
	Deadline Dates (ALL)	04-Mar-2024							



SPIN ID	Program Title	Sponsor Name	Sponsor Number	<b>Deadline Date</b>	Funding Amount		
	Synopsis	The ICIS-Pfizer Award for Excellence in Cytokin Award), represents the pinnacle of scientific a upon a leading biomedical research scientist, contributions to cytokine & interferon research	chievement in cytokine & interferwho may not be an ICIS member,	ron research. This Av	ward is bestowed		
	Applicant Types						
	Funding Limit	10,000.00 see detail					
	Limited Submission	No					
015167	Postdoctoral Scholar Awards	International Retin Foundation, Inc.	al Research	15-Mar-2024	35,000 USD		
	Contact Name	Sandra Blackwood, MPA, Executive Director					
	Contact Telephone	205-325-8103					
	Contact Email	sblackwood@irrfonline.org					
	Sponsor Website	Link to sponsor website					
	Program URL	Link to program URL					
	Deadline Dates (ALL)	15-Mar-2024					
	Synopsis	Three IRRF Scholar Awards have been designated in honor of individuals who played a critical role in the development of the International Retinal Research Foundation and are meant to serve as a memorial to their efforts. Three awards are given: The Alston Callahan, MD Scholar Award; The Charles D. Kelman, MD Scholar Award; and The Loris and David Rich Scholar Award. The IRRF Postdoctoral Scholar Awards were established to provide salary and research support in the amount of \$35,000 per year for a postdoctoral scholar nearing the end of his/her training.					
	Applicant Types						



SPIN ID	Program Title	Sponsor	Name	Sponsor Number	<b>Deadline Date</b>	Funding Amount
	-	35,000.00 maximum				
	Limited Submission	No				
059434	New Investigator Program		International Society for Roon Aggression	esearch	15-Mar-2024	Not Specified
	Contact Name	Dominic Parrott				
	Contact Telephone					
	Contact Email	parrott@gsu.edu				
	Sponsor Website	<u>Link to sponsor website</u>				
	Program URL	Link to program URL				
	Deadline Dates (ALL)	15-Mar-2024				
	Synopsis	in the early stages of the junior faculty within 3 ye	II) Program is intended to end ir aggression research career ars of their terminal graduate and an ISRA World Meeting a	. ISRA encourages graduate e degree to apply for the p	e students, postdoct rogram. Awardees r	toral fellows, and eceive partial
	Applicant Types					
	Funding Limit	0.00 see detail				
	Limited Submission	No				
123056	Request for Applications: Glyco Monitoring in Individuals at Ris		Juvenile Diabetes Research Foundation International	1	25-Jan-2024 [LOI/Pre-App	900,000 USD
	Contact Name	Raquel Lopez-Diez, Ph.D.				



The Development Office offers assistance with many non profit opportunities. Please contact the Development Office's Corporate and Foundation Relations team by email at <a href="DevCorpFound@mountsinai.org">DevCorpFound@mountsinai.org</a> for assistance or questions.

SPIN ID	Program Title	Sponso	r Name	Sponsor Number	<b>Deadline Date</b>	Funding Amount		
	Contact Telephone +1  Contact Email	diez@jdrf.org						
	·	ponsor Website Link to sponsor website  Program URL Link to program URL						
	Deadline Dates (ALL) 25-Jan-2024 [LOI/Pre-App], 08-Mar-2024							
	The Juvenile Diabetes Research Foundation (JDRF) has issued a request for applications (RFA) to support pioneering research proposals aimed at advancing our understanding of glycemic changes during disease progression in presymptomatic individuals, with the potential to improve progression biomarkers and monitoring their transition to clinical diagnosis. The knowledge gained in this RFA may eventually be applicable to support regulatory decisions and be part of monitoring guidelines, enabling more effective early identification and timely intervention by healthcare professionals, including the use of innovative treatments like the recent FDA-approved teplizumab treatment, as well as other immunotherapies currently in clinical trials. As such, its implementation would mark a significant milestone in the pursuit of delaying or preventing T1D and its associated complications.							
	Applicant Types							
	Funding Limit 90	00,000.00 maximum						
	Limited Submission No	)						
002667	Tuition Scholarships for Graduate	Studies	Kosciuszko Foundation		04-Mar-2024	7,000 USD		
	Contact Telephone 21 Contact Email <u>tu</u>	•	<del>_</del>	r for Americans				



Non Federal Funding Opportunities: March 2024

SPIN ID	Program Title		Sponsor Name	Sponsor Number	<b>Deadline Date</b>	Funding Amount				
	Program URL	Link to program	<u>URL</u>							
	Deadline Dates (ALL)	04-Mar-2024								
	Synopsis	such as masters \$7,000. Funding is based on appl achievements, a	Kosciuszko Foundation Tuition Scholarships support American students of Polish descent for graduate level studiosuch as masters and Ph.D. studies, at colleges and universities in the United States. Scholarships range from \$1,00 \$7,000. Funding is only for full-time studies in the United States and English Schools of Medicine in Poland. Select is based on application completeness, recommendation of teachers and professors, academic excellence and achievements, applicant's interests, motivation, the applicant's essay, involvement in the Polish American community. Financial need is taken into consideration.							
	Applicant Types									
	Funding Limit	7,000.00 maxim	um							
	Limited Submission	No								
121248	Discovery Grant Program (DGF	<u>P)</u>	Leukemia and Lymphom	a Society	04-Mar-2024	750,000 USD				
	Contact Name									
	Contact Telephone	914-821-8301								
	Contact Email	researchprogram	ns@lls.org							
	Sponsor Website	Link to sponsor	<u>website</u>							
	Program URL	Link to program	URL							
	Deadline Dates (ALL)	04-Mar-2024								
	Synopsis	The Leukemia and Lymphoma Society (LLS) offers the Discovery Grant Program (DGP) in the form of a research award								



The Development Office offers assistance with many non profit opportunities. Please contact the Development Office's Corporate and Foundation Relations team by email at <a href="mailto:DevCorpFound@mountsinai.org">DevCorpFound@mountsinai.org</a> for assistance or questions.

SPIN ID	Program Title	Sponsor Name		Sponsor Number	<b>Deadline Date</b>	Funding Amount	
	Annelina et Tonon	can lead to an understanding of blo detecting and monitoring cancer p		•	•	ethods for	
	Applicant Types	750,000.00 maximum					
	Limited Submission						
051093	Specialized Center of Research	(SCOR) Program Leukem	ia and Lymphoma S	Society	28-Mar-2024	5,000,000 USD	
	Contact Name						
	Contact Telephone	914-949-5213					
	Contact Email	researchprograms@lls.org					
	Sponsor Website	<u>Link to sponsor website</u>					
	Program URL	Link to program URL					
	Deadline Dates (ALL)	28-Mar-2024					
	Synopsis	LLS's Specialized Center of Research (SCOR) grant program is intended to bring together established investigators from one or several institutions to develop a focused research program, foster new interactions and cooperation, and enhance interdisciplinary research among the participants. The overall goal of this mechanism is to enhance the development of innovative strategies for the treatment, diagnosis or prevention of hematological malignancies. Strategies that move discoveries from the bench to the clinic are of high importance as are integrated translational projects.					
	Applicant Types						
	Funding Limit	1,000,000.00 per year					



Non Federal Funding Opportunities: March 2024

SPIN ID	Program Title	S	ponsor Name	Sponsor Number	Deadline Date	Funding Amount	
	Limited Submission	No					
069873	Alfred W. Bressler Prize in Visi	on Science	Lighthouse Guild		01-Mar-2024	25,000 USD	
	Contact Name	Ms. Fernanda Gai	·cia-Piña				
	Contact Telephone	212-769-7833					
	Contact Email	awards@lighthou	seguild.org				
	Sponsor Website Program URL  Link to program URL  Deadline Dates (ALL) 01-Mar-2024						
	Synopsis			of vision science whose leader eye disease or rehabilitation			
	Applicant Types						
	Funding Limit	25,000.00 maxim	um				
	Limited Submission	No					
067718	Pisart Award in Technological	<u>Innovation</u>	Lighthouse Guild		01-Mar-2024	25,000 USD	
	Contact Name	Fernanda Garcia-	Peña, Director of Research Op	erations			
	Contact Telephone	212-769-7833					
	Contact Email	awards@lighthou	seguild.org				
	Sponsor Website	Link to sponsor w	<u>ebsite</u>				
	Program URL	Link to program L	<u>IRL</u>				
		•					



SPIN ID	Program Title		Sponsor Name	Sponsor Number	<b>Deadline Date</b>	Funding Amount			
	Deadline Dates (ALL)	01-Mar-2024							
		developed tech	d was established in 1981 to recognize nology that improves the lives of peop ighthouse Guild to inspire people who	le with vision loss. Their et	forts will have dire				
	Applicant Types								
	Funding Limit	25,000.00 maxii	000.00 maximum						
	Limited Submission	No							
089679	Global Team Science Awards		Lupus Research Alliance		01-Mar-2024	Not Specified			
	Contact Name	Contact Name Diomaris Gonzalez, Director, Grant Programs							
	Contact Telephone	646-884-6056							
	Contact Email	dgonzalez@lup	usresearch.org						
	Sponsor Website	Link to sponsor	<u>website</u>						
	Program URL	Link to program	<u>l URL</u>						
	Deadline Dates (ALL)	01-Mar-2024							
	Synopsis	The Global Team Science Award supports interdisciplinary, collaborative, and highly synergistic projects that push the boundaries of innovation and bridge research and clinical efforts in lupus. The successful Teams will focus on unraveling human lupus heterogeneity by applying cutting-edge technologies to address critical questions that could bring about breakthroughs in lupus care, research or drug development.							
	Applicant Types								
	Funding Limit	0.00 see detail							
	Limited Submission	No							



SPIN ID	Program Title	Sponsor I	Name	Sponsor Number	<b>Deadline Date</b>	Funding Amount
108503	Grant Program		Mathers (G.Harold and Lei Foundation	la Y.)	01-Mar-2024	Not Specified
	Contact Name					
	Contact Telephone					
	Contact Email	support@mathersfoundat	tion.org			
	Sponsor Website	Link to sponsor website				
	Program URL					
	Deadline Dates (ALL)	01-Mar-2024				
	The G. Harold and Leila Y. Mathers Foundation's mission is to advance knowle scientific research that will benefit mankind. Basic scientific research, with potential to this goal, and fundamental to the Foundation's operating principles					
	Applicant Types					
	Funding Limit	0.00 not provided				
	Limited Submission	Yes				
013071	Neurology - Neurocritical Care	Fellowship (Minnesota)	Mayo Clinic College of Me Science	dicine and	15-Mar-2024	Not Specified
	Contact Name	Chelsea Becker, Education	n Coordinator			
	Contact Telephone	507-266-1787				
	Contact Email	becker.chelsea@mayo.ed	<u>u</u>			
	Sponsor Website	Link to sponsor website				



The Development Office offers assistance with many non profit opportunities. Please contact the Development Office's Corporate and Foundation Relations team by email at <a href="mailto:DevCorpFound@mountsinai.org">DevCorpFound@mountsinai.org</a> for assistance or questions.

SPIN ID	Program Title	Sponsor I	Name	Sponsor Number	<b>Deadline Date</b>	<b>Funding Amount</b>		
	Program URL Deadline Dates (ALL)	Link to program URL 15-Mar-2024						
	Neurocritical care is one of the newest and fastest-growing specialties in medicine. Critical care neurology entails a multidisciplinary approach to treating life-threatening neurological diseases. The Neurocritical Care Division at May Clinic in Rochester, Minnesota, is responsible for two services: A primary care service in a 20-bed Neuroscience Intensive Care Unit (ICU). The model of care in the ICU is closed: All orders in patients under the Division's care are written by its team, in agreement with neurosurgery when pertinent. Anesthesia support is available for supervision of invasive procedures, but all procedures are expected to be performed by the neurocritical care fellow. A consulting service, in which the Division staffs neurological consultations in all other adult ICUs at Saint Mary's and Methodist hospitals.							
	Applicant Types							
	-	0.00 see detail						
	Limited Submission	No						
012941	Neurology - Clinical Neurophys Electroencephalography, Epile	<del> </del>	Mayo Clinic College of Med Science	licine and	01-Mar-2024	Not Specified		
	Contact Name	Channing Dallstream, Edu	cation Coordinator					
	Contact Telephone	480-301-4395						
	Contact Email	dallstream.channing@ma	yo.edu					
	·	<u>Link to sponsor website</u>						
	_	Link to program URL						
	Deadline Dates (ALL)	01-Mar-2024						



Non Federal Funding Opportunities: March 2024

SPIN ID	Program Title	Sponsor	Name	Sponsor Number	<b>Deadline Date</b>	Funding Amount
	Synopsis	•	cottsdale, Arizona, offers a o p Program to prepare recipie			
	Applicant Types					
	Funding Limit	0.00 see detail				
	Limited Submission	No				
011835	Epilepsy Fellowship (Minnesot	<u>a)</u>	Mayo Clinic College of Me Science	dicine and	01-Mar-2024	Not Specified
	Contact Name	Julie Nguyen, Education (	Coordinator			
	Contact Telephone	507-284-8687				
	Contact Email	Nguyen.Julie@mayo.edu	!			
	Sponsor Website	Link to sponsor website				
	Program URL	Link to program URL				
	Deadline Dates (ALL)	01-Mar-2024				
	The Epilepsy Fellowship at Mayo Clinic's campus in Rochester, Minnesota, provides advanced training in epileps Synopsis electroencephalography (EEG). This one-year fellowship is designed for those who wish to acquire advanced knowledge and skills in the comprehensive management of people with epilepsy and related disorders.					
	Applicant Types					
	Funding Limit	0.00 see detail				
	Limited Submission	No				



SPIN ID	Program Title	Sp	oonsor Name	Sponsor Number	<b>Deadline Date</b>	Funding Amount	
011996	Adult Cardiothoracic Anesthes (Minnesota)	iology Fellowship	Mayo Clinic College Science	of Medicine and	31-Mar-2024	Not Specified	
	Contact Name	Linda Anderson, E	ducation Coordinator				
	Contact Telephone	507-255-1246					
	Contact Email	Imanderson@may	<u>ro.edu</u>				
	Sponsor Website	Link to sponsor we	<u>ebsite</u>				
	Program URL Link to program URL  Deadline Dates (ALL) 31-Mar-2024						
	Synopsis	The Adult Cardiothoracic Anesthesiology Fellowship at Mayo Clinic's campus in Rochester, Minnesota offers excelled training and a range of opportunities for individuals pursuing an academic career in cardiovascular and thoracic (CV anesthesiology, or individuals who will manage these cases in the private setting. Some fellows have sought training tailored to the cardiothoracic and vascular practices seen in the private setting; others have concentrated in echocardiography, worked on clinical or laboratory-based research projects, or focused on the congenital practice. There is also a wealth of opportunities related to thoracic or major vascular surgery.					
	Applicant Types						
	Funding Limit	0.00 see detail					
	Limited Submission	No					
114189	Research Grants (RG)		Muscular Dystroph	y Association	26-Jan-2024 [LOI/Pre-App]	100,000 USD	
	Contact Name						
	Contact Telephone	800-572-1717					



SPIN ID	Program Title	Sponsor	Name	Sponsor Number	<b>Deadline Date</b>	Funding Amount			
	Contact Email	grants@mdausa.org							
	Sponsor Website	Link to sponsor website							
	Program URL	RL Link to program URL							
	Deadline Dates (ALL) 26-Jan-2024 [LOI/Pre-App], 22-Mar-2024								
	Synopsis	Muscular Dystrophy Association (MDA) Research Grants are awarded to independent, established investigators to Synopsis accelerate progress toward understanding and treating neuromuscular disease. Applications will be accepted for no more than \$100,000 per year for 3 years.							
	Applicant Types								
	Funding Limit	100,000.00 maximum							
	Limited Submission	No							
017091	Development Grants (DG)		Muscular Dystrophy Associ	ation	26-Jan-2024 [LOI/Pre-App]	210,000 USD			
	Contact Name								
	Contact Telephone	800-572-1717							
	Contact Email	grants@mdausa.org							
	Sponsor Website	<u>Link to sponsor website</u>							
	Program URL	Link to program URL							
	Deadline Dates (ALL)	26-Jan-2024 [LOI/Pre-App	o], 22-Mar-2024						
Synopsis  The purpose of the Development Grants program is to expand the number of scientists conducting meritoric neuromuscular disease research funding postdoctoral investigators in the laboratory of a senior investigator									



SPIN ID	Program Title	Sponsor Nan	ne	Sponsor Number	<b>Deadline Date</b>	Funding Amount	
		whose guidance the research	er will be given flexibility	to work independently or	as part of a collabo	rative effort.	
		Applications will be accepted	for no more than \$70,00	0 per year for 3 years.			
	Applicant Types						
	Funding Limit	70,000.00 per year	,000.00 per year				
	Limited Submission	No					
120678	Tier II Research Grant: Research Fellow-Initiated	<u>th or Clinical Scientist</u>	ational MPS Society, Inc.		15-Jan-2024	Not Specified	
	Contact Name Matthew Ellinwood						
	Contact Telephone	919-806-0101					
	Contact Email	matthew@mpssociety.org					
	Sponsor Website	Link to sponsor website					
	Program URL	Link to program URL					
	Deadline Dates (ALL)	15-Jan-2024 , 15-Mar-2024 [LOI/Pre-App]	.OI/Pre-App], 15-May-202	24 , 15-Jul-2024 [LOI/Pre-A	.pp], 15-Sep-2024 ,	15-Nov-2024	
	Synopsis	The National MPS Society is initiating a revised research grants program to encourage submission and funding of the best possible MPS and ML research applications through building out a predictable yet flexible program of research calls and grant mechanisms. The goal is for these revisions to provide predictability to the research community and flexibility to the Society through which to meet the goals of improved lives and outcomes to those in the MPS and ML family.					
	Applicant Types						
	Funding Limit	0.00 see detail					



SPIN ID	Program Title	Sponsor Name	Sponsor Number	<b>Deadline Date</b>	Funding Amount				
	Limited Submission	Yes							
120683	Tier III Research Grant	National MPS Society,	Inc.	15-Jan-2024	25,000 USD				
	Contact Name	Matthew Ellinwood							
	Contact Telephone	919-806-0101							
	Contact Email	matthew@mpssociety.org							
	Sponsor Website	<u>Link to sponsor website</u>							
	Program URL Link to program URL  Deadline Dates (ALL) 15-Jan-2024 , 15-Mar-2024 [LOI/Pre-App], 15-May-2024 , 15-Jul-2024 [LOI/Pre-App], 15-Sep-2024								
	Synopsis	best possible MPS and ML research applications to calls and grant mechanisms. The goal is for these	The National MPS Society is initiating a revised research grants program to encourage submission and funding of the best possible MPS and ML research applications through building out a predictable yet flexible program of research calls and grant mechanisms. The goal is for these revisions to provide predictability to the research community and flexibility to the Society through which to meet the goals of improved lives and outcomes to those in the MPS and family						
	Applicant Types								
	Funding Limit	25,000.00 maximum							
	Limited Submission	Yes							
120673	<u>Tier I Research Grant</u>	National MPS Society,	Inc.	15-Jan-2024	Not Specified				
	Contact Name	Matthew Ellinwood							
	Contact Telephone	919-806-0101							
	Contact Email	matthew@mpssociety.org							



SPIN ID	Program Title	Sponsor N	lame	Sponsor Number	<b>Deadline Date</b>	Funding Amount			
	Sponsor Website Link to sponsor website								
	Program URL Link to program URL								
	Deadline Dates (ALL) 15-Jan-2024 , 15-Mar-2024 [LOI/Pre-App], 15-May-2024 , 15-Jul-2024 [LOI/Pre-App], 15-Sep-2024								
	The National MPS Society is initiating a revised research grants program to encourage submission and funding of the best possible MPS and ML research applications through building out a predictable yet flexible program of research calls and grant mechanisms. The goal is for these revisions to provide predictability to the research community and flexibility to the Society through which to meet the goals of improved lives and outcomes to those in the MPS and family.								
	Applicant Types								
	Funding Limit	0.00 see detail							
	Limited Submission	Yes							
011340	Eric Dostie Memorial College S and von Willebrand Disease Ble		NuFactor		01-Mar-2024	1,000 USD			
	Contact Name					_			
	Contact Telephone	800-323-6832							
	Contact Email								
	Sponsor Website	Link to sponsor website							
	Program URL	Link to program URL							
	Deadline Dates (ALL)	01-Mar-2024							
	Synopsis	The Eric Dostie Memorial ( similar bleeding disorder o	College Scholarship awards f r have a family member wit	inancial assistance to stud h a bleeding disorder. The	ents who either ha scholarship will aw	ve hemophilia or a rard \$1,000 each			



The Development Office offers assistance with many non profit opportunities. Please contact the Development Office's Corporate and Foundation Relations team by email at <a href="mailto:DevCorpFound@mountsinai.org">DevCorpFound@mountsinai.org</a> for assistance or questions.

SPIN ID	Program Title	Spon	sor Name	Sponsor Number	<b>Deadline Date</b>	Funding Amount	
	Applicant Types Funding Limit Limited Submission	must submit an essay improvement and end 1,000.00 see detail	an best demonstrate scholastic a describing how his or her educa richment.	· · · · · · · · · · · · · · · · · · ·		• • •	
108598	Summer Research Scholars Aw	vard (SUMMERS)	Pediatric Infectious Disease	es Society	24-Mar-2024	3,000 USD	
	Contact Telephone Contact Email Sponsor Website	pids@idsociety.org Link to sponsor websi Link to program URL 24-Mar-2024					
	Synopsis	The PIDS Summer Research Scholars Award (SUMMERS), established in 2021 through the support of Sanofi Pasteur promotes careers in pediatric infectious diseases by funding summer research projects of students at various levels training. The award is intended to support scholarship in pediatric infectious diseases broadly, including basic scient translational, clinical, epidemiology, and quality improvement research. Given the brevity of the summer research experience, focused studies or well-defined contributions to larger research projects will be most successful. Scholarship in \$3,000 stipend paid in two installments of \$1,500.					
	Applicant Types Funding Limit	3,000.00 maximum					



Non Federal Funding Opportunities: March 2024

SPIN ID	Program Title	Sponsor Name	Sponsor Number	Deadline Date	Funding Amount			
Limited Submission No								
086556	PFF Scholars Program	Pulmonary Fibrosis Fo	oundation	29-Mar-2024	100,000 USD			
Contact Name Zoe Bubany, VP of Board and External Relations								
	Contact Telephone	888-733-6741						
	Contact Email	zbubany@pulmonaryfibrosis.org						
	Sponsor Website	<u>Link to sponsor website</u>						
	Program URL	L Link to program URL						
Deadline Dates (ALL) 29-Mar-2024								
	Synopsis	The PFF Scholars Program is designed to support opportunities to future leaders in the field of pul \$100,000 USD to be given over a two-year period doctoral trainees, instructors, or Assistant profes	monary fibrosis. Awards will be d to encourage early stage inve	e offered from betwe stigators (individuals	en \$75,000 and must be post-			
	Applicant Types							
	Funding Limit	100,000.00 maximum						
	Limited Submission	No						
099444	New Investigator Operating Gr	ants Research Manitoba		01-Mar-2024	Not Specified			
	Contact Name							
	Contact Telephone	204-924-7070						
	Contact Email	helpdesk@researchmb.ca						
	Sponsor Website	<u>Link to sponsor website</u>						



The Development Office offers assistance with many non profit opportunities. Please contact the Development Office's Corporate and Foundation Relations team by email at <a href="mailto:DevCorpFound@mountsinai.org">DevCorpFound@mountsinai.org</a> for assistance or questions.

SPIN ID	Program Title	Sponsor	Name	Sponsor Number	<b>Deadline Date</b>	Funding Amount		
	Program URL	Link to program URL						
	Deadline Dates (ALL)	01-Mar-2024 , 15-Mar-20	024					
	Synopsis	sciences and engineering designed to defray the di	provincial funding agency, whi g, and social sciences and hum prect costs of research such as mall equipment and computer	nanities in Manitoba. New s personnel costs, supplies	Investigator Opera and expendable m	ting Grants are aterials,		
	Applicant Types							
	Funding Limit 0.00 see detail							
	Limited Submission	No						
104670	Mentored Nurse Practitioner/I for Workforce Expansion	Physician Assistant Award	Rheumatology Research Fo	oundation	01-Mar-2024	4 25,000 USD		
	Contact Name							
	Contact Telephone	404-365-1373						
	Contact Email	Foundation@rheumatolo	ogy.org					
	Sponsor Website	<u>Link to sponsor website</u>						
	Program URL	Link to program URL						
	Deadline Dates (ALL)	01-Mar-2024						
	The Rheumatology Research Foundation offers a Mentored Nurse Practitioner/Physician Assistant Award for Workforce Expansion, offering support to provide tailored training for nurse practitioners or physician assistants are new to the field of rheumatology. The applicant must present a detailed budget not to exceed \$25,000 in directors.							



Non Federal Funding Opportunities: March 2024

SPIN ID	Program Title	Sp	oonsor Name	Sponsor Number	<b>Deadline Date</b>	Funding Amount	
	Applicant Types						
	Funding Limit 25,000.00 maximum						
	Limited Submission	No					
076607	Career Development Award		Society for Surgery of the Alimentary Tract		15-Mar-2024	100,000 USD	
	Contact Name						
	Contact Telephone	978-927-8330					
	Contact Email						
	Sponsor Website	Link to sponsor we	<u>ebsite</u>				
	Program URL	Link to program UI	<u>RL</u>				
	Deadline Dates (ALL)	15-Mar-2024					
	Synopsis	This award of \$50, the establishment	000 per year for two years is a caree of investigators, basic or clinical, in	er development award for digestive diseases.	young faculty mem	bers is to assist in	
	Applicant Types						
	Funding Limit	50,000.00 per year	r				
	Limited Submission	No					
066849	Mentored Clinical Scientist Res Development Award (K08)	search Career	Society for Vascular Surger	у	12-Feb-2024	Not Specified	
	Contact Name						
	Contact Telephone	800-258-7188					



SPIN ID	Program Title		Sponsor Name	Sponsor Number	<b>Deadline Date</b>	Funding Amount			
	Contact Email	svsfoundation@	vascularsociety.org						
	Sponsor Website	Link to sponsor	<u>website</u>						
	Program URL	Program URL Link to program URL  Deadline Dates (ALL) 12-Feb-2024, 12-Mar-2024, 12-Jun-2024, 12-Jul-2024, 12-Oct-2024, 12-Nov-2024							
	Deadline Dates (ALL)								
	Synopsis	The Mentored Clinical Scientist Research Career Development Award (KO8) will prepare clinically trained individuals for careers that have a significant impact on the health-related research needs of the Nation. This program provides support and protected time for an intensive, supervised research career development experience in the fields of biomedical, behavioral, or clinical research, including translational research.							
	Applicant Types								
	Funding Limit	50,000.00 per y	ear						
	Limited Submission	No							
019649	Clinical Research Seed Grants		Society for Vascular Surger	у	01-Mar-2024	25,000 USD			
	Contact Name								
	Contact Telephone	312-334-2300							
	Contact Email	SVSFoundation(	මvascularsociety.org						
	Sponsor Website	Link to sponsor	<u>website</u>						
	Program URL	Link to program	URL						
	Deadline Dates (ALL)	01-Mar-2024							
	Synopsis	Synopsis The SVS Foundation offers the Clinical Research Seed Grant in recognition of the importance of clinical investigation in vascular disease.							



SPIN ID	Program Title	Sponsor	Name	Sponsor Number	<b>Deadline Date</b>	Funding Amount	
	Applicant Types						
	Funding Limit 25,000.00 maximum						
	Limited Submission	No					
067272	Grants Program		Sorenson Legacy Foundation	on	01-Mar-2024	Not Specified	
	Contact Name	Lisa Meiling					
	Contact Telephone	801-461-9700					
	Contact Email lisa@sorensonlegacyfoundation.org						
	Sponsor Website	ponsor Website Link to sponsor website					
	Program URL	Link to program URL					
	Deadline Dates (ALL)	01-Mar-2024 , 01-Jun-202	24 , 01-Sep-2024				
	Synopsis	by the late biotechnology Beverley Taylor Sorenson	ndation was created to impro pioneer and entrepreneur Ja the foundation provides sup ion to health care, scientific a	ames LeVoy Sorenson and oport for a wide range of e	his wife, education	philanthropist	
	Applicant Types						
	Funding Limit	0.00 not provided					
	Limited Submission	No					
057037	Stanford Maternal and Child H (MCHRI) Postdoctoral Support		Stanford University		04-Mar-2024	Not Specified	
	Contact Name						



SPIN ID	Program Title		Sponsor Name	Sponsor Number	Deadline Date	Funding Amount			
	Contact Telephone	650-724-0279							
	Contact Email	ct Email mchri_admin@stanford.edu							
	Sponsor Website	<u>Link to sponsor website</u>							
	Program URL	Link to program	URL						
	Deadline Dates (ALL)	04-Mar-2024							
	Synopsis	Synopsis The Stanford Maternal and Child Health Research Institute (MCHRI) Postdoctoral Support funds innovative matern and child health-focused research across all disciplines for: Postdoctoral Fellows - (\$90K/year, 2 years).							
	Applicant Types								
	Funding Limit	0.00 see detail							
	Limited Submission	No							
091400	Early Career Awards		Thrasher Research Fund		19-Mar-2024 [LOI/Pre-App]	25,000 USD			
	Contact Name	Brittni Smith, Pl	nD						
	Contact Telephone	801-240-4720							
	Contact Email	SmithBA@Thra	sherResearch.org						
	Sponsor Website	Link to sponsor	<u>website</u>						
	Program URL	Link to program	URL						
	Deadline Dates (ALL)	19-Mar-2024 [L	OI/Pre-App], 07-May-2024 , 05-Sep-20	)24 [LOI/Pre-App], 29-Oct-	2024				
	Synopsis	The Fund recog funding. Theref	nizes that young investigators may findore, the purpose of this program is to	d it difficult to remain in pe encourage the developme	ediatric research becant of medical researc	ause of a lack of h in child health			



SPIN ID	Program Title	Sponsor N	lame	Sponsor Number	Deadline Date	Funding Amount
			to new researchers, helping to be independent investigate	_	is important area. Th	ne goal is to fund
	Applicant Types					
	Funding Limit Limited Submission	25,000.00 see detail No				
105810	NSF-BSF Joint Funding Research Computational Neuroscience (		United States - Israel Binati Science Foundation	ional	07-Mar-2024	400,000 USD
	Contact Name	Dr. Rachel (Heni) Haring				
	Contact Telephone	972-2-5828239 x110				
	Contact Email	heni@bsf.org.il				
	Sponsor Website	Link to sponsor website				
	Program URL					
	Deadline Dates (ALL)	07-Mar-2024 , 13-Mar-202	24			
	Synopsis	As part of the NSF-BSF joint program, the U.SIsrael Binational Science Foundation (BSF) invites collaborative research proposals in Computational Neuroscience (CRCNS), at the U.S. National Science Foundation (NSF). The NSF-BSF program is not a "special" program and NSF does not set aside money for potential grants. Rather, NSF-BSF proposals are evaluated together with standard NSF proposals in a review process managed by the regular NSF core programs in the participating disciplines. It is essential that the U.S. PI has a clear understanding of the NSF-BSF framework before embarking on proposal preparation.				
	Applicant Types					
	Funding Limit	80,000.00 per year				



SPIN ID	Program Title	Sponsor I	Name	Sponsor Number	Deadline Date	Funding Amount		
	Limited Submission	No						
013502	Mentoring Summer Research I (MSRIP)	nternship Program	University of California, Riv	erside	01-Mar-2024	4,500 USD		
	Contact Name	Laura McGeehan, Program	n Director					
	Contact Telephone	951-827-3680						
	Contact Email	laura.mcgeehan@ucr.edu						
	Sponsor Website	Link to sponsor website						
	Program URL	Link to program URL						
	Deadline Dates (ALL)	01-Mar-2024						
		The Mentoring Summer Research Internship Program (MSRIP) is an eight-week summer research program desig for UCR undergraduate students from educationally and/or economically disadvantaged backgrounds. Participal work under the supervision of a faculty mentor on the mentor's research project. MSRIP is intended to encourage outstanding students from diverse backgrounds to pursue their PhD by strengthening their academic and profest development. The program provides an opportunity for these students to develop a competitive profile with whiseek admission to UC Riverside and the University of California in general, as well as colleges and universities nationwide.						
	Applicant Types							
	Funding Limit	4,500.00 maximum						
	Limited Submission	No						
045984	Kennan Institute - George F. Ke	ennan Fellowship	Wilson (Woodrow) International Center for Scholars	tional	15-Mar-2024	12,000 USD		



SPIN ID	Program Title		Sponsor Name	Sponsor Number	Deadline Date	Funding Amount	
	Contact Name						
	Contact Telephone	202-691-4000					
	Contact Email	Contact Email Sponsor Website Program URL Deadline Dates (ALL)  Synopsis  Synopsis  Synopsis  Synopsis  Program URL  The George F. Kennan Fellowships were established with the goal of supporting experts from diverse, policy-oriented sectors such as media, business, local government, law, civil society, and academia to examine important political, social, economic, cultural, and historical issues in Russia, Ukraine, and the region. Among the aims of the new fellowships are to build bridges between traditional academia and the policy world, as well as to maintain and increase collaboration among researchers from Russia, Ukraine, the U.S., and beyond.					
	Sponsor Website						
	Program URL						
	Deadline Dates (ALL)						
	Synopsis						
	Applicant Types						
	Funding Limit	4,000.00 per m	onth				
	Limited Submission	No					

